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ABSTRACT
Stem cells have been a focus of growing scientific interest both as a tool for studying
early development and as a potential source of transplantable cells for regenerative
medicine. Since their derivation in 1998, human embryonic stem (ES) cells have
received much of this attention principally because of their ability to proliferate
seemingly indefinitely in vitro and to differentiate along multiple lineages,
essentially giving rise to every cell in the body (Reubinoff et ai, 2000; Thomson et
al., 1998). However, before human ES-derived transplantation becomes a reality for
patients, problems associated with prolonged and functional engraftment,
histocompatability, homogeneous cell populations, and the risk of tumours arising
from the accidental transplantation of undifferentiated human ES cells, must first be
addressed.
Despite the risk of malignancy associated with undifferentiated human ES cells, their
indefinite growth in culture has provided an opportunity to manipulate their fate.
This thesis has investigated the possibility of using the exogenous cell surface
markers; the Galal-3Galpl-4GlcNAc-R (a-gal) epitope and the murine major
histocompatibility complex (MHC) class I molecule H2-Kk, under the transcription
control of the human telomerase reverse transcriptase (hTERT) promoter to
selectively identify undifferentiated human ES cells for selective elimination.
Provided within is evidence to show the successful genetic manipulation of
iv
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undifferentiated human ES cells with al,3galactosyltransferase (al,3Gal) gene,
providing comparable cell surface expression of the a-gal epitope with endogenous
a-gal expression on the ovine foetal fibroblast cell line (PDFF). However, the use of
the H2-Kk gene as a potential lysis epitope was not so successful. Despite successful
integration and transcription of the H2-Kk gene, cell surface expression of the H2-Kk
epitope was not achieved, and proof of protein translation could not be found.
Expression of the a-gal epitope on undifferentiated human ES cells elicits a severe,
yet highly specific cytolytic response; on average 95% of the transgenic human ES
cells were lysed compared with just 8-12% of wild type non-expressing H9 cells,
when exposed to human serum containing active-complement. In addition, when
transgenic human ES cells were differentiated the a-gal epitope was down regulated,
in the same manner as established markers of undifferentiated human ES cells (TRA-
1-81 and SSEA-4). Following differentiation the transgenic a-gal expressing cell
line (M2) survived exposure to active serum-complement.
This novel system for selective ablation could potentially provide natural immune
protection, through the presence of circulating antibodies to a-gal that would protect
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1.1 The Promise ofRegenerative Medicine
Stem cells have been a focus of growing scientific interest both as a tool for studying
the earliest events of development and as a potential source of transplantable cells to
regenerate missing or damaged tissues, or to restore functions lacking in individuals
with acquired or inherited disorders. The isolation of embryonic stem (ES) cells,
which display a unique ability to differentiate into all cells of the adult body, has
heightened this interest over the last two decades (Reubinoff et al, 2000; Thomson et
al, 1998; Evans & Kaufman, 1981; Martin, 1981).
Zoe Hewitt
Chapter 1 - Introduction.
1.1.1 The Differentiation Potential of ES cells into Therapeutically Relevant
Lineages.
Within the last decade, a number of important advances towards obtaining
therapeutically useful cell types have been achieved through studies of directed in
vitro differentiation. The majority of this work has focused on the differentiation of
murine ES cells as a model for therapeutically useful cell types to treat a number of
the world's most debilitating diseases, a selection of which can be found in Table
1.1.1. Initially, differentiation was achieved using spontaneous differentiation
protocols and genetic manipulation to isolate and enrich for specific sub-sets of cells
(Miyashita et al., 2002; Perlingeiro et al., 2001; Klug et al., 1996). However,
strategies have since been developed, based on an understanding of embryo
development in vivo, which utilise the addition of specific growth factors to
encourage homogenous differentiation into specific cell types (Yusas et al., 2005;
Kawaguchi et al., 2005; Kim et al., 2002).
The derivation of human ES cells in 1998 has had exciting implication for the field
of regenerative medicine (Reubinoff et al, 2000; Thomson et al, 1998).
Extrapolation of the advances made with murine ES cells have indicated that human
ES cells will differentiate, in most respects, in a similar manner, although there may
be slight differences in the exogenous cues. Table 1.1.2 provides a selection of
significant advances made with human ES cells paralleling those made with murine
ES cells (Table 1.1.1).
Chapter 1 - Introduction.
Table 1.1.1: A summary of some of the most recent advances in the development of
therapeutically useful cells from murine ES (mES) cells, providing a brief description of the
works and references.






ES-derived neurones were shown to stimulate
recovery of the spinal cord following transplantation








Dopaminergic neurones, differentiated through EBs,
released significant levels of dopamine and sustained
trains of action potentials characteristic of mature
neurones.
Expression ofNurrl prior to differentiation increased
the occurrence of dopaminergic neurones (78%).
Transplantation resulted in a significant (P<0.001)
improvement in rotational behaviour compared to
that observed from wild type ES cell-derived
dopaminergic neurone transplants.
ES cells differentiated into dopamine-releasing














Functional engraftment of oligodendrocytes, derived
from mES, in md rats. Six out of 9 rats showed
donor derived myelin sheaths and showed evidence







Directed differentiation of retinal progenitor
neurones through co-culture with PN1 retinal cells
led to 6% of the progenitors expressing rhodopsin, a









ES cells differentiated into inner ear progenitors,
when transplanted into chicken embryos resulted in
integration into the developing cochlear hair cell
layer, preferentially at sites of slight injury to the
epithelium layer. Donor cells expressed specific






ES derived insulin-producing cells clusters (IPCCs),
maintained similar topology and organisation to
normal pancreatic islets when injected into diabetic
mice. Insulin production was lower than primary
pancreatic islets, but this report has improved on the
early attempts.
Transplantation of IPCCs into a diabetic mouse
model showed maintenance of body weight and
extended survival. When grafts were removed, the










Spontaneously differentiated mES cells were
enriched for cardiomyocytes by the presence of a
selection cassette. When engrafted into the hearts of
adult dystrophic mice, they formed stable
intracardiac grafts, for up to 7-weeks, in mice.
Directed differentiation through the inhibition of
BMP signalling with Noggin treatment increased
production of cardiomyocytes 100-fold, 95.3% of















Hematopoietic progenitors isolated from EBs gave
rise only to primitive erythroid cell types in vitro.
When clonally injected into irradiated mice, they
gave rise to multiple myeloid cell types as well as B-
& T-lymphocytes, which under went maturation in
vivo.
A sub-population of flkl+/CD45- pre-hematopoietic
stem cells was identified following the co-culture of
mES with OP9 stromal cells. Specific differentiation
into B- and T-lymphocytes was initially poor but was











Male and female mES cells were shown to
spontaneously differentiate into oogonia after 50
days in 2D culture. These oogonia entered meiosis
and recruited adjacent cells to form follicle-like
structures and later developed into blastocysts.
In vitro differentiation (EBs) of ES cells into PGC,s
followed by co-culture with dissociated male gonads
resulted in the formation of testicular tubes and
mature sperm in the lumens, when transplanted back
into host testis capules. Controls containing only
gonadal aggregates (no ES-derived PGCs) resulted in
tubules but no sperm.
ES-derived sperm were used to fertilise oocytes
through intracytoplamic injection: 50% went to the










Hepatocytes Spontaneous differentiation of hepatocytes was
achieved in vitro (through EBs) and in vivo (through
teratomas formation). Hepatocytes isolated from
teratomas and expanded in vitro were found to have
characteristic hepatocyte metabolism and when
transplanted back into the spleens of carbon
tetrachloride treated mice they migrated to the liver,
were indistinguishable from host hepatocytes and










Osteoblasts Differentiation of osteoblasts from EBs, in the
presence of known osteogenic factors resulted in
expression of osteogenic markers, calcium
deposition and classic bone morphology.
Treatment of EBs with retinoic acid, before addition
of growth factors resulted in specific bulk
differentiation of osteoblasts, chondrocytes and
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Table 1.1.2: A summary of some of the most recent advances in differentiation of
therapeutically useful cell types from human ES (hES) cells, providing a brief description of the
works and references.








Retinoic acid (RA) and p-nerve growth factor
significantly enhance the differentiation of hES
cells into neurones in vitro. RA led to maturation
of neurones that expressed dopamine and serotonin
receptors.
Neural-spheres differentiated from hES cells, were
directed to differentiate into all 3 neural cell
lineages by the addition of extrinsic growth
factors. When hES-derived neural progenitors
were injected into mice, they differentiated
appropriately and migrate along established
developmental tracks
Undifferentiated hES cells modified to express
GTPCH I, a gene involved in tyrosine hydroxylase
activity (dopaminergic neurones) underwent in
vivo differentiation when transplanted into rat
models of Parkinson's disease. Cells survived for
up to 6 weeks and improved rotational behaviour
without the formation of tumours.
In vitro derivation of oligodendrocyte progenitors
(OPC's) from hES cells, which enhance
remyelination and promoted motor function in rats
following spinal cord injury, without the formation

















Modifying the protocol described by Lumelsky et
al., (2001) for mES cells, by reducing the level of
glucose in the medium and allowing the cells to
aggregate prior to differentiation, hES cells were
differentiated into IPCCs that secreted a 30-fold
increase in insulin, and that continued to
proliferate in their differentiated state for up to a
month. However, the gene expression profile of
hES-derived IPCC's indicated that they were








Undifferentiated hES cells were co-cultured with
irradiated mouse bone marrow cells (SI7 cells)
and allowed to spontaneously differentiate. From
the mixed population CD34+ cells were isolated
and plated in methylcellulose culture medium











Directed differentiation of hES cells through co-
culture with visceral-endoderm cell lines resulted
in cardiomyocytes that had classical morphology,
expressed characteristic markers and displayed
action potentials that were comparable to those
observed in 16-week-old foetal atrium and
ventricle tissue.
Cardiomyocytes, differentiated in vitro through
EBs and the addition of 5-aza2'-deoxycytidine,
responded appropriately in vitro to various
cardioactive drugs. The use of Percoll gradient
separation resulted in a 4-fold enrichment of
differentiated cardiomyocytes, which also
contained a subpopulation that appeared to be








Hepatocytes Differentiation of hepatocyte-like cells from hES
cells through treatment with sodium butyrate.
Isolation of hepatocyte-like cells was low (10-15%
of the total culture) and cell death was high,
however, those cells, which survived, had
morphology similar to primary hepatocytes and









Osteoblasts Differentiation of committed osteoblasts from EBs
in the presence of known osteogenic factors
resulted in expression of osteogenic markers,
calcium deposition and classic bone morphology.
In vivo differentiation of mineralised tissue from
hES cells transplanted into mice in poly-D, L-
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1.2 The Limitations ofRegenerative Medicine
While the promise of human ES-derived regenerative medicine has exciting
implications for modern medicine, there remain a number of significant challenges
before cell-transplantation can become a reality for patients. The challenge of
differentiating ES cells so that they are available in sufficient number to achieve
adequate engraftment to improve physiological conditions over long periods of time
has already received significant attention (as discussed 1.1.1). However, while a
number of reports have now demonstrated the ability of ES cells to differentiate and
incorporate into host tissues (Keirstead et al., 2005; Reubinoff el al., 2001; Zhang et
al., 2001; McDonald et al., 1999; Klug et al., 1996) the evidence for this engraftment
has been based upon the expression of characteristic markers, 4-8 weeks after
transplantation. Recently, there has been the first published study that has assessed
the ability of stem cell-derived cell grafts to provide long-term functional
improvement (Keirstead et al., 2005).
In this report, Keirstead et al., (2005) demonstrate derivation of functional
oligodendrocyte progenitors cells (OPC's) from human ES cells. When transplanted
into rat spinal cords, 7 days post injury, these cells not only survived, migrated,
matured and incorporated into host tissue, as indicated by morphology and the
expression of characteristic markers, they also enhanced remyelination of axons and
promoted motor function, as soon as 1-week post transplant (Keirstead et al., 2005).
Remyelination was assessed over 12-months and indicated that OPC-transplanted
rats displayed approximately twice the amount of remyelination one year after
transplantation compared to sham transplanted control rats. Interestingly, the authors
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described the existence of a therapeutic window, restricted to the early post-injury
period, in which this therapy was effective. OPC's transplanted 10-months after
spinal cord injury showed cell survival and migration but there was no evidence of
remyelination or improved locomotive ability after a year in situ (Keirstead et al.,
2005).
One of the main restrictions in determining functional improvement and long-term
survival of ES cell grafts is that the majority of the models of human diseases are
rodent models, with short life spans. However, if ES cells could be derived from
farm animals, showing the same success in differentiation, it would significantly
enhance the study of cell transplantation. Attempts have been made to this end, and
ES-like cells have been derived from cows and pigs (Wang et al., 2005; Picard et al.,
1990; Li et al., 2004). However, as yet pluripotent cells with indefinite proliferative
capability have not been isolated. The increased life span of farm animals would
allow for the analysis of homologous transplants, of specific cells types, over several
years, which would help to determine the benefits, and any possible long-term
problems, associated with transplantation of ES-derived cells.
Currently the major obstacle associated with organ and tissue transplantation, is the
issue of histocompatiblity, which must be addressed before ES-derived cell grafts
can be used therapeutically. Therapeutic cloning, the derivation of patient-specific
embryos, is one suggested method by which graft rejection of transplanted human ES
cell derivatives might be prevented. Initially it was considered that this prevention
strategy would be difficult to achieve since the frequency of successful cloning
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(success being determined in terms of live births) has been shown to be very low,
ranging from 3.4% in sheep to as low as 0.3% in Pigs (Wilmut et al., 1997; Polejaeva
et al., 2000, respectively). However, researchers have recently reported the
derivation of human ES cells from embryos produced by somatic nuclear transfer
(NT) (Hwang et al., 2004) and have indicated a significantly better than expected
success rate, increasing from 3.3% success in the first report (Hwang et al., 2004) to
over 35% a year later (Hwang et al., 2005). The group indicated that the success of
NT-human ES cell derivation was reduced when using oocytes donated by women
over the age of 30, which could have significantly limited this technology from
becoming a widely practiced clinical application. However, there is evidence to
suggest that the number of "banked" ES cell lines that would be required to match
the human leukocyte antigen (HLA) for the majority of human genotypes, with the
exception of individuals with rare genotypes, could be achieved with only 150 blood
matched donors, or as few as 10 highly selected donors for the most common HLA
haplotypes (Taylor et al., 2005). The authors went on to show that banking greater
than 150 blood matched donors would not significantly increase the ability to match
patient HLA. Together with the report of Hwang et al., (2005) these data suggest
that somatic nuclear transfer could be a plausible technique to overcome the issue of
histocompatibility, although studies into the proliferation, differentiation and stability
of these cells need to be performed.
A further cause for concern with ES-derived cell transplants is the potential for
immune pathology caused by activation of lymphocytes or hyperfunction, where
cells trying to supply a missing function at a regulated level, such as insulin, fail and
Chapter 1 - Introduction.
over produce. Selective ablation strategies have been developed (see section 1.5)
which could be used to target the elimination of a graft in the event of post-transplant
complications (Schuldiner et al., 2003; Fareed & Moolten, 2002).
In addition to the risk of immune pathology and hyperfunction, there is also a serious
risk that transplanted cells may result in the formation of malignancies either as a
result of tissues maintaining growth potential or arising from the unintentional
transplantation of undifferentiated human ES cells within a therapeutic population.
These potentially malignant cells may develop, or persist, during the production of a
transplantable cell line, or could arise during the stage of rapid cell proliferation,
which will be required to obtain adequate numbers of cells for transplantation
(Fareed & Moolten, 2002). Murine models have shown the potential of
undifferentiated human ES cells to differentiate inappropriately after transplantation,
forming teratomas or even highly malignant teratocarcinomas (Reubinoff et al, 2000;
Thomson et al, 1998) and therefore, it is essential to address this risk before ES
derived-cells enter the clinic.
This thesis describes an attempt to address concerns of tumorigenecity from human
ES-derived regenerative medicine, before this therapy enters the clinic. Presented
within is an investigation into strategies which selectively eliminate undifferentiated
human ES cells, utilising restricted expression (see section 1.3.5.2) of a variety of
different cell surface markers (see section 1.6) to undifferentiated human ES cells
and showing the application of an appropriate cell selection or ablation technique
(see section 1.7).
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1.3 Introduction to Stem Cells
Stem cells have been defined by their ability to divide asymmetrically: one daughter
cell remains as a stem cell, to maintain the original stem cell population, while the
other is directed down a specific developmental pathway that commits it to mature
into a single, or one ofmany, specialised cell types.
Conventional wisdom holds that adult (or somatic) stem cells are constrained in their
developmental potential to their tissue of origin and hence were thought to be
restricted in their therapeutic potential. Conversely, embryo derived pluripotent stem
cells can give rise to essentially any cell type in the animal body (Donovan &
Gearhart, 2001; Thomson & Odorico, 2000; Reubinoff et al, 2000; Keller &
Snodgrass, 1999; Thomson et al, 1998 Thomson et al, 1995; Evans & Kaufman,
1981; Martin, 1981). At present, three types of embryo-derived multipotent stem cell
lines have been isolated from mammals - embryonal carcinoma (EC) cells, the stem
cells of teratocarcinomas (Kleinsmith & Pierce, 1964); embryonic germ (EG) cells
derived from the primordial germ cells (PCG's) of post-implantation embryos
(Shamblott et al, 1998; Matsui et al, 1992); and embryonic stem (ES) cells derived
from pre-implantation embryos (Reubinoff et al, 2000; Thomson et al, 1998;
Thomson et al, 1995; Evans & Kaufman, 1981; Martin, 1981).
1.3.1 Multipotent Adult Stem Cells
Recently the notion that adult stem cells are constrained in their lineage potential to
the tissue of their origin has been challenged. It has been reported that adult stem
cells have an inherent plasticity that allows them to respond to extrinsic signals,
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raising hopes that patient-derived adult stem cells may be used to treat a wide variety
of diseases (reviewed by Bianco et al., 2001; Brazelton et al., 2000; Ferrari et al.,
1998). However, although the plasticity of adult stem cells has been reported by
many groups and for many different tissues, reports of stem cell plasticity have been
criticised. Most of the objections to stem cell plasticity seem to revolve around the
low frequency at which it occurs and also that the majority of the reported data has
been based on pools of bone marrow derived stem cells which may contain several
tissue specific progenitor cells which co-exist (reviewed by Wagers & Weissman
2004 and Lakshmipathy & Verfaillie 2004).
Wagers et al., (2002) have evaluated the in vivo cell fate of haematopoietic stem cells
(HSC) through the generation of chimeric mice produced by transplanting a single
green fluorescent protein (GFP) tagged HSC into lethally irradiated recipients
(Wagers et al., 2002). The authors reported that out of over 15,000,000 cells
examined only 8 cells (1 in the brain and 7 in the liver) were GFP positive and not of
the haematopoietic lineage (Wagers et al., 2002). In agreement with other reports
(Terada et al., 2002; Ying et al., 2002) Wagers et al (2002) proposed that HSC
plasticity could be explained by a spontaneous fusion event between the stem cell
and a non-haematopoietic cell. Spontaneous fusion, as with stem cell plasticity does
not occur at a high frequency but these observations have been seen repeatedly in
different groups (Terada et al., 2002; Ying et al., 2002), including our own (Pells et
al., 2002).
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In recent years there have been reports of adult stem cells with extensive potential for
differentiation, into multiple lineages; multipotent adult progenitor cells - MAPC's
(Jiang et al., 2002) and marrow isolated adult multilineage inducible (MIAMI) cells
(D'lppolito et al., 2004). Both reports indicated the isolation of a stem cell
population from the bone marrow which had the ability to grow for extended periods
of time, expressing a number of markers found to be expressed by ES cells (Oct-4,
Rex-1 and telomerase). Furthermore, these cells could differentiate in vitro into
multiple cell types representing all three germ layers. In addition, MAPC's have
been shown, at the single cell level, to contribute to most, if not all, somatic cell
types when injected into an early blastocyst (Jiang et al., 2002). The potential of
multipotent adult stem cells (MAPC's and MIAMI cells) is very exciting, however,
until independent laboratories have repeated these results, their true potential as a
source of cells for therapy remains unclear.
1.3.2 Embryonal Carcinoma Cells
The potential of multipotent stem cells was first realised in the early 1960's with the
isolation of embryonal carcinoma (EC) cells (Martin & Evans, 1974; Evans, 1972;
Kleinsmith & Pierce, 1964). EC cells are responsible for the formation of highly
malignant germ cell tumours, known as teratocarcinomas, which are characterised by
the presence of disorganised tissues representative of all three germ layers: ectoderm,
endoderm and mesoderm, and a single population of multipotent stem cells from
which they were derived (Kleinsmith & Pierce, 1964). Characterisation of EC cells
has shown that they have an indefinite replicative capacity (self-renewal) and that
transplantation of a single EC cell resulted in the formation of a new teratocarcinoma
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(Kleinsmith & Pierce, 1964). There is also evidence to suggest that certain
established EC cell lines can undergo normal embryonic development when injected
back into a mouse blastocyst, giving rise to chimeras with tissues derived from both
the host blastocyst and the EC cells, suggesting that EC may be pluripotent (Waters
& Rossant 1986; Illmensee & Mintz 1976; Papaioannou et al., 1975). However,
such chimeras have been found to develop abnormally (Rossant & McBurney 1982;
Papaioannou et al., 1978), casting doubt on the potential of EC cells, and indicating
that perhaps the risk associated with using tumour-derived, aneuploid cell lines (EC
cells) would be inappropriate for therapeutic use in humans. Nevertheless, EC cells
have played a fundamental role in furthering the field of regenerative medicine, since
it was an understanding of the biology of EC cells and early embryo development
that provided Martin Evans and Matt Kaufman and independently Gail Martin, with
the necessary grounding to derive pluripotent stem cells (see section 1.3.4) directly
from murine blastocysts (Evans & Kaufman, 1981: Martin, 1981).
1.3.3 Embryonic Germ Cells
A second source of embryo-derived multipotent stem cells was derived from the
primordial germ cells (PGC) of post-implantation embryos. These stem cells, termed
embryonic germ (EG) cells to reflect their origin, were derived at the point of PGC
migration from the posterior primitive streak to the genital ridge. In the mouse this
occurs at 8.5 days post coitum (dpc) (Matsui, et al, 1992) and in humans from
embryos between 5-9 weeks post-fertilisation (Shamblott et al, 1998). As with EC
cells, EG cells have been shown to have the capacity for self-renewal and have been
shown to be multipotent (Shamblott et al, 1998; Matsui, et al, 1992). The potential
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of murine EG cells has been shown both with the formation of teratocarcinomas and
coat colour chimeras (Stewart et al, 1994; Labosky et al, 1994). However, there
appears to be a window in which murine EG cells are pluripotent, which seems to be
restricted to the early gestational period. For example, EG cells lines derived from
PGC's of mouse strains 129/Sv and C57BL/6 at 8.5 dpc have been shown to
successfully contribute to the germ-line of chimeras (Stewart et al, 1994; Labosky et
al, 1994), while EG cells derived from the same C57BL/6 mouse strain but from
PGC's at 12.5 dpc could not (Labosky et al, 1994). The reason(s) for this are not
fully understood, although, it has been suggested that changes in methylation patterns
and genetic imprinting, when compared to those of ES cells for example, may have
an affect on the ability of some EG cells to contributed to the germ-line (Labosky et
al, 1994). The potential of human EG cells has been demonstrated in vitro,
differentiation of human EG cells gave rise to derivatives which expressed markers
from all three embryonic germ layers, however, in vivo differentiation of human EG
cells has not resulted in the formation of teratomas (Shamblott et al, 1998), possibly
reflecting a later developmental status for EG cells then evidenced in ES cells for
example (see section 1.3.4).
1.3.4 Embryonic Stem Cells
By comparing the properties of embryonic cells with those of established EC cell
lines at varying stages of development, Evans and Kaufman found that the epiblast
cells of the early post-implantation embryo (5.5dpc) most closely reflected the cell-
surface antigen expression and protein synthesis patterns of EC cells. However,
isolation and explantation of sufficient cells from embryos at the epiblast stage of
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development was technically very challenging. To overcome this issue, pre-
implantation blastocysts were induced into an experimental state of dormancy
(diapause), by ovariectomy at 2.5dpc, allowing the embryo to hatch from the
surrounding zona, while remaining free-floating in the uterine lumen. The
suspension of implantation led to an increased cell number within the embryo
without advancing embryo development and in turn made isolation of the epiblast
more successful. These blastocysts were then cultured in conditions optimised for
EC cells and provided the first karyotypically normal, truly pluripotent embryonic
stem (ES) cell lines which appeared to be unrestricted in their proliferation (Martin
1981; Evans & Kaufman, 1981). The ability of murine ES cells to develop into
specialised cell types, representative of all three embryonic germ layers, has been
tested in three independent assays: in vitro differentiation, giving rise to cell
derivatives expressing markers representative of all three germ layers (see Table
1.1.1); differentiation into teratomas or teratocarcinomas when placed in syngeneic
adult or immunocompromised mice; and in vivo differentiation when introduced into
the blastocoel cavity of a pre-implantation embryo (Donovan & Gearhart, 2001).
Following the successful isolation of ES cells from mouse (Evans & Kaufman, 1981;
Martin, 1981), there are now a number of established primate cell lines from both
Rhesus (Thomson et al, 1995) and Cynomolgus (Suemori et al., 2001) monkey,
marmoset (Thomson et al., 1996) and human (Reubinoff et al, 2000; Thomson et al,
1998).
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1.3.5 Human Embryonic Stem (ES) Cells
Human embryonic stem (ES) cells were first derived by James Thomson and his
colleagues in 1998 (Thomson et al., 1998). Embryos, donated by patients' consent,
from IVF clinics, were cultured to the blastocyst stage and a total of 14 inner cell
masses (ICM's) were isolated. From these, five independent Wisconsin human ES
cell lines were established, three with a stable XY karyotype (HI, HI3 and HI4) and
two with a stable XX karyotype (H7, and H9). Amongst the unique properties
reported for ES cells, the ability to self renew is one of their defining characteristics,
the other being the ability to differentiate into multiple cell types of the adult body.
Thomson et al., (1998) reported that all five of the Wisconsin cell lines grew in
continuous culture for at least six-months, never experiencing replicative crisis; that
they differentiated (in vitro and in vivo) into multiple cell types from all three germ
layers; maintained their normal karyotype and expressed high levels of telomerase
activity (Thomson et al., 1998), indicating that these lines were in fact ES cells.
1.3.5.1 In Vitro Culture Techniques
The early-derived human ES cell lines were maintained in culture conditions, which
paralleled those defined for murine ES cells, on a feeder-layer of mouse embryonic
fibroblasts (MEF), in medium that was supplemented with serum and leukaemia
inhibitory factor (LIF) (Reubinoff et al., 2000; Thomson et al., 1998). However,
unlike murine ES cells, human and non-human primate ES cells were found to be
unresponsive to exogenous LIF, when removed from their feeder-cells, resulting in
spontaneous differentiation (Reubinoff et al., 2000; Thomson et al., 1998; Thomson
et al., 1995).
-17-
Chapter 1 - Introduction.
Initially, human ES cells, like non-human primate ES cells were passaged using a
combination of mechanical and collagenase IV or dispase disaggregation, which
maintained cells in small clumps at passage (Reubinoff et al., 2000; Thomson et al.,
1998; Thomson et al., 1996; Thomson et al., 1995). Human ES cells were initially
maintained in small clumps at passage based on experience with non-human primate
ES cells, which had indicated significantly improved cell survival compared to
passage as a single cell suspension (Thomson et al., 1995). However, while
attempting to prove the pluripotency of clonal human ES cell, Amit et al., (2000)
found that cell survival of single cell suspensions of human ES cells was
significantly improved by serum-free culture, supplemented with recombinant human
basic fibroblast growth factor (hbFGF). They also demonstrated that serum-free
medium that lacked hbFGF resulted in spontaneous differentiation of human ES
cells, yet addition of hbFGF alone, or together with LIF, was insufficient to maintain
human ES cells in an undifferentiated state, in the absence of feeder-cells (Amit et
al., 2000). These data suggested a number of things; 1) that a component of bovine
serum was potentially toxic to undifferentiated human ES cells when they were
exposed as single cells, 2) serum-free culture significantly increased survival, but
reduced proliferation, without the addition of hbFGF, 3) hbFGF was not sufficient to
maintain ES cells in an undifferentiated state and 4) that the feeder layer was
essential for the maintenance of self-renewal (Amit et al., 2000).
By 2001, a new method of human ES cell culture had been described (Xu et al.,
2001), which substituted culture of ES cells on feeder-cell layers, with a synthetic
-18-
Chapter 1 - Introduction.
extra-cellular matrix (Matrigel) using serum-free medium pre-conditioned by MEFs
in the presence of hbFGF. It was this basic method of culture that was used in the
present study (see section 2.4.1). However, the ultimate goal for the field of
regenerative medicine is to use derivatives of ES cells to treat degenerative disease.
There are concerns that since current human ES cells lines have been derived on or
cultured using either mouse feeders or MEF conditioned medium, mouse laminin
(main component of matrigel) or serum, there is the possibility of cross species
transfer of infectious agents. Therefore, the regulatory bodies have perceived current
human ES cell lines to be xenografts. Consequently, extensive research has been
undertaken to overcome this issue by defining derivation and culture conditions
which do not involve contact with animal cells or animal products (Amit et al., 2004;
Amit et al., 2003; Cheng et al., 2003; Hovatta et al., 2003; Richards et al., 2003;
Richards et al., 2002). Recently, the first human ES cell lines have been successfully
derived in completely defined conditions (in the absence of serum and serum
replacement), and free from all animal products. Importantly these ES cell lines have
been shown to be comparable to human ES cells derived using standard conditions,
in terms of their marker expression, chromosomal stability and differentiation
potential (Fletcher et al., in preparation; Li et al., 2005).
1.3.5.2 Characterisation ofHuman ES cells
Since the derivation of murine ES cells, much has been learnt of their gene
expression profile, which has been shown to be closely related to the gene expression
profile of the inner cell mass (Pelton et al., 2002). Those characteristic markers
-19-
Chapter 1 - Introduction.
include telomerase activity, expression of the Oct3/4, Nanog, Sox-2 and Rex-1 genes
and cell surface expression of the carbohydrate epitopes SSEA-1 and -3 and the
liver/bone/kidney isozyme of alkaline phosphatase (reviewed by Ginis et al., 2004).
It is interesting to note that the characteristics ofmurine ES cells are similar to those
observed for human EC and ES cells, however, there are also a number of
differences, such as the expression of SSEA-1 and lack of TRA-1-60 and TRA-1-81
staining on murine ES cells. This section will compare the characteristic markers of
murine ES cell with those of human EC and human ES cells.
Telomerase activity and self-renewal
DNA replication requires DNA polymerase, which functions by extending an RNA
primer in a 5' to 3' direction (Figure 1.3.1). After initiation of DNA synthesis the
RNA primers are removed and DNA polymerase extends the newly synthesised
DNA across the gaps left by the primers, with the help of DNA ligase, to complete
strand synthesis. However, when the RNA primer is removed from the far 5' end of
the chromosome, DNA polymerase cannot complete the strand, as it has nothing to
prime from, resulting in a shorter replicate strand (Figure 1.3.1). Telomere
shortening, as it is known, occurs at each round of replication and has thus been
proposed to act as a mitotic clock, signalling the progression of a cell towards the
end of its lifespan (Allsopp et al., 1992).
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Figure 1.3.1: Schematic representation of the problem associated with completely replicating a
linear chromosome. After semi conservative replication, the new strands have RNA primers at
their 5' ends. RNA primers are removed and DNA polymerase fills in the resulting gaps and
DNA ligase joins the adjacent fragments. However, at the 5' end of each new strand, gaps
remain because DNA polymerase cannot initiate new DNA synthesis.
Telomerase is a ribonucleoprotein which functions, independently of DNA
polymerase, to add telomeric repeat sequences (TTAGGG, in humans) to the ends of
chromosomes, maintaining chromosome length and integrity (Greider & Blackburn,
1996). Telomerase is comprised of two components: human Telomerase RNA
(hTER), an RNA element that serves as a template for the polymerase activity of the
second component, telomerase reverse transcriptase (hTERT), which is responsible
for the enzymatic activity of telomerase (Tzukerman et al., 2000; Kyo et al., 2000;
Meyerson et al., 1997). In order to reconstitute telomerase activity in vitro, both
hTER and hTERT are necessary (Weinrich et al., 1997).
Diploid human somatic cells do not express telomerase; consequently, telomeres
shorten with age and cells enter replicative senescence after a finite proliferative life
span in tissue culture (Allsopp et al., 1992). The re-introduction of telomerase
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activity has been demonstrated, in some human somatic cells, to extend their
replicative life span (Bodnar et al., 1998) suggesting a significant correlation
between telomerase expression and immortality in human cell lines. Conversely,
telomerase activity has been readily detected at the earliest gestational stages during
human embryonic development (Wright et al., 1996) and in accordance with their
origin, human ES cells have also been observed to be strongly telomerase positive
(Reubinoff et al., 2000; Tzukerman et al., 2000; Thomson et al., 1998). Furthermore
as seen in the developing foetus (Wright et al., 1996), a time-dependent decline of
telomerase activity was reported following induction of differentiation (Tzukerman
et al, 2000). The authors reported disappearance of telomerase activity after 14 days
of differentiation, which they correlated with a marked reduction in hTERT promoter
activity (Tzukerman et al, 2000).
Down regulation of the hTERT promoter following onset of differentiation in human
ES cells, reported by Tzukerman et al, (2000), made this promoter an ideal candidate
for use in the selective elimination strategies reported in this thesis. In addition to its
regulated expression in undifferentiated ES cells, Tzukerman et al, (2000) also
demonstrated that activation of telomerase is a major mechanism in the molecular
pathogenesis of most, but not all, malignant tumours. Up-regulation of hTERT in
80-90% of the malignancies (Kim et al., 1994) provides a potential way of
controlling cells that revert back to an undifferentiated state or become neoplastic
after transplantation of therapeutic cells in vivo.
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Octamer Binding Protein 4 COct-4)
The Oct-4 gene encodes a transcription factor belonging to the POU (Pit, Oct, Unc)
family of domain transcription factors. The POU domain is a bipartite DNA-binding
domain which, in the case of Oct-4, binds to an octamer sequence motif present in
the promoter or enhancer regions of target genes, thereby regulating their expression
(Nordhoff et al., 2001; Hansis et al., 2000; Nichols et al., 1998). Oct-4 expression
has been reported to be specific to ES cells, preimplantation embryos, epiblasts and
germ cells (Okamoto et al., 1990; Scholer et al., 1989). In mice, Oct-4 expression
has been demonstrated to be essential in the zygote for establishment of the
pluripotent stem cell population in the ICM (Nichols et al., 1998). At gastrulation,
Oct-4 expression is down-regulated in an anterior-posterior pattern. The only cells
maintaining Oct-4 expression after this stage are primordial germ cells (PGC's),
arising at day 7.2 of mouse development (reviewed by Pesce & Scholer, 2001).
Expression of Oct-4 is maintained in female germ cells until the initiation of sexual
differentiation of the gametes and meiosis at 13-14dpc and until the beginning of
spermatogenesis in the newborn male (reviewed by Pesce & Scholer, 2001).
Oct-4 is one of the key regulators of pluripotent and germ line cells, maintaining
them in the cycle of totipotency. Mouse embryos and ES cells that have an inactive
Oct-4 gene lose their pluripotency and spontaneously differentiate into trophoblast
lineages (Niwa et al., 2000). However, over-expression of Oct-4 is unable to
maintain ES cells in a state of self-renewal; in fact a two-fold increase in Oct-4 was
sufficient to induce differentiation into primitive endoderm and mesoderm, while
repression of Oct-4 leads to loss of pluripotency and dedifferentiation to
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trophoectoderm (Niwa et al., 2000). Thus it is the absolute level of Oct-4 that
controls cell fate.
In addition to murine ES cells, Oct-4 mRNA has also been reported in human EC
cells (Schoorlemmer et al., 1995) and undifferentiated ES cells of non-human
primates (Mitalipov et al., 2003) and humans (Reubinoff et al., 2000). Sequence
comparison of the promoter/enhancer regions of the human Oct-4 gene with that of
the mouse ortholog revealed a common organisation of e/.v-regulatory elements
(Nordhoff et al., 2001). Since the expression pattern of human Oct-4 was
comparable to that of the mouse it was suggested that Oct-4 might have a similar
function in preventing human totipotent embryo cells from differentiating (Hansis et
al., 2000). In accordance with this hypothesis, as in murine EC and ES cells (Wang
& Schultz, 1996; Rosner et al., 1990) Oct-4 expression has been shown to be down-
regulated in primate ES cells, following differentiation (Mitalipov et al., 2003;
Reubinoff et al., 2000; Kraft et al., 1996; Schoorlemmer et al., 1995) and
inactivation of the Oct-4 gene, through RNA interference for example, leads to
spontaneous differentiation of ES cells (Zaehres et al., 2005; Matin et al., 2004; Hay
et al., 2004).
Taken together, these data show that Oct-4 is not expressed in terminally
differentiated cells but is highly expressed in pluripotent cells, making the Oct-4
promoter another candidate, in this project, for restricting the expression of desired
cell surface marker genes, to undifferentiated human ES cells.
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Nanog a homeoprotein capable of maintaining self-renewal
Initially, the need for the addition of LIF to maintain murine ES cells in their
undifferentiated state led researchers to believe that it and the LIF
receptor/gpl30/STAT3 pathway were fundamental for the maintenance of self-
renewal. However, a number of mutant mice, deficient in components of the LIF
pathway, formed normal ICMs (Nichols et al., 2001) and furthermore, self-renewal
of human ES cells have been shown to be LIF independent (Amit et al., 2000;
Reubinoff et al., 2000) suggesting that LIF is not fundamental for all self-renewal.
This theory was confirmed with the identification and characterisation of the
homeoprotein Nanog, which was able to maintain self-renewal in murine ES cells
independently of the LIF/gpl30/STAT3 pathway (Chambers et al., 2003; Mitsui et
al., 2003). Nanog mRNA has since been found in EG cells of mouse and in human
EC and ES cells (Zaehres et al., 2005; Ginis et al., 2004; Chambers et al., 2003).
Constitutive expression of Nanog, maintains murine ES cells in an undifferentiated
state in the absence of LIF, while knockout and knockdown studies have shown that
both mouse and human ES cells spontaneously differentiate without Nanog in
conditions that would otherwise support undifferentiated growth (Zaehres et al.,
2005; Chambers et al., 2003; Mitsui et al., 2003). Furthermore, when RNA
interference was used to knockdown either Oct-4 or Nanog separately in human ES
cells, a corresponding down-regulation of the opposite protein was observed,
indicating a reciprocal co-ordination of the expression of Oct-4 and Nanog (Zaehres
et al., 2005). The restricted expression of Nanog provides another potential
candidate to provide ES restricted expression of transgenes.
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Differences in characteristic marker expression between Mouse and Human EC and
ES cells
As with telomerase, Oct-4 and Nanog, restricted expression of the zinc finger
protein, Rexl (Rogers et al., 1991) and the transcription factor, Sox2 (Yuan et al.,
1995) to pluripotent stem cells and preimplantation embryos, have also been
described in human ES cells (reviewed by Ginis et al., 2004). However, expression
of cell surface carbohydrate stage specific embryonic antigens (SSEA-) -1,-3 and -4
differ between murine EC and ES cells and their primate counterparts. Human EC
cells and all primate ES cells have been shown to express high levels of SSEA-3 and
-4, as well as tumour recognition/rejection antigens (TRA) -1-60 and -1-80, when in
their undifferentiated state (Reubinoff et al., 2000; Thomson et al., 1998; Thomson
et al., 1996; Thomson et al., 1995; Andrews, et al., 1985). Upon differentiation of
human EC and ES cells, expression of these cell surface proteins is rapidly down-
regulated while expression of SSEA-1 is transiently up regulated (Draper et al.,
2002). By contrast, mouse EC and ES cells do not express TRA-1-60 or TRA-1-81
and expression of the SSEA markers has the reverse pattern to human EC and ES
cells, with positive SSEA-1 expression while undifferentiated and up regulation of
SSEA-4 upon initiation of differentiation. Despite these differences in cell surface
markers between ES cells from human and mouse, human ES cells have been shown
to have cell surface markers characteristic of the developing human embryo,
implying that the observed differences are probably species related (Henderson et al.,
2002). Although interestingly, undifferentiated human EG cells displaying positive
expression of TRA-1-60, TRA-1-81, SSEA-1 and -4, but are negative for SSEA-3
(Pan et al., 2005; Park et al., 2003; Shamblott, et al., 1998).
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Evidence for the restricted expression of genes, such as telomerase, Oct-4 and Rex-1
etc., to preimplantation embryos, germ cells and pluripotent ES cells, provides an
opportunity to use the promoters of these genes to drive lineage specific expression
of reporter genes, which can then be used to identify undifferentiated ES cells in
vitro (Gerrard et al., 2005; Eiges et al., 2001). Furthermore, the presence of
endogenous cell surface epitopes that are naturally down-regulated upon
differentiation provides an opportunity to assess the ability of these epitopes to
identify undifferentiated human ES cells from a mixed population. This thesis will
explore the potential of such ES specific characteristics to selectively eliminate
undifferentiated human ES cells from within a mixed population as a method of
removing the tumorigenic risk associated with ES-derived therapy.
1.3.5.3 Genetic Manipulation ofHuman ES Cells
Although there is a risk of malignancy associated with human ES cells, their
indefinite growth in culture provides a unique opportunity to manipulate to some
extent their fate, which means they continue to be a useful tool for the development
of regenerative medicine. In 2001, Eiges et al. reported the first transgenic human
ES cells, which carried the green fluorescent protein (GFP) gene under the
transcriptional control of the Rexl promoter (Eiges et al., 2001). In this paper the
authors described a comparison of a number of different techniques for delivering
foreign DNA into ES cells, and assessed their efficiencies. By contrast to mice,
where electroporation was found to be the method of choice for DNA delivery into
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ES cells, Eiges et al., (2001) reported that the most efficient method in human ES
cells was the polyethylenimine, ExGen 500. Consequently, there are a number of
reports in the literature documenting the use of Exgene 500 for the transfection of
human ES cells, however the majority of these reports originate from the Benvenisty
Laboratory (Urbach et al., 2004; Lavon et al., 2004; Schudiner et al., 2003; Eiges et
al., 2001), with other researchers choosing cationic lipids such as FuGene 6 and
Lipofectamine 2000, untested by Eiges et al., (2001), as their method of choice to
genetically modify human ES cells (Hay et al., 2004; Park et al., 2003; Zwaka &
Thomson, 2003; Lebkowski et al., 2001).
The use of cationic reagents for the transfection of human ES cells significantly
increased cell survival compared to electroporation (personal observation).
However, a disadvantage of these techniques was the high incidence of multicopy
arrays at the site of integration (Pells S., and Priddle H., unpublished data). There
are a number of reports, especially in plants and Drosophila, which demonstrate gene
silencing from a transgenic locus when repeat copies of a transgene are arranged as a
concatameric array (reviewed by Hcnikoff, 1998). It was hypothesised that
reconfiguration of heterochromatin, initiated by the integration/repositioning of
multiple copy arrays of euchromatic genes near to a region of heterochromatin, was
responsible for the mosaic gene expression pattern, often referred to as position-
effect variegation (PEV) (reviewed by Weiler & Wakimoto 1995).
To determine whether the same was true in the mammalian system, Garrick et al.,
(1998), developed a strategy to test this hypothesis. Using the Lox/Cre system of
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site-specific recombination the authors generated transgenic mice containing
different copy numbers (>100, 5 and 1 copy) of a P-galactosidase transgene. This
allowed specific analysis of variations in P-galactosidase expression as a direct result
of copy number by eliminating variation as a result of position effects. The report
clearly demonstrated that a reduction in copy number significantly increased
transgene expression (Garrick et al., 1998). In accordance with this work, McBurney
et al., (2002) also described evidence of repeat induced gene silencing (RIGS) in
murine EC cells, however, in addition to RIGS, this report demonstrated that gene
silencing of a single transgene copy also occurred with time in culture. The authors
described how the addition of inhibitors of histone deacetylase temporarily prevented
gene silencing, until they were removed, suggesting that there is an alternative
method to RIGS by which transgenes are silenced (McBurney et al., 2002).
The effects of PEV, often associated with random integration of transgenes, can be
successfully overcome, through the use of gene targeting. The inclusion of sequence
homology in the transgenic construct can be used to target the integration of a
transgene into a specific locus, possibly pre-characterised to have stable expression.
In 2003, Zwaka and Thomson reported the first example of homologous
recombination in human ES cells. In this report the authors indicated that chemical
transfection reagents (ExGen 500 and FuGene 6) were unsuccessful for homologous
recombination and reported the first successful application of electroporation for
human ES cells (Zwaka & Thomson, 2003). However, in 2004, Benvenisty's group
reported the production of a model of Lesch-Nyhan Disease, through gene targeting
of male human ES cells at the HPRT locus, using ExGene 500 (Urbach et al., 2004).
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The disadvantage of gene targeting, over the use of random integration of transgenes,
is the frequency at which homologous recombination events take place. In the two
reports mentioned above absolute targeting efficiencies ranged from as low as
0.2x10"7 using ExGene 500 (Urbach et al., 2004) to the maximum efficiency of
4.0x10"7 following electroporation (Zwaka & Thomson, 2003), compared to a
random transfection efficiency of between lxlO"6 and 2.3xl0"5 respectively.
Another strategy to overcome PEV that has received significant interest over recent
years is the use of viral transduction, in particular the use of lentiviral vectors (Martin
et al., 2005; Gropp et al., 2003; Ma et al., 2003) or adenoviral (Ad) or adeno-
associated viral (AAV) vectors (Smith-Arica et al., 2003). However, although viral
transduction has been reported to be both highly efficient and stable (Martin et al.,
2005; Gropp et al., 2003; Ma et al., 2003), there are a number of issues which
hamper its routine use; 1) their limited capacity for DNA content, approximately 8kb
for lentivirus and only 4.5kb for AAV, 2) that viral methods may induce immune
responses and engender the possibility of recombination/mutation between vector
and recipient DNA in vivo and 3) the associated need for complex preparations of the
viral vectors and designated work areas to ensure their safe use.
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1.4 The Risk of Tumorigenesis
The tumorigenic potential of undifferentiated ES cells is known to be significant
following subcutaneous injection into SCID mice resulting in the formation of
teratomas (Reubinoff et al, 2000; Thomson et al, 1998; Thomson et al., 1995; Evans
& Kaufman, 1981). However, in vitro differentiation prior to transplantation reduces
this risk and there are now a number of reports showing successful engraftment of
ES-cell derivatives, in the absence of teratoma formation (Keirstead et al., 2005;
Abraham et al., 2004; Li et al., 2003; Kim et al., 2002; Zhang et al., 2001; Reubinoff
et al., 2001; Briistle et al., 1999; McDonald et al., 1999). Interestingly, all of these
reports share a common factor: the transplants are all xenogenic, either mouse to rat
or chicken, or human to rat or mouse. Homologous, mouse-to-mouse, engraftments
have been reported in the literature as being successful. Lumelsky et al. (2001)
reported survival and positive staining for insulin from ES-cell derived islet-like cells
in diabetic mice for up to 6-weeks post transplantation; Klug et al. (1996) reported
stable intra-cardiac grafts from differentiated ES-cells in adult dystrophic mdx mice
for up to 7-weeks and Perlingeiro et al., (2001), reported contribution of ES-derived
haematopoietic cells to the bone marrow, peripheral blood and spleen when injected
into irradiated mice. Unfortunately, however, these reports did not discuss the
presence or absence of teratomas, and there is a growing body of evidence that has
demonstrated the occurrence of teratomas at high frequency when homologous
transplants of ES-derived cells are used (Asano et al., 2003; Erdo et al., 2003;
Wakitani et al., 2003).
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In 2002, Hoehn et al., demonstrated that undifferentiated murine ES cells
transplanted into the brains of rats, with an experimental induced stroke injury, could
migrate to a site of injury and undergo appropriate differentiation with no evidence
of teratomas, an observation that has been reported by others (Park et al., 2003;
Bjorklund et al., 2002; Hoehn et al., 2002). The authors hypothesised that the
absence of teratomas in that model was perhaps not related to the differentiation
status of the ES cells, but that it reflected a tumour suppressive effect of the
xenogenic host tissue (Hoehn et al., 2002). In successive work, the group compared
the incidence of teratoma formation in transplantation experiments with murine ES
cells into the xenogenic rat model and into a homologous mouse model of stroke
(Erdo et al., 2003). The authors reported that despite the use of undifferentiated ES
cells, tumorigenesis in the rat was rare, with only 2 out of 22 rat brains displaying
small microscopically visible tumours near the site of implantation. By contrast, 10
out of the 11 mouse brains exhibited large, macroscopic tumours that displayed
characteristics of malignant teratocarcinomas (Erdo et al., 2003). Xenogenic
transplants of human ES cells into SCID mice result in the formation of teratomas,
and are currently used to prove that human ES cells have the potential to differentiate
into cell types representative of all three germ layers, in vivo. This indicates that not
all xenogenic transplants are protected from tumour formation, suggesting that
perhaps mice are more prone to tumours that other animals. To test this, rat ES cells
would need to be transplanted as homologous and xenogenic grafts and the incidence
of tumour formation assessed.
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Interestingly, the report by Erdo et al., (2003) also indicated that tumorigenesis was
induced by as few as 500 undifferentiated (Oct-4 positive) murine ES cells
irrespective of the site of implantation. Furthermore, pre-differentiation of murine
ES cells into neural progenitors, containing less than 0.5% Oct-4 positive cells still
resulted in 86% of the mice developing tumours within 2-weeks of transplantation
into the brain. The report went on to show that within the tumour tissue, the number
ofOct-4 positive cells had increased, implying that undifferentiated cells proliferated
prior to tumour formation (Erdo et al., 2003).
Whether rats have tumour suppressive properties or mice have an increased risk of
tumour formation, any potential for tumour development from therapeutic ES cell
therapy must be addressed and evaluated before any considerations of clinical use
can be pursued.
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1.5 Strategies to Eliminate Potentially Tumorigenic Cells
Recently, two groups have reported selective ablation strategies for ES cells, Fareed
and Moolten (2002) in mouse and Schuldiner et al. (2003) in human ES cells. Both
of these strategies are based upon a toxic gene-therapy approach: the introduction of
the herpes simplex virus thymidine kinase (HSV-tk) suicide gene.
In general a suicide gene encodes an enzyme that is not normally present in
mammalian cells, that converts an inactive prodrug into a toxic product, conferring
sensitivity to that drug. This technique was initially used, with great success, as an
inducible toxin for studying loss of cell function in animal models, since it overcame
the issue of embryo lethality associated with cell function knockouts (Heyman et al.,
1989; Borrelli et al., 1988). HSV-tk is the most extensively studied suicide gene and
has been used in cancer elimination strategies with varying degrees of success
(Kuriyama et al., 1996; Beck et al., 1995; Golumbek et al., 1992; Culver et al.,
1992). The HSV-tk enzyme efficiently phosphorylates the harmless prodrug
ganciclovir (GCV) into a monophosphorylated molecule, which is subsequently
converted by cellular phosphokinases into the toxic triphosphate substrate. The
triphosphate form of GCV is then incorporated into elongating DNA during cellular
division resulting in inhibition of DNA synthesis through chain termination,
therefore, selectively killing dividing cells (Kuriyama et al., 1996; Mar et al., 1985).
Normal mammalian cells are protected from the inactive drug, since GCV is a
relatively poor substrate for their cellular thymidine kinases. Consequently,
concentrations of GCV that are lethal to HSV-tk expressing cells are non-toxic to
wild type cells (Borrelli et al., 1988).
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The transfer of GCV mediated inhibition of DNA synthesis was first reported by
Culver et al., (1992) between HSV-tk+ and HSV-tk" tumour cells (now referred to as
the bystander effect). Since then it has been shown that efficient tumour reduction
can be achieved whether the population contains 10% or 100% HSV-tk transduced
cells (Wu et al., 1994). However, the bystander effect has only been observed when
co-cultures of positive and negative cells were grown at high density and it was
suggested that transfer of the toxic effects ofGCV occurred through physical contact,
probably through gap junctions (Wu et al., 1994; Bi et al., 1993). Furthermore,
transfer of phosphorylaled GCV has been shown not to be restricted to neighbouring
cells of the same cell type or even of the same species, increasing the potential of this
strategy for use in the treatment of cancers (Chen et al., 1995; Wu et al., 1994).
The reports of Fareed and Moolten (2002) and Schuldiner et al., (2003) describe the
use of HSV-tk as a possible fail-safe system against immune pathology,
hyperfunction or the emergence of malignancies as a result of ES-derived grafts.
Fareed and Moolten (2002) demonstrated that undifferentiated mouse ES cells are
highly sensitised to GCV by FISV-tk transduction and that they retain sensitivity,
although to a lesser extent requiring increased concentrations of GCV, when
differentiated along haematopoietic lineages. Consequently, with slightly elevated
concentrations of GCV, still within those approved by the regulatory bodies, ES-
derived grafts, which have developed post-transplantation side effects, could be
selectively removed. In addition, the authors reported that HSV-tk negative murine
ES cells were sensitive to clinically applied levels of GCV in the absence of co-
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culture, suggesting that if gene expression was lost in vivo, the ability to eliminate
undifferentiated ES cells could be maintained using this technique (Fareed &
Moolten, 2002).
In a similar strategy, Schuldiner et al., (2003) recently reported that undifferentiated
human ES cells, which constitutively expressed HSV-tk, were specifically eliminated
in vitro and in vivo when GCV was administered. Established tumours were
significantly reduced in size and lost growth potential as a result of GCV
administration, with no evidence of toxicity to untransduced cells (Schuldiner et al.,
2003). However, the report provided no data to support sensitivity or protection of
differentiated derivatives of these HSV-tk expressing human ES cells and so it is
unknown as to whether, as shown for mice, increased concentrations of GCV would
be required to completely eliminate a therapeutic graft, if the need should arise.
The reports of both Fareed and Moolten, (2002) and Schuldiner et al., (2003)
demonstrate the lack of a "bystander effect" between ES cells. If this were true for
differentiated derivatives of ES cells, then following administration of GCV areas
surrounding the graft would be protected from collateral damage. Alternatively, if
ES cell derivatives do demonstrate a "bystander effect", then should GCV be
administered to control tumour growth this could lead not only to complete loss of
the therapeutic graft, resulting in onset of disease, which would require further
intervention, but could potentially cause further damage to the surrounding tissue.
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The strategy reported in this thesis utilises restricted expression (see section 1.3.5.2)
of a foreign cell surface epitope, which leads to exclusive expression on
undifferentiated, potentially tumorigenic, human ES cells. This epitope can then be
used to specifically eliminate undifferentiated human ES cells from a mixed
population in vitro, or in vivo through either an innate or acquired form of immunity
i.e. vaccination against the foreign epitope.
The advantage of this strategy is that when the elimination strategy is applied in
vitro, functional ES-derived therapeutic cells will be protected from its action, unlike
those reported in the ElSV-tk strategy, which have constitutive expression of the
suicide gene, this reduces the risk of inadvertently transplanting potentially
tumorigenic cells. If part of an ES-derived cell graft led to post-transplantation
malignancy in vivo, using the strategy reported in this thesis, only the malignant part
of the graft would be removed, leaving behind the rest of the graft to function
appropriately. However, with the HSV-tk strategy, elimination of the whole graft
would follow treatment with GCV, which would require further intervention to
prevent onset of disease symptoms.
Immunisation against the foreign epitope has the possibility to provided in vivo
surveillance for undifferentiated, dedifferentiated or malignant cells, which either
evaded in vitro elimination or occurred post-transplant. The advantage of this over
treatment with GCV is obviously the time at which it occurs. Immune surveillance
will be able to tackle emerging malignancies before they become significant or are
clinically detectable, which is when GCV administration would start.
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However, exclusive expression of foreign epitopes to undifferentiated cells is a
strategy that will only eliminate potentially tumorigenic cells, it will not be possible
to remove grafts with hyperfunction or immune pathology using this technique. It is
likely that in the future, combination strategies will need to be developed; with one
elimination strategy that is targeted to removing potentially tumorigenic cells, while
the other strategy is constitutive to the whole graft.
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1.6 Candidate Identification Markers
The strategy used in this project relies upon efficient identification and elimination of
contaminating undifferentiated ES cells from a mixed population. To achieve this
the intention was to express, under the transcriptional control of either the hTERT or
Oct-4 promoter (Section 1.3.5.2), a cell surface marker of foreign origin that could be
used to induce either an in vitro or in vivo immune response or which could be used
in cell sorting techniques.
1.6.1 H2-Kk - a murine major histocompatibility complex antigen
In the mouse the classical class 1 major histocompatibility (MHC) antigens, or H-2
antigens, are encoded at three loci: K, D and L (Drezen et al., 1993; Warner &
Gollnick, 1993). The primary immune function of MHC class I molecules is to
present peptides to CD8+ cytotoxic T-cells allowing them to recognise foreign
molecules in the context of self. In addition, MHC class I molecules are also
responsible for the protection of self-cells from lysis by natural killer (NK) cells
(Drezen et al., 1993).
H-2 is expressed on virtually all mouse tissues; however, there is a level of cell-
specific regulation, with the highest level of expression being observed in lymphoid
organs and the liver, and low expression seen in testis and brain (Drezen et al.,
1993). Furthermore, H-2 expression is developmentally regulated. Initially, a degree
of controversy surrounded expression of MHC class I on preimplantation embryos,
but with the increased sensitivity of quantitative RT-PCR and RIA's (Radio-
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Immuno-Assay) this has since been confirmed (Warner & Gollnick, 1993). Active
H-2 mRNA transcript has been detected as early as the two-cell stage of development
(Jin et al., 2002); however, H-2 cell-surface expression was detectable only at day 10
of gestation, using RIA (Ozato et al., 1985). H-2 mRNA expression increases
dramatically between day 11 and day 13 post coitum, and progressively thereafter,
reaching adult levels at around six-weeks postpartum (Warner & Gollnick, 1993).
MHC has been the subject of intense study over the years, and consequently there are
a number of commercial products available in this area. Miltenyi Biotec Ltd. supplies
a plasmid that contains a truncated version of an H2-K alloantigen, H2-Kk, called
pMACS id. II, and also a selection of IgG2 antibodies against H2-Kk that could be
employed in this investigation. Endogenous expression of H2-Kk is restricted to a
limited number of mouse strains, including AKR/J, CBA/Ca CBA/J, CBA/N,
C3H/Bi and C3H/He, which will be used as positive controls. Strains BALB/cJ or
BALB/cAnN and 129/sv express MHC I of a different haplotype and will be used as
negative controls.
1.6.2 The a-galactosyl (a-gal) epitope and anti-a-gal antibodies
The a-galactosyl epitope (Galal-3Galpl-4GlcNAc-R termed a-gal) is an abundant
(>106 epitopes/cell) carbohydrate structure present on the cell surface of all non-
primate mammals, prosimians and South American monkeys (Galili et al., 1988a;
Galili et al., 1987a). Its synthesis is catalysed by the glycosylation enzyme
al,3galactosyltransferase (al,3Gal) within the trans-Golgi network. The activity of
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a 1,3Gal is to transfers galactose from uridine diphosphate galactose (UDP-Gal) to
the N-acetyl-lactosamine acceptors on carbohydrate side chains of glycoproteins and
glycolipids creating the a-gal epitope:
(Gaip 1 -4GlcNAc-R+UDP-gal ^^'actosyitranstw Gala 1 _3Galp j _4GlcNAc-R+UDP).
The activity of al,3Gal was first described in rabbit bone marrow by Basu and Basu
(1973) and has since been observed in non-primate mammals, prosimians and New
World monkeys (NWM), but not in monkeys of the Old World (OWM), apes or
humans (Galili et al., 1988a). The loss of al,3Gal activity in humans has been
attributed to two prominent mutations within the gene, which have resulted in a
frame shift, leading to a premature stop codon and consequently a truncated protein
(Galili & Swanson, 1991; Larsen et al., 1990). Using comparative genome studies,
DNA from species of hominoids (apes), gorilla, orangutan, OWM, human, NWM
and non-primate mammals has been assessed for the degree of acquired mutations in
the a1,3Gal gene over time (Galili & Swanson, 1991). These studies have indicated
that a 1,3Gal gene suppression was constrained to the Old World, but occurred
independently in apes and monkeys following their divergence less than 28 million
years ago (Galili & Swanson, 1991).
It has been hypothesised that a 1,3Gal gene suppression in ancestral primates resulted
from an extreme selection pressure, probably caused by a pathogen, confined to the
Old World which led Old World primates into near extinction (Galili & Swanson,
1991; Galili et al., 1988a). In support of this hypothesis, expression of a-gal epitopes
has been found on numerous strains of virus, bacteria and some protozoa (Rother &
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Galili, 1999; Galili et al., 1988b; Avila 1999) and in addition there is also evidence
to suggest that toxins, such as enterotoxin A of Clostridium difficile, use cell surface
a-gal epitopes as receptors for their activity (Phelps et al., 2003; Clark et al., 1987).
There are reports of analogous examples of pathogens that have shaped the evolution
of Old World primates, such as Epstein Barr virus (EBV) and geographical variation
in the resistance of humans to pathogens such as the Smallpox virus (reviewed by
Galili, 1999a).
Whatever the evolutionary event that was responsible for the fixation of mutations
within the al,3Gal gene in ancestral primates, it is likely that the transition was not a
gradual process. Fossil evidence from the early Miocene (17-22 million years ago)
shows that there were significantly more species of apes than at the present time, and
that the relative number of individual ape fossils discovered from that period was
high. Conversely after this period, ape fossils began to disappear, becoming very
rare after 7-8 million years ago. It has been speculated that this massive extinction in
the ape population could reflect the event that led to al,3Gal suppression (reviewed
by Galili, 1999a).
Apes, humans and OWM have been shown to produce a high titre of natural anti-a-
gal antibody, which is not present in the sera of non-primate mammals and NWM,
the reciprocal of the al,3Gal gene expression pattern (Galili et al., 1987a; Galili et
al., 1984). Anti-a-gal is the most abundant natural antibody found in humans, the
IgG form of this polyclonal antibody was found at serum concentrations of between
30-70pg/ml, constituting 1% of total circulating IgG (Galili et al., 1984, 1985).
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Furthermore, with the exception of a drop in production between ages 3-6 months,
which corresponds to a decrease in total maternal IgG and the initiation of self-IgG
synthesis, production of anti-a-gal remains constant throughout life reaching adult
levels by age 2-4 years (Wang et al., 1995; Galili et al., 1984). The continuous
production of anti-a-gal throughout life suggested that chronic antigenic stimulation
was responsible for the maintenance of such high antibody titre. In the 1970's it was
shown that natural anti-blood-group antibodies interacted with carbohydrate
structures shared between the normal gastrointestinal bacteria and human blood-
group antigens, and it was suggested that this stimulus was responsible for the
constant production of anti-blood group antibodies (Springer et al., 1971). Through
direct immunostaining and ELISA, anti-a-gal was also found to readily bind to a
variety of E. coli, Klebsiella, Serratia and Salmonella isolates from normal stool
samples, suggesting that gastrointestinal bacteria also provide antigenic stimulation
for the production of anti-a-gal (Galili et al., 1988b). However, although the
production of anti-a-gal antibody remains constant, binding affinity between
individuals varies significantly (as much as 25-fold), with a significant increase in
the amount of low-affinity binding of anti-a-gal antibodies in the elderly, age 70-90
(Oostingh et al., 2003; Wang et al., 1995). The low binding affinity of anti-a-gal is
thought to be due to a lack of ionic bonds between anti-a-gal and the a-gal epitope
although the reason for increased low affinity antibody in the elderly remains
unknown (Galili et al., 1999b).
It has been shown that specificity of anti-a-gal IgG is dependent upon an individual's
blood type. The structure of the blood group-B antigen and a-gal are similar and it
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has been shown that less than 25% of anti-blood group-B antibodies from blood
group-A and -O individuals are specific to the blood group-B antigen, the rest are
cross-reactive anti-a-gal B antibodies (Galili et al., 1987b). It has also been shown
that there is slight cross-reactivity to the blood group-A antigen suggesting that sera
from blood group-0 individuals has the broadest spectrum of anti-a-gal antibody
activity (Galili et al., 1987b). As expected, individuals of blood group-AB or-B have
the narrowest spectrum of anti-a-gal IgG activity, which is specific to the a-gal
epitope; immune tolerance prevents the occurrence of B-lymphocyte clones that
produce cross-reactive anti-a-gal B antibodies, as a mechanism against autoimmunity
(Oostingh et al., 2003; McMorrow et al., 1997; Galili et al., 1987b). It is unclear
whether this blood group dependent difference in the spectrum of anti-a-gal IgG
activity alters the overall titre of antibody able to bind a-gal in the event of immune
challenge (Oostingh et al., 2003; McMarrow et al., 1997; Galili et al., 1984). There
was no evidence of blood group dependent IgM activity (Oostingh et al., 2003;
McMarrow et al., 1997).
The interaction between anti-a-gal antibodies and the a-gal epitope is of major
clinical significance, especially in the field of transplantation. The level of natural
anti-a-gal antibody described thus far, indicates the level of anti-a-gal in response to
a steady state of stimulation by normal gastrointestinal bacteria. However, when
stimulated by the transplantation of non-primate organs or tissues (xenografts), the
level of anti-a-gal IgG production, in particular, increases dramatically resulting in
rapid rejection of the graft, a process termed hyper acute rejection (HAR).
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There is significant evidence to support HAR as a result of a-gal; transplantation of
pig islets to humans for example, increased anti-a-gal IgG production 20- to 200-fold
(Galili et al., 1995; Satake et al., 1994), grafting of pig articular cartilage and
meniscus tissue in cynomolgus monkeys increased anti-a-gal IgG 30- to 300-fold
(Galili et al., 1997), while intravenous infusion of pig bone marrow into baboons
(Kozlowski et al., 1998) and ex vivo perfusion of pig livers in humans (Cotterell et
al., 1995) increased anti-a-gal IgG by 200-fold and 60-fold after 7-21 and 10 days
respectively. Importantly, the observed increases in anti-a-gal antibody production
occurred despite heavy immunosuppression, suggesting that removal of anti-a-gal
antibody from xenograft recipients prior to engraftment would be insufficient to
protect the graft from rejection. Long-term suppression of anti-a-gal antibody
production in graft recipients or suppression of a-gal expression on the donor graft
would be necessary to prevent HAR (Yan et al., 2003; Chung et al., 2003; Sendai et
al., 2003; Phelps et al., 2003; Dai et al., 2002; Sepp et al., 1999). However, both of
these strategies could increase the risk to both the donor and/or the recipient through
infection, since a-gal and anti-a-gal play an important role in protection against
pathogen invasion (Kobayashi & Cooper, 1999).
Although a-gal expression on donor grafts and anti-a-gal antibody production in
recipients is an obstacle for transplantation therapy, in terms of advances in the
treatment of cancers, natural immunity to a-gal expression holds great promise. In
1998, Link et al., reported for the first time that transduction of human cancer cells
with retroviral vectors containing the a 1,3Gal gene, resulting in greater than 90%
specific lysis of infected cells by human serum, showing that pretreated cells failed
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to establish tumours after transplantation into mice (Link et al., 1998). Since then
several other reports have shown that numerous human cancer cell lines can be
efficiently eliminated by human serum following transfection/transduction with the
al,3Gal gene and their ability to establish tumours following treatment can be
reduced (Aubert et al., 2003; Unfer et al., 2003; Sawada et al., 2002; Yoshimura et
al., 2001; Jager et al., 1999). Furthermore, Yoshimura et al., (2001) reported that
lysis of a-gal expressing human pancreatic and hepatocellular carcinomas were
efficient irrespective of the blood type of serum from which the anti-a-gal antibodies
were obtained (Yoshimura et al., 2001). In combination with the possibility of
directed gene therapy of human tumours through the transduction of tumour cells
with a 1,3Gal, there is also the possibility of using a-gal as a method for improving
tumour vaccination technology, by increasing the immunogenicity of tumour
vaccinations. By immunizing al,3Gal knockout mice with irradiated tumours cells
that were engineered to express a-gal on their cell surface, LaTemple et al., (1999),
were able to show an improved protective immune response against the same tumour
cells which lacked the a-gal epitope (LaTemple et al., 1999). Expression of a-gal on
the surface of irradiated tumour cells acted as an opsonin, encouraging phagocytosis
by antigen presenting cells, which in turn led to the presentation of tumour associated
antigens and the stimulation of T-cells towards tumour cells that didn't express a-gal
(LaTemple et al., 1999).
The use of a-gal as a mechanism to initiate cell death directly in transfected cells or
to indirectly target cells through immunization, provides evidence that the response
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to the presence of a-gal epitopes is not restricted to the endothelium of vascularised
tissues and organs, as is the case in HAR.
1.6.3 Cell Surface epitopes endogenous to Human ES cells.
As described in section 1.3.5.2, there are endogenous cell surface epitopes that are
used to characterise undifferentiated human ES cells, namely the stage specific
embryonic antigens-3 and -4 and the tumour recognition/rejection antigens-1-60 and
-1-81.
1.6.3.1 Stage Specific Embryonic Antigens (SSEA-1
Stage specific embryonic antigens (SSEA-) are cell surface markers which are
developmentally regulated (reviewed by Fenderson el al., 1990). SSEA-3 and -4
make up different portions of an extended globoseries oligosaccharide found in
glycolipids and glycoproteins. They are expressed on human EC, ES and EG cells
and on erythrocytes (Henderson et al., 2002; Tippett et al., 1986) as determined by
antibody binding assays with the monoclonal antibodies MC631 and MC813-70
respectively. However, their expression is not necessary indicative of cells with
undifferentiated growth potential. Human EC cells negative for expression of both
SSEA-3 and -4 when transplanted into mice were shown to give rise to malignant
teratocarcinomas. When placed back into culture, EC cells isolated from these
tumours expressed both SSEA-3 and -4 (Andrews et al., 1985). SSEA-1 is a
fucosylated polylactosamine antigen, also referred to as Lewis X antigen (LeX),
which has been found to be expressed on murine EC and ES cells (Muramatsu &
-47-
Chapter 1 - Introduction.
Muramatsu 2004; Fox et al., 1981) on human EG cells (Shamblott et al., 1998) and
transiently on differentiating human ES cells (Draper et al., 2002).
1.6.3.2 Tumour Recognition/Rejection Antigens (TRA-)
Tumour recognition/rejection antigens (TRA-) -1-60 and -1-81 were first described
on the cell surface of human EC cells, and were used as a method of detecting and
evaluating the progression of germ cell carcinomas (Marrink et al., 1991; Andrews et
al., 1984). There are two commercially available antibodies Tra-1-60 and Tra-1-81
(Chemicon) which have been found to bind to different epitopes of a keratan sulphate
proteoglycan on the surface of a number of tumour derived cell lines (Andrews et al.,
1996; Andrews et al., 1984). There is little else known about these antigens, other
than that they are also strongly expressed on human EG cells and undifferentiated ES
cells from primates (Reubinoff et al., 2000; Thomson et al., 1998; Thomson et al.,
1996; Thomson et al., 1995) and that their expression is rapidly lost with
differentiation (Draper et al., 2002).
The expression patterns or SSEA- and TRA- make them ideal candidates for use in
selective elimination strategies for the removal of contaminating undifferentiated ES
cells from a differentiated population. This natural ability of SSEA- and TRA- will
be compared to transgenic identification strategies utilising H2-Kk and a-gal.
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1.7 Eliminating Specific Cell Populations
With the transcriptional regulation of the foreign epitope being controlled by either
hTERT or Oct-4, and the expression of SSEA and TRA- being naturally restricted,
expression should only be observed on undifferentiated human ES cells. Eliminating
only these cells in vitro prior to transplantation would rely on methods of either
specific cell killing or depletion of these cells through cell sorting, while in vivo
elimination would rely upon activation of innate or acquired immunity.
1.7.1 Complement Mediated Cell Lysis
Complement is a major component of the innate immune system, involved in self-
non-self recognition. It is composed of a series of circulating plasma proteins,
distinct membrane-bound receptors and regulatory proteins that work together and
with other cells of the immune system to eliminate foreign cells. Once activated, the
complement cascade plays a pivotal role in the initiation of a number of immune
responses including; chemotaxis of inflammatory cells, enhancement of phagocytosis
by neutrophils and monocytes, facilitation in the clearance of immune complexes and
mediation of cell lysis by the formation of a membrane attack complex (MAC)
(reviewed by Walport, 2001).
1.7.1.1 Complement activation
Activation of complement can be achieved through one of three methods; the
"Classical" antibody-antigen dependent pathway, the "alternative" pathway or the
"lectin" pathway. Non-immune activators, such as susceptible foreign surfaces, i.e.
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bacteria and yeast cell walls, initiate the alternative pathway (reviewed by Song et
al., 2000). Activation via this pathway is an immediate line of defence that requires
no immunological memory and begins the complement cascade by direct cleavage of
C3 (Lambris, 1990). Similarly, the lectin pathway is activated by mannose-binding
lectin (MBL), a serum protein, which binds particular carbohydrates such as
mannose or N-acetylglucosamine on the surface of microorganisms (Turner, 1996;
Kawasaki et al., 1983). While the alternative pathway directly activates C3, in the
lectin pathway, after binding with sugars on bacterial surfaces, MBL associates with,
and activates, specific serine proteases, MBL-associated serine protease (MASP),
which then cleave C4 and C2, activating the classical pathway (1.7.1.2) (reviewed by
Song et al., 2000).
1.7.1.2 Complement Activation via the Classical Pathway
It is the binding of antibody to antigen that was used in this thesis as a method of
initiating complement-mediated lysis. Antigen-bound antibody molecules trigger the
classical pathway of complement activation, either as immunoglobulin (IgG or IgM)
bound directly to a cell surface antigen or as an antigen-antibody immune complex.
Inactive serum protein CI interacts with the Fc portion of either two molecules of
bound IgG or one molecule of bound IgM to form a recognition complex that
initiates the complement cascade. It is only when the antibodies bind to their antigen
that binding sites, known as antibody receptor sites, for Clq are uncovered.
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IgG isotypes vary in their capacity to bind Clq, in humans IgG3 has the greatest
capacity followed by IgGi and IgG2. IgG4 cannot bind Clq and is not a complement-
fixating antibody (Bindon et al., 1988). Once bound, Clq undergoes a
conformational change, which causes two Clr molecules to cleave and activate each
other. Subsequently, these cleave and activate the Cls molecules, which will then
activate the next two complement proteins, C4 and C2, (Figure 1.7.2).
Lipid Bilayer
Figure 1.7.1: Schematic representation of the CI Complement recognition complex. Binding of
antibody to Clq activates Clr and Cls, which leads to cleavage of C4 and C2
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C2b p
Figure 1.7.2: Schematic representation of the formation of C3 convertase. Activated Cls cleaves
C4 into C4a and 4b. C4b binds C2, which is subsequently cleaved by Cls releasing the C2b
fragment. The resulting C4b2a complex is capable of cleaving C3 and hence has been named C3
convertase
Activation of C4 and C2 involves the cleavage of a specific peptide bond within each
molecule, which results in the dissociation of peptide fragments, C4a and C2b, and
the exposure of a binding site in the larger fragments C4b and C2a. The C4b peptide
binds to the cell membrane while C2a attaches to the C4b fragment forming the
C4b2a complex. This complex is enzymatically active and is referred to as C3
convertase, since it binds and cleaves C3, the next inactive complement component.
The C3 convertase is an unstable enzyme and undergoes a time and temperature-
dependent decay, lasting only seconds, unless there is a sufficient quantity of C3
within close proximity of the cell-bound complex to mediate the next stage
(reviewed by Goldsby et al., 2000 & Roitt, 1997).
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Activation of C3 results in the generation of a second convertase enzyme, C5
convertase, which occurs when C3 is cleaved by C3 convertase into C3a and C3b.
The larger fragment C3b attaches both to the cell membrane and to the C3
convertase, creating a catalytic site to accommodate C5 and hence the complex is
named C5 convertase (Figure 1.7.3).
Figure 1.7.3: Schematic representation of the activation of C3: C3 is cleaved by C3 convertase
into C3a and C3b fragments. C3a is released into the circulation where is it involved in the
inflammatory response as an anaphylatoxin. C3b is either bound to the C3 convertase to form
C5 convertase, or it is released, either to be bound directly by the cell membrane or to near by
bacterium as a method of opsonization.
In addition to forming C5 convertase, C3b fragments can also be bound directly to
the cell membrane, activating the alternative pathway or may diffuse away from the
surface (but not more than 40nm) and coat immune complexes, opsonizing them for
the phagocytes. C3 activation signifies an amplification step in the complement
cascade, with a single C3 convertase molecule generating up to 200 molecules of
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C3b, given the opportunity (Figure 1.7.3) (reviewed by Goldsby et al., 2000 & Roitt,
1997).
Whichever initiation pathway activates the complement cascade, formation of C5
convertase signifies the beginning of the same terminal attack sequence (cell lysis),
known as the membrane attack complex (MAC).
1.7.1.3 The Membrane Attack Complex
The membrane attack complex (MAC) is a multimolecular assembly of complement
components C5-C9, which forms as a consequence of complement activation.
Formation of the MAC complex begins with the cleavage of C5 by the C5 convertase
(C4b2a3b), into C5a and C5b. C5a is released once formed into the circulation
where is plays no further part in the complement cascade, instead it has an important
role in inflammation, in the recruitment of phagocytes. C5b on the other hand,
attaches to the cell membrane, uncovering binding sites for C6 and C7, producing a
stable C5b67 complex attached to the cell membrane (Figure 1.7.4). C5b is a very
labile molecule, if it remains unbound by C6 for more than 2 minutes it dissociates
(reviewed by Goldsby et al., 2000).
Binding of C7 to the C5b6 complex results in a hydrophilic-amphiphilic structural
transition, generating hydrophobic binding regions for the membrane phospholipids.
Consequently, the C5b67 complex anchors into the cell membrane, committing
MAC assembly to that membrane site, forming receptors for C8. Flowever, if the
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reaction occurs on a non-cellular activating surface, then the hydrophobic sites
cannot anchor the complex and it is released. Released C5b67 complex can insert
themselves into the membrane of nearby cells, which if uncontrolled, could initiate
an innocent bystander effect (reviewed by Goldsby et al., 2000).
C5a
Figure 1.7.4.Schematic representation of the Membrane Attack Complex (MAC). Binding of
C5b to the membrane acts as an anchor for C6 and C7, which encourages the binding of C8. C8
instigates the formation of small pores, but it is the binding of several C9 molecules which
exaggerates the pores leading to membrane leakiness and death
Binding of C8 instigates the formation of small transmembrane channels of less than
lnm in functional diameter (Ramm et al 1982). These small pores cause the cells to
become slightly leaky, and while they may be sufficient to cause lysis of red blood
cells and nucleated cells (Martin et al., 1987) killing of bacteria requires a more
significant sized pore (Joiner et al., 1985). Each membrane-bound C5b678 complex
acts as a receptor for multiple C9 molecules. The recruitment of several C9
molecules initiates a substantial conformational change in these minor membrane
attack complexes, from a globular, hydrophobic-form to an elongated, amphiphilic-
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form, which spans 7-10nm in diameter, which transverse the membrane and
exacerbates membrane leakiness, leading to cell death as a result of osmotic lysis
(reviewed by Goldsby et al., 2000).
1.7.1.4 Regulation of the Complement System
Although innate immunity is critical in providing a rapid first line of defence, it is
important that it can still recognise self from non-self. Activated complement, if
unregulated, can cause injury to host tissues through a bystander effect (Morgan,
1995). To prevent complement-mediated autologous attack, host tissues express a
number of fluid-phase and membrane-bound regulators of complement (Table 1.7.1)
(Hourcade et al., 1989). The regulation of complement activity focuses on 2 key
stages of the active cascade, the C3/C5 convertase and formation of MAC.
Collectively these regulatory proteins ensure that inappropriate complement
activation does not occur within normal host tissue.
There are three common membrane-bound proteins; membrane co-factor protein
(MCP or CD46), decay-accelerating factor (DAF or CD55), and membrane inhibitor
of reactive lysis (MIRL, most commonly known as CD59), which play an important
role in regulating the complement cascade. The complement regulators DAF and
MCP function to prevent assembly of the C3/C5 convertase enzymes. DAF is an
effective decay accelerator in both the classical and alternative pathways and
functions to block the formation of C3/C5 convertase by rapidly dissociating the
enzymatic component C2a or Bb from membrane bound C4b or C3b respectively.
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DAF has been reported to have a higher affinity for C4b and C3b when they are
complexed with their respective catalytic subunits and therefore recycles from C4b
and C3b sites to active C3 convertase enzymes (reviewed by Meri & Jarva, 1997).
MCP on the other hand has no decay activity but blocks formation of C3/C5
convertase by binding to dissociated C4b or C3b preventing its association with the
enzymatic component C2a or Bb and acting as an efficient cofactor for the serine
protease factor-I, which irreversibly cleaves the C4b and C3b. Finally, CD59
protects cells from non-specific complement-mediated lysis by inhibiting formation
of the MAC. CD59 binds to both C8 and C9 and thus prevents the assembly of the
poly-C9 MAC and insertion into the cell membrane (Fluang et al., 2001; reviewed by
Goldsby et al., 2000; reviewed by Meri & Jarva, 1997).
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DAF and CD59 are expressed on the plasma membrane of unfertilised human
oocytes and preimplantation embryos while expression of MCP does not appear until
the 4-to-8-cell stage, which is thought to coincide with genomic expression of the
preimplantation human embryo (Fenichel et al., 1995). Interestingly, all three of
these complement regulators are expressed at the blastocyst stage of development,
the stage at which ES cells are isolated (Fenichel et al., 1995).
Following the demonstration that DAF, MCP and CD59 were highly expressed on
foetal derived trophoblasts that come into direct contact with maternal blood and
tissues, it has been suggested that regulators of complement play an important role in
the protection of the human conceptus from maternal complement during pregnancy,
(Holmes et al., 1992; Holmes et al., 1990). In rodents, a fourth complement
regulator, complement receptor 1-related gene/protein y (Crry) is present and
functions to regulate the deposition of C3 and C4 in a similar manner to MCP and
DAF. In knockout studies, Crry deficiency was found to result in embryo lethality as
a consequence of spontaneous activation of C3 and deposition of C3b on the
trophoectoderm and ectoplacental cone (Xu et al., 2000). While the majority of
complement regulation on the developing foetus has been shown to be associated
with expression of regulators by the placenta, arising from the trophoblast cells,
expression of complement regulatory proteins has also been reported early in foetal
development, in the developing liver for example (Simpson et al., 1993) and thus
may be expressed on human ES cells, which could affect the success of selective
elimination strategies that utilise complement-mediated lysis.
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1.7.2 Fluorescence Activated Cell Sorting (FACS)
The power of flow cytometry lies in its ability to analyse several parameters, on tens
of thousands of individual cells within a few minutes, rather than relying on a bulk
measurement from a whole population. The field of flow cytometry began in the
I9301s and was gradually developed to become a commercially available Leclmique
by the mid I970's (reviewed by Radcliff & Jaroszeski, 1998). Fluorescence
activated cell sorting has been used to separate many different cell types (reviewed
by Ormerod, 1999) and has recently been shown to successfully sort undifferentiated
human ES cells (Eiges et al., 2001).
The underlying principle of flow cytometry is that light is scattered and fluorescence
is emitted, as light, from an excitation source, strikes a moving particle. All flow
cytometers, whether for analysis or for cell sorting, function using four basic
systems: fluidic, illumination, optical/electronic and data storage/analysis. The
fluidic system is fundamental to flow cytometry and determines how light from the
illumination system meets the moving particles. Briefly, sheath fluid, usually
phosphate-buffered saline (PBS), is directed by air pressure through a flow chamber
or nozzle, depending on the type of machine. The sample (as a single-cell
suspension) is directed into the stream of sheath fluid and together they pass through
the flow chamber/nozzle, as a sample stream. The pressure of the sheath fluid aligns
the cells in single-file, a process referred to as hydrodynamic focusing, which
consequently enables the light source to intersect individual cells. Illumination in the
majority of flow cytometers comes via a laser beam, which has been directed to
intersect the sample stream. Light scatter and fluorescent light emission occurs in all
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directions (360°) when the focused laser beam strikes a moving particle within the
stream. These signals are then quantified by the optical and electronic system.
Typically, flow cytometers can collect and quantify at least five different parameters.
Two of these parameters are properties of light scatter; forward-angle light scatter
(FSC) and side-angle (90°) light scatter (SSC). FSC is the result of diffraction,
which provides basic morphological information such as relative size. SSC is the
result of refraction and reflection and indicates granularity within the cytoplasm of
cells, which can be indicative of cellular complexity. The remaining three
parameters are associated with fluorescence emission. Most available cytometers
allow examination of fluorescence from three different regions of the visible
spectrum, Green (FL1) ~520nm, Orange-Red (FL2) ~570nm and Red (FL3)
~620nm. In this thesis the fluorochromes fluorescein isothiocyanate (FITC) and R-
phycoerythrin (PE) were used as probes, which are detected by the FL1 and FL2
channels respectively.
The final system, which is fundamental in the interpretation of flow cytometry
experiments, is data analysis and presentation. The most common form of display
for flow cytometry data is as a histogram. Histograms are used to display data from
a single parameter and are very simple to interpret. Overlaying histograms can be
used to effectively assess small differences in a single parameter between many
different samples, as long as the data from the independent samples was acquired
using the same parameter settings. In addition, data is often displayed either as a dot
plot, which indicates individual events, or as a contour density plot, which shows
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data for a population of cells using a series of concentric lines. The power of these
two plots is that they allow the investigator to visualise two parameters (e.g. FSC and
SSC or FL1 and FL2 fluorescence) simultaneously.
There can be a number of pit-falls with data generated by flow cytometry, if the
experimental design was not carefully planned. The most important aspect of
experimental design for flow cytometry is ensuring that the cytometer is
appropriately configured. In order to obtain meaningful results, it is imperative that
negative and positive experimental controls are used as reference points. Generally
two negative control samples are required; one contains just the cell sample and is
used to position the cells of interest, by adjusting the FSC and SSC, so that they
appear on scale, while also setting a baseline for any cellular autofluorescence. The
second negative control sample is used in situations where fluorochrome-conjugated
antibodies are used as probes. Here the cell sample is treated either with a directly
conjugated isotype control antibody, which has all of the properties of the
monoclonal antibody but which is non-specific, or with the same secondary
fluorochrome-conjugated antibody used for indirect staining but in the absence of the
primary antibody. These negative controls can either be used to subtract non-specific
fluorescence from the fluorescence values of experimental samples, or they can be
used to determine a fluorescence threshold for judging positive/negative expression
of the antigen of interest. In addition to negative controls, it is important that a
positive control is also included; usually this takes the form of a cell line, which is
known to stain strongly with the antibody of choice. Positive controls a) ensure the
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success of labelling protocols and b) they provide an approximation of the
fluorescence intensity that positively expressing experimental cells might have.
Analysis by flow cytometry using two or more fluorochromes has inherent
complications that must be controlled for. Usually a fluorochrome will emit a
spectrum of light that is strongest in a narrow bandwidth that corresponds to a
defined detection channel. In addition weaker emission outwith the detection range
will also be obseived. It is this light emitted outside of the detection range of a
particular channel that can cause complications when combinations of different
fluorochromes are used for analysis. A consequence of overlapping spectral
emission ranges is the detection of false-positives. This can be overcome by
selecting fluorochromes that have minimal spectral overlap, or alternatively the
cytometer can be adjusted electronically to compensate for spectral overlap.
Compensation relies on controls, identical to the one being labelled with
combinations of fluorochrome, which have been stained only with a single label.
These controls are then analysed by the inappropriate channel, and the cytometer is
adjusted to subtract any crossover fluorescence.
In addition to ensuring that the cytometer is appropriately configured there are also a
number of other potential problems that investigators should be aware of. For
example, investigators should be aware of the occurrence of false positives, which
can result from the use of supra-optimal levels of fluorochrome-conjugated antibody.
Antibodies should always be titrated on a positive control cell line and also on the
experimental cell suspension, before they are used experimentally in flow cytometry.
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Supra-optimal levels of antibody could result in the misinterpretation of experimental
shifts in the mean peak values as a result of non-specific binding. In addition, when
a sample suspension is very concentrated cells may exit the flow chamber/nozzle
together and there may not be enough distance between them for the cytometer to
resolve a single event at a time. This problem is referred to as coincidence, and can
be avoided by either diluting the single cell suspension or by reducing the rate at
which the sample passes through the cytometer.
When properly controlled, flow cytometry is a powerful tool for the collection of
vast quantities of analytical data in a short space of time. In the case of rare events it
is important that large numbers of events are processed at one time and that small
changes are repeatedly observed before strong conclusions are drawn. However, cell
sorting by flow cytometry could be a powerful alternative to complement-mediated
lysis as a method for selectively removing minority populations of undifferentiated
ES cells from a mixed population in vitro.
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1.8 Project Objectives
A potential barrier to the clinical application of human ES-derived cells in
regenerative medicine is the co-inoculation of undifferentiated human ES cells, with
tumorigenic potential. The application of human ES-derived cell therapy therefore,
requires the development of efficient strategies for the removal of undifferentiated
ES cells from within a potentially therapeutic population. To address these concerns:
1) Engineered clones of undifferentiated human ES cells expressing defined
cell-surface epitopes under the transcriptional regulation of hTERT or Oct4
promoters were isolated.
2) These clones were then used to investigate the use of complement-mediated
lysis or cell sorting strategies for the elimination of contaminating
undifferentiated ES cells from within a mixed population of human ES-
derived cells. The efficiency of these strategies was verified by subsequent
culture and analysis of recovered cells for the presence of undifferentiated ES
cells.
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MATERIALS
METHODS
2.1 Bacterial Transformation & Culture
2.2 Preparation of Plasmid DNA
2.3 DNA Manipulation and Subcloning
2.4 Maintenance of Cells in Culture
2.5 Estimation of Cell number
2.6 Storage of Cells
2.7 Manipulation of Cell Lines: Methods of Transfection
2.8 Characterisation ofNormality and Pluripotentiality ofHuman ES cells
2.9 Analysis of Gene Expression
2.10 Strategies for the Selective Elimination ofHuman ES Cells
MATERIALS
All chemicals used were analar grade and purchased from BDH or Sigma unless
otherwise stated.
Bacterial Transformation & Culture
Luria-Bertani (LB) Medium
1% Bacto-tryptone (Difco), 0.5% Bacto-yeast extract (Difco), 125mM Sodium
chloride (NaCl).
LB-Agar
LB medium containing 1.5% agar (Difco).
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SQC-medium
2% Bacto-tryptone, 0.5% Bacto-yeast extract, lOmM NaCl, 2.5mM potasssium
chloride (KC1), 20mM Mg2+ stock (1M MgCl26H20/ 1M MgS047H20) and 20mM
glucose (Fisons).
Ampicillin Selection
Stock solution 50mg/ml used at concentrations of 50-100pg/ml
Kanamycin Selection
Stock solution lOOmg/ml used at concentrations of 30-50pg/ml
Preparation of Plasmid DNA
Mini Prep Solutions (Promega)
Cell Resuspension Solution (Promega)
50mM tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) pFI 7.5, lOmM
ethylenediaminetetraacetic acid (EDTA) and lOOpg/ml RNase A
Cell Lysis Solution (Promega)
200mM sodium hydroxide (NaOH), 1% (w/v) sodium dodecyl sulphate (SDS)
Neutralising Solution (Promega)
1.32M potassium acetate pH 4.8
Column Wash Solution (Promega)
80mM potassium acetate, 8.3mM Tris-HCl pH 7.5 40pm EDTA, 55% absolute
ethanol
Maxi Prep Solutions (Qiagen)
Re-suspension buffer PI (Qiagen)
50mM Tris-HCl pH 8.0, lOmM EDTA and lOOpg/ml RNase A
Cell lysis buffer P2 (Oiagen)
200mM NaOH, 1% SDS (w/v)
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Neutralisation buffer P3 (Oiagen)
3M Potassium acetate pH 5.5
Equilibration buffer OBT (Oiagen)
750mM NaCl, 50mM 3-[N-morpholino]propanesulfonic acid (MOPS) pH 7.0, 15%
isopropanol (v/v) and 0.15% Triton X-100 (v/v)
Column Wash buffer OC (Oiagen)
1.0M NaCl, 50mM MOPS pH 7.0 and 15% isopropanol (v/v)
Elution buffer OF (Oiagen)
1.25M NaCl, 50mM Tris-HCl pH 8.5 and 15% isopropanol (v/v)
TE Buffer
lOmM Tris-HCl pH 8.0 and ImM EDTA.
DNA manipulation and Subcloning
Restriction Digest
Buffer H (Roche)
500mM Tris-HCl, 1M NaCl, lOOmM magnesium chloride (MgCh), lOmM
Dithioerythritol, pH 7.5 at 37°C
SEBuffer B (SibEnzyme)
lOmM Tris-HCl, lOmM MgCl2, ImM dithiothreitol (DTT) pH 7.6 at 25°C
Agarose Gel Electrophoresis
IPX TBE Buffer
0.89M Tris-HCl pH8.0, 0.89M borate and 0.02M EDTA
Type III DNA Loading dye (6X1
0.25% bromophenol blue, 0.25% xylene cyanol and 30% glycerol
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Gel Purification (OIAquick)
Elution Buffer (Qiagen)
lOmM Tris-HCl, pH 8.5
Cell Culture
Maintenance of Cell Lines
Sterile Phosphate Buffered Saline [PBS]
0.16M NaCl, 0.003M KC1, 0.008M disodium hydrogen phosphate and 0.001M
potassium dihydrogen phosphate in distilled water, supplied in tablet form (Oxoid).
Reconstituted in distilled water (dH^O) and autoclaved prior to use.
Trypsin/EGTA (TEG) Solution.
92.7mM NaCl, 0.845mM di-sodium hydrogen orthophosphate (Na2HP04), 1.58mM
potassium dihydrogen orthophosphate (KH2PO4), 4.46mM KC1, 5mM D-glucose
(Fisons), 22.28mM Tris-HCL, 0.0009% Phenol red, 0.25% trypsin, 1.05mM
ethylenebis(oxyethylenenitrilo)tetraaceetic acid (EGTA) and 0.000105% polyvinyl
alcohol, in distilled water. Adjust pH to 7.6.
EDTA/PBS
0.5mM EDTA in sterile PBS and filter sterilised.
Collagenase IV
234U/mg collagenase IV (Gibco) in KO-DMEM (lmg/ml) filter sterilised.
Trypsin/EDTA (TED) Solution (Sigma)
0.5g/l porcine trypsin and 0.2g/l EDTA in Hanks' Balanced Salt Solution with
phenol red
Basic Fibroblast medium
Dulbecco's modified eagles medium (DMEM; Sigma) supplemented with 10%
(v/v) foetal bovine serum (FBS; Globepharm), O.lmM Non-Essential Amino Acids
(NEAA; Gibco) and 2mM L-glutamine (Gibco).
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Basic human ES medium
Knock-Out (KO) DMEM (Gibco) supplemented with 20% (v/v) KO-serum
replacement (Gibco), 0.1mM NEAA, 2mM L-glutamine and 0.1mM P-
mercaptoethanol (Gibco). Recombinant human basic fibroblast growth factor
(hbFGF; Sigma) was added fresh at 4ng/ml.
Quench medium
KO-DMEM supplemented with 10% (v/v) FBS.
PDFF medium
Glasgow's minimum essential medium (GMEM; Sigma) supplemented with 10%
(v/v) FBS, 2mM L-glutamine and 0.1mM NEAA
RPMI- complete medium
Roswell Park Memorial Institute Medium 1640 (RPMI-1640; Sigma) supplemented
with 10% (v/v) FBS and 2mM L-glutamine
Complete 199 Medium
Medium-199 (Sigma) supplemented with 10% (v/v) FBS, O.lmM NEAA and 2mM
L-glutamine
lx Penicillin/Streptomycin
lOOU/ml penicillin and lOOpg/ml streptomycin, purchased in solution from Gibco.
2x Freeze mix
Specific for each cell line, but in general 50% (v/v) complete culture medium
supplemented with 30% (v/v) serum and 20% dimethyl sulfoxide (DMSO) (Table
2.6.1).
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G418 (geneticin)
Stock solution made by dissolving G418 Sulphate (PAA Lab, GmbH Austria) in




KO-DMEM supplemented with 10% (v/v) FBS, 0.1mM NEAA, 2mM L-glutamine
and 0.1mM p-mercaptoethanol.
Osteogenic Differentiation Medium
Basic differentiation medium supplemented with lOmM P-glycerophosphate 50pM
ascorbic acid and 0.1 pM dexamethasone.
Cytogenetic Analysis
Hypotonic Solution
0.56% (w/v) KC1 in distilled water.
2XSSC
0.3M Sodium chloride and 0.03M tri-sodium citrate dissolved in distilled water.
Giemsa stain




40% (v/v) heat inactivated rabbit serum in FACS staining buffer
FACS Staining Buffer
PBS supplemented with 2% (v/v) FBS and 2mM EDTA
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Immunochemistry
Paraformaldehyde
10% (w/v) paraformaldehyde (PFA) was dissolved in heated PBS as a stock
solution. Dilutions to 4%, 1% and 0.1% were made in PBS for experimental use.
With Antibody
Blocking serum
10% (v/v) normal serum (as appropriate) in PBS supplemented with 0.1%
polyoxyethylene sorbitan monolaurate (Tween-20). Blocking serum was diluted
1:10 (1%) for antibody dilutions
With Lectin
Wash Solution
9+ 9+ • •
Complete sterile PBS (containing Mg /Ca ) supplemented with 1% (v/v) bovine
serum albumin (BSA; Gibco).
BS-IBj Stain
200pg of fluorescein isothiocyanate conjugated Bandeiraea simplicifolia isolectin
B4 (BS-IB4; Sigma) dissolved in complete PBS supplemented with 10% (v/v)
newborn calf serum (NCS) to a final concentration of 5pg/ml. For flow cytometry
PBS minus Mg2+/Ca2+ was used.
With Giemsa
Giemsa (BDH) was diluted to 10% in water.
With Acridine Orange and Ethidium Bromide (AO:EtBr)
AO:EtBr solution
lOmg/ml stock solutions of acridine orange and ethidium bromide (Sigma) diluted
in complete PBS to 0.2mg/ml
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Protein Analysis
Protein Lysis Buffer
50mM Tris-HCl pH7.6, 140mM NaCl and 1% (v/v) Triton-X 100, in sterile
distilled water. Immediately prior to use, one protease inhibitor cocktail tablet
(Roche) was dissolved in lOmls of lysis buffer.
2X SDS loading buffer
lOOmM Tris-HCL pH6.8, 4% SDS, 0.2% bromophenol blue and 20% glycerol in
distilled water. 200mM dithiothreitol (DTT; Biorad) was added as appropriate.
IPX Tris-Glycine Running Buffer
250mM Tris-HCl, 2.5M glycine and 1% SDS pH adjusted to 8.3 with concentrated
hydrochloric acid (HC1) in distilled water.
Western Transfer Buffer
0.5M Tris-HCl, 3.84M glycine pH adjusted to 8.3 with concentrated HC1 in
distilled water. 20% methanol added to IX buffer prior to use.
Immunoblotting Blocking solution
5% (w/v) skimmed milk powder (Marvel) with 1% (v/v) FBS, 1% (v/v) BSA and
0.1% (v/v) Tween-20 in PBS.
Immunoblotting Wash Solution
0.1% Tween-20 in PBS
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METHODS
2.1 Bacterial Transformation & Culture
2.1.1 Bacterial Strains
In the course of this thesis a variety of bacterial strains were used to perform specific
functions. Subcioning efficiency DH5a competent cells (Invitrogen) and XL 1-Blue
competent or subcioning grade competent cells (Stratagene) were used
interchangeably for routine circular plasmid transformation and following simple
cloning steps such as small or sticky ended insert ligations. However, following
complex cloning steps of large fragments or blunt ended inserts, XLIO-Gold
ultracompetent cells (Stratagene) were used.
2.1.2 Transformation ofCompetent Bacteria
The following is an example of a transformation protocol, however, there are discrete
differences in the protocol for the different bacterial strains and these can be found in
Table 2.1.1.
Ultracompetent cells (Epicurian Coli, XLIO-Gold, Strategene) were thawed slowly
on ice. The cells were dispensed into pre-cooled 1.5ml microcentrifuge tubes
containing lOOpl volumes to which 4pl of P-mercaptoethanol (Strategene) was
added. The cells were incubated on ice for 10 minutes, with gentle mixing every 2
minutes. 2pl of a ligation reaction or plasmid DNA was added to one tube and as a
control 2pl of pUC18 DNA was added to a second tube. Tubes were then incubated
on ice for 30 minutes before being exposed to a 30 second heat shock at 42°C. The
tubes were then returned to ice for a further 2 minutes before adding 900gl of pre-
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heated (42°C) SOC medium. Tubes were then incubated at 37°C for lhour with


















DH5 a 50pl None 20 min 20 sec 37°C lhr
XL 1-Blue
competent lOOpl 1.7pl (supplied)




50pl None 20 min 45 sec 42°C 30 min
XLIO-Gold lOOpl 4pl (supplied) 30 min 30 sec 42°C 1 hr
Table 2.1.1: Specific bacterial strain differences in transformation protocol.
2.2 Preparation of Plasmid DNA
2.2.1 Small Scale (Mini) Preparation
Small scale DNA isolation was performed using the Wizard Plus Minipreps System
(Promega). Plasmid DNA was extracted from individually picked bacterial colonies
incubated for 12-16 hours in a 15ml polypropylene tube containing 3-5ml of LB
medium supplemented with an appropriate antibiotic at 37°C with gentle agitation at
180rpm.
Cultures were harvested by centrifugation (10,000g; lOminutes) and the supernatant
discarded. Bacterial pellets were re-suspended in 300pl of resuspension solution and
transferred to 1.5ml microcentrifuge tubes prior to the addition of an equal volume of
cell lysis solution. The suspension was mixed gently by inversion and incubated at
room temperature for 5 minutes. The addition of neutralising solution (300pl)
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stopped the lysis reaction before centrifugation (10,000g; 5 minutes; room
temperature). The supernatant (clear lysate) was passed through a resin solution in a
mini-column/syringe assembly, by vacuum, and the flow-through discarded. The
columns were then washed with 2ml of column wash solution, again by vacuum and
the flow-through discarded. The columns were transferred to 1.5ml microcentrifuge
tubes and excess column wash removed by centrifugation (10,000g; 1 minute; room
temperature). DNA was eluted by the addition of lOOpl of sterile dH20 and
centrifugation (10,OOOg; 1 minute; room temperature).
2.2.2 Large Scale (Maxi) Preparation
Large scale DNA isolation was performed using the Qiagen Plasmid Maxi Kit
(Qiagen) this procedure is designed to yield 500pg of DNA. A single bacterial
colony, grown on selective LB agar plates, was picked and used to inoculate a 3ml
starter culture of selective LB medium in a 15ml polypropylene tube. This culture
was incubated at 37°C with gentle agitation (180rpm) for 8 hours before being used
to inoculate 100ml selective LB medium, which was grown for 12-16 hours (with
agitation (180rpm) at 37°C).
Cultures were harvested by centrifugation (6000g; 15 minutes; 4°C) and the
supernatant discarded. The bacterial pellet was resuspended in 10ml of chilled (4°C)
resuspension buffer Pl. Following resuspension, 10ml of cell lysis buffer P2 was
added and mixed by gentle inversion and incubated at room temperature for 5
minutes. Chilled (4°C) neutralisation buffer P3 (10ml) was added mixed thoroughly
by gentle inversion and incubated on ice for 15 minutes. Cell lysates were collected
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by centrifugation (20000g; 30 minutes; 4°C) and the supernatants filtered through
3MM paper (Whatman). A QIAGEN-tip 500 was equilibrated with 10ml of buffer
QBT and the filtered supernatant was allowed to pass through the QIAGEN-tip
column by gravity. The QIAGEN-tip was then washed twice with 30ml buffer QC
and the DNA eluted with 15ml of buffer QF into a cortex tube. DNA was
precipitated by gently mixing 0.7 volumes of isopropanol (room temperature) to the
elution followed by centrifugation at 15000g for 30 minutes at 4°C. The pellet was
washed with 1ml 70% ethanol (room temperature), collected and transferred to a
1.5ml microcentrifuge tube, before being centrifuged at lOOOOg for 5 minutes. The
70% ethanol wash was repeated and once removed the pellet was air-dried before
being resuspended in 0.5-lml ofTE buffer.
2.2.3 DNA Quantification
Spectrophotometric measurements were used to determine the quantity and quality of
the DNA preparations. Typically a DNA sample was diluted 1:50 with TE buffer
and the absorbance read at 260nm to give the concentration of nucleic acid in the
sample. An OD of 1 corresponds to approximately 50pg/ml of double stranded
DNA. The ratio between readings at 260nm and 280nm provided an estimation of
the purity and hence quality of the DNA preparation. Pure DNA has an OD260/OD280
ratio of 1.8; contamination with protein produces a lower ratio.
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2.3 DNA Manipulation and Subcloning
2.3.1 Restriction Endonuclease Digestion
Plasmid DNA was digested with 5 units of restriction enzyme for every pg of DNA
in a microcentrifuge tube using the supplied manufacturer's buffer and instructions.
Typically the final reaction volume was 50(0.1. Tubes were incubated at the
appropriate temperature, usually 37°C, for 2 hours or until a complete digestion was
observed by agarose gel electrophoresis. Restriction endonucleases were obtained
from either Roche or New England BioLabs Inc (NEB).
2.3.2 Agarose Gel Electrophoresis
Agarose powder was dissolved in IX TBE (0.8-1.2% w/v) by microwave heating and
allowed to cool. Ethidium bromide (0.5pg/ml) was added to the agarose prior to
pouring the gel using horizontal, buffer-immersed electrophoresis gel kit (Anachem).
DNA samples were mixed with 6X Type III loading dye before loading into the lane
wells; at least one lane was reserved for 5pi of molecular weight marker
(Hyperladder Type I, Roche). An electrical current between 30 and lOOvolts was
applied. Following electrophoresis, DNA was visualised using a UV
transilluminator and images captured using Multi-Analyst software (BioRad).
2.3.3 Purification ofDNA fragments from Agarose Gels
DNA fragments were electrophoresed through an agarose gel, excised using a clean
sharp scalpel (visualised under long-wavelength UV light) and transferred to a
microcentrifuge tube. The gel slice was then processed using a QIAquick column
(Qiagen) in accordance with the manufacturer's instructions.
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The weight of the agarose was determined and 3 volumes of buffer QG to 1 volume
of gel were added (e.g. 300pl buffer to lOOmg gel). This was incubated at 50°C for
approximately 10 minutes until the gel slice had dissolved. To the mix, 1 gel volume
of isopropanol was added and the sample transferred to a QIAquick column held
within a 2ml collection tube. The QIAquick column was then microcentrifuged at
10,000g for one minute to bind the DNA. This step was repeated a second time to
increase DNA yield, after which the flow-through was discarded. The column was
washed with 750pl of buffer PE for 5 minutes to remove any remaining agarose and
excess salts, followed by a third 1 minute microcentrifugation. The flow through
was discarded and the column re-centrifuged to remove any remaining buffer (1
minute). The column was then placed in a clean 1.5ml microcentrifuge tube. 30pl of
elution buffer was added and the column was allowed to stand for 1 minute before
being microcentrifuged for a final 1 minute to elute the DNA.
2.3.4 Cloning by Polymerase Chain Reaction (PCR)
High-fidelity PCR using PfuTurbo DNA Polymerase (Stratagene) was used to clone
the H-2Kk cDNA using pMAC KK II (Milteny Biotech) plasmid DNA as a template.
During preparation of the reaction all reagents (Table 2.3.1) were maintained on ice
and the final reaction mix overlaid with mineral oil, to prevent evaporation. PCR
reactions were placed in a thermocycler (Hybaid MBS 0.2) and cycled through the
temperatures specified in Table 2.3.1.
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60s at 63°C 20
60s at 72°C cycles
180s at 72°C
Table 2.3.1: PCR Conditions for Cloning the H2-Kk cDNA from the pMAC Kk II Plasmid
(Milteny Biotech). Primers were produced by MWG.
PCR with PfuTurbo produces a blunt-end DNA fragment, thus the H2-Kk cDNA was
treated with Taq DNA polymerase (Roche), which adds a single deoxyadenosine to
the 3'-ends of the amplified fragment. The resulting "A-tail" allows very efficient
cloning of the PCR product into the TA vector system (Promega). Briefly, the PCR
fragment was precipitated (2.3.5.2) from the reaction mix and resuspended in 7pl of
sterile dfBO. Added to this was 10X Roche Taq buffer plus magnesium chloride
(MgCh), 2mM mixed dNTP and 5 units of Taq (Roche) in a final volume of lOpl.
The reaction was incubated at 70°C for 15 minutes before running and purifying the
fragment by agarose gel electrophoresis and gel purification (section 2.3.3). The
purified DNA fragment was then ligated (section 2.3.5) into the TA cloning system
(pGEM-TEasy Promega). The advantage of the pGEM-TEasy vector system was the
multiple cloning sites at each end of the integration site, thus providing multiple
options for subsequent cloning steps.
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2.3.5 Ligation
DNA ligations were performed using the Rapid DNA Ligation Kit (Roche). This
system enables ligation of both sticky- and blunt-ended DNA fragments in less than
10 minutes at room temperature. Ligation reactions contained no more than 250ng
of total DNA (vector + insert) in a total reaction volume of 21 pi. The molar ratio of
vector to insert was typically 1:5. However, ratios of 1:3 and 1:20 were occasionally
employed, depending on the size of the DNA insert fragment.
The following example describes a typical ligation reaction using a 1:5 vector to
insert ratio, lng vector DNA (lOkb) and 50ng of DNA insert (lkb) were dissolved
with 2pl of 5x DNA Dilution Buffer (Roche) in a total volume of lOpl (sterile dH20
was added as required). After gentle mixing, 10pl of 2x T4 DNA Rapid Ligation
Buffer (Roche) was added and mixed thoroughly. Finally the reaction was
supplemented with 5 units (lpl) of T4 DNA Ligase (Roche), mixed gently, and
incubated at room temperature for 5minutes, before being transformed into
competent bacteria (section 2.1.2).
2.3.5.1 Vector Backbone De-phosphorylation
Prior to ligation, vector backbones with compatible-ends were incubated (lhour at
37°C) with shrimp alkaline phosphatase (SAP) (Roche) in order to de-phosphorylate
them, preventing self-ligation. SAP was removed by ethanol precipitation of DNA
(section 2.3.5.2).
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2.3.5.2 Ethanol Precipitation
DNA samples were precipitated with 0.1 volume of 3M Sodium Acetate pH5.5 and
2.5 volumes of absolute ethanol, mixed and then chilled at -20°C for 1-2 hours. The
DNA was pelleted by microcentrifugation (10,000g, 20 minutes at room
temperature) and the supernatant discarded. The DNA pellet was then washed twice
with 70% v/v ethanol (centrifuged at 10,000g for 2 minutes between washes) to
remove salts. The pellet was then air-dried and resuspended in an appropriate buffer
(TE or sterile dfEO). Care was taken to dry the pellet sufficiently, as ethanol inhibits
certain enzymatic reactions, but not to over-dry the pellet as this can affect the ability
ofDNA to go into solution. DNA samples were stored at -20°C.
2.3.5.3 Generating Compatible Ends
Where required, blunt ends from 3' overhangs were generated using Klenow
(Roche). This was achieved by incubating the DNA fragment with 1-5 units of
Klenow enzyme in its own reaction buffer and lOmM of mixed dNTP's in a total
reaction volume of 50pl for 20 minutes at room temperature. The reaction was
stopped by removal of the enzyme through ethanol precipitation (section 2.3.5.2).
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2.4 Maintenance of Cells in Culture
2.4.1 Human Embryonic Stem Cells (hES)
Human embryonic stem cells were cultured in a feeder-free culture system, with
media "conditioned" by a mouse embryonic feeder layer using a protocol adapted
from that of Xu et ah, (2001). Murine embryonic fibroblasts (MEFs) were derived
from mid-gestation foetuses (13.5 days) and maintained in culture to produce
"conditioned" media (CM) for the maintenance of human ES cells. An F1 hybrid
strain (C57B1/6 x CBA) was used extensively and was found to produce the best
quality CM in our hands.
2.4.1.1 Derivation ofMouse Embryonic Fibroblasts (MEFs)
The uterine horns of a pregnant female mouse were taken at day 13.5 of pregnancy
and the foetuses removed into sterile PBS, supplemented with 200U/ml
penicillin/200pg/ml streptomycin. Each individual foetus was dissected away from
the placenta, decapitated and had the soft red viscera removed. The remaining soft
body tissue was then subjected to a cycle of enzymatic digestions and physical
disaggregation. Individually the foetuses were incubated with 2ml of Trypsin/EGTA
(TEG) for 5 minutes at 37°C and briefly vortexed to help disaggregate the cells,
before being returned to the incubator for a further 5 minutes. This cycle was
repeated 2-3 times, until the majority of the body tissue had been disaggregated. To
this cell suspension 3ml of basic fibroblast medium (DMEM supplemented with 10%
(v/v) Foetal Bovine Serum (FBS), 2mM L-glutamine and 1% (v/v) Non Essential
Amino Acids (NEAA)) was added, to neutralise the actions of trypsin, and the cells
vortexed for a final time. Large aggregated clumps of cellular debris were allowed to
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settle before the supernatant (single cell suspension) was collected and transferred to
a plastic cell culture treated flask (NUNC). Typically, the cell suspension produced
by 1 foetus was used to seed a single 80cm2 flask.
MEFs were maintained in culture (section 2.4.1.2) for at least 1 passage after
derivation, in the absence of antibiotics, prior to freezing (section 2.6), to reduce the
risk of passing microbial contamination to other cell lines in culture.
2.4.1.2 Maintenance ofMouse Embryonic Fibroblasts
MEFs were cultured in basic fibroblast medium directly on tissue culture plastic
(NUNC) at 37°C in a humidified incubator with 5% CO2. Expansion of MEFs was
necessary and passage was performed when cells reached 90% confluence as
follows. Culture media was aspirated and cells washed with PBS to remove traces of
serum, if left serum reduces the efficiency of the enzymatic digestion. The cells
were then incubated with a minimal volume of TEG solution for 2-3 minutes, or until
the cells had rounded and become refractive. The cells were further encouraged to
detach by gently tapping the side of the flask. Immediately after detachment, serum-
containing medium was added to neutralise the effects of the trypsin. The cells were
collected by centrifugation at 200g for 5 minutes, after which the supernatant was
discarded and the cell pellet resuspended in basic fibroblast medium before being
transferred to a new tissue culture flask (NUNC) of appropriate volume. Typically
MEFs would grow in culture for 4 passages before they senesced.
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2.4.1.3 Production ofConditionedMedia (CM) from Mouse Embryonic Fibroblasts
It is hypothesised that feeder-cells produce/secrete a growth factor when they are
exposed to basic human ES medium (KO-DMEM (Gibco) supplemented with 20%
(v/v) KO serum replacement (Gibco), 1% NEAA (Gibco), ImM L-glutamine
(Gibco) and O.lmM P-mercaptoethanol (Gibco)), in response to the presence of
recombinant human basic fibroblast growth factor (hbFGF), and that this currently
elusive factor is essential for the maintenance of pluripotent human ES cells.
This media, referred to as conditioned medium (CM), was made by removing MEF
cultures at approximately 80% confluence, from their normal culture medium and
replacing it (after a PBS wash) with basic human ES media containing 4ng/ml
hbFGF (Sigma). After 18-24 hours of exposure to the MEFs, the CM was retrieved,
filtered through a 0.2pm low protein-binding filter (Nalgene) and supplemented with
addition L-glutamine (ImM) and a further 4ng/ml hbFGF before being used to
culture human ES cells. Excess CM was stored at -20°C and used at later dates,
media that had been stored for more than 2 months was discarded.
2.4.1.4 Culture Conditions for Human Embryonic Stem Cells
In order to maintain human ES cells in an undifferentiated state they were cultured
on growth factor reduced (GFR) matrigel (Becton Dickinson), a matrix of laminin,
collagen IV, entactin and heparan sulphate proteoglycan. Matrigel was thawed on
ice and diluted 1:100 in cold KO-DMEM (Gibco) before being used to coat tissue
culture treated plastic vessels (NUNC). Polymerisation of the matrigel took 1 hour at
room temperature, after which the solution was removed and the plastic ware washed
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to remove any excess. Human ES cells were then seeded at the desired density and
grown at 37°C in a humidified incubator with 5% CO2 and fed daily with conditioned
medium.
The expansion of human ES cells was performed in a similar manner to that ofMEFs
(section 2.4.1.2) using TEG, however, in the course of this study it has been
necessary to use different passaging regimes including the use of collagenase IV
treatment and EDTA treatment, the differences between which are outlined in Table
2.4.1.
Typically, human ES cells were passaged when they reached 70-95% confluence,
depending on the passaging regime. The culture medium was removed and when
appropriate the cells were washed with KO DMEM to remove dead cells and debris.
Cells were then incubated with the appropriate disaggregation agent at 37°C and
monitored periodically under the microscope. The duration of the incubation with
the disaggregation agent was governed by the cells; when they started to round up
and become refractive the agent was disabled as appropriate (Table 2.4.1).
Following centrifugation the human ES cells were resuspended in CM and plated at
the required density on matrigel coated tissue culture plastic and cultured at 37°C in a
humidified incubator with 5% CO2. Culture medium was replenished daily.
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results in the loss of colony
cells. Remaining cell clumps
become too small and result






If cells are allowed to
become too confluent EDTA
disaggregation is less
efficient, cells become








results in increased cell lysis
and the formation of clumps.
If not exposed for long
enough, cells refuse to detach
from their matrix and have to
be mechanically removed
Table 2.4.1: Variation between different passaging regimes used for the culture of
undifferentiated human ES cells.
2.4.2 Human Multipotential Ervthroid Progenitor Cells (K562) and Human
Promonocvtic Cells (U937)
Both cell lines were obtained frozen from the European Collection of Cell Culture
(ECACC, Salisbury, Wiltshire, UK) and tested for mycoplasma. Cells were cultured
in accordance with the protocol supplied. Briefly, cells were maintained in RPMI
1640 medium supplemented with 10% (v/v) FBS and 2mM glutamine (referred to as
RPMI complete medium) in suspension at a cell density of between 1-I0xl05
cells/ml (K562) and between 2-9x106 cells/ml (U937). Suspension cultures were
maintained at 37°C in a humidified incubator with 5% CO2 and were passaged every
2-3 days by adding fresh medium and returning the cells to their proliferative cell
density. The cells were harvested by centrifugation at 200g for 5 minutes.
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2.4.3 Human Embryonic Kidney Cells (HEK 293)
HEK 293 cells were obtained from Dr Wei Cui (Roslin Institute, Edinburgh), and
maintained in DMEM supplemented with 10% (v/v) FBS, 2mM L-glutamine and 1%
(v/v) NEAA. Monolayer cultures were maintained directly on tissue culture plastic
(NUNC) at 37°C in a humidified incubator with 5% CO2, medium was refreshed
every 48 hours. Cells were passaged when they reached 80-90% confluence as
described for MEF (see section 2.4.1.2) except that Trypsin/EDTA (TED) was used
for disaggregation.
2.4.4 Ovine Foetal Fibroblasts (PDFF)
Ovine foetal fibroblasts (FF) from the Polled Dorset (PD) breed were derived by Dr
Angelika Schnieke (PPL Therapeutics, Roslin, Midlothian). Monolayer cultures of
PDFF were maintained in GMEM supplemented with 10% (v/v) FBS, 2mM L-
glutamine and 1% NEAA, on 0.1% gelatin-coated tissue culture plastic (NUNC) at
37°C in a humidified chamber with 5% CO2. Medium was replenished every 48
hours and cells were passaged using TEG as described for MEF (see section 2.4.1.2)
when they reached 80-90% confluence.
2.4.5 Porcine Kidney Epithelial Cells (LLC-PK1)
LLC-PK1 cells were obtained from the ECACC and tested for mycoplasma.
Monolayer cultures were maintained directly on tissue culture plastic (NUNC) at
37°C in a humidified incubator with 5% CO2, in Medium 199 (Sigma) supplemented
with 10% (v/v) FBS, 2mM L-glutamine and 1% (v/v) NEAA that was refreshed
every 48 hours. Cells were passaged when they reached 80-90% confluence as
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described for MEF (2.4.1.2) except that Trypsin/EDTA (TED, Sigma) was used as a
disaggregation agent.
2.4.6 Derivation and Maintenance ofAdult Murine Fibroblasts
It was necessary to isolate fibroblasts from adult tissues of the CBA and Balb C
mouse strains, to act as positive and negative controls, respectively, for H2-Kk
expression. Lung, liver and spleen tissues were used for this isolation.
All tissues were collected and washed 3 times in sterile PBS containing 200U/ml
penicillin/200gg/ml streptomycin to reduce the risk of bacterial contamination. The
tissues, maintained in l-2ml of sterile PBS, were then macerated into small pieces
using mincing scissors before being passed through a size 18G needle, in an attempt
to titurate the tissues and free the cells. The macerated tissue was then re-suspended
in 4ml of TEG and incubated at 37°C for 3-5 minutes. The trypsin was inactivated
by the addition of 5-10ml of serum containing medium, which was then mixed by
vortex for 1 minute before being centrifuged at 200g for 5 minutes. The supernatant
was discarded and the pellet resuspended in 10-20mls of basic fibroblast media,
depending on the amount of tissue collected. Persistent large clumps of tissue were
allowed to settle for 5 minutes and the remaining suspension plated on to tissue
culture plastic (NUNC) to adhere. Culture media was replaced 48hours after
isolation and the cells were subsequently maintained in the same manner as MEFs
(see section 2.4.1.2).
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2.5 Estimation of Cell number
Cells were harvested as previously described (section 2.4) and generally resuspended
in 5-10ml of appropriate medium. After mixing the suspension thoroughly, a sample
was counted using a haemocytometer. A total of 64 squares containing cells were
counted, averaged and the cell number determined using the formula in Figure 2.5.1
A B




Figure 2.5.1: Formula for counting cells using a haemocytometer
Cell viability was determined using trypan blue staining. A 1:1 mix of 0.5% trypan
blue and cell suspension was made immediately prior to counting. Viable cells
exclude the blue dye while non-viable cells take it up. The percentage of viable cells
was then determined.
2.6 Storage of Cells
Subconfluent monolayer cultures or log-phase growth suspension cultures were
harvested and pelleted as previously described (2.4). The cell pellets were then
resuspended in complete culture media to which an equal volume of 2x freezing mix
was added, for difference between cell lines see Table 2.6.1. One ml aliquots were
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transferred to 2ml cryotubes (Sarstedt) and frozen overnight at -80°C before being
transferred to -150°C freezers for long-term storage.














































Table 2.6.1 Components of the 2x freezing mix for the different cell lines used in this thesis.
Following the addition of the freeze mix, all cells were stored at -80°C for 24 hours before being
transferred to -150°C freezers for long-term storage.
Cells recovered from long-term storage (-150°C) were thawed rapidly at 37°C, and
resuspended in appropriate basic culture medium. The cells were then pelleted at
200g for 5 minutes to remove traces of DMSO and plated out in complete growth
medium as previously described (section 2.4). With the exception of non-adherent
cells, the medium was always refreshed 16-24 hours after resuscitation.
- 90 -
Chapter 2 - Materials and Methods
2.7 Manipulation of Cell Lines: Methods of Transfection
2.7.1 Lipofection
In the early stages of this thesis lipofection was the only option for the genetic
manipulation of human ES cells. The lipofection protocols were robust and provided
good transfection frequency for both transient and stable modifications. However,
lipofection favours multi-copy integration, which increased the risk of gene silencing
through the recognition of repeat sequences (as discussed in section 1.3.5.3).
Human ES cells were transfected using the Lipofectamine 2000 (LF2000) system
(Invitrogen) following a modified manufacturer's protocol provided by Geron
Corporation. Human ES cells were seeded at a density of lxl 05 cells per well of a 6-
well plate and cultured for 48 hours (to give 90% confluence) prior to the
introduction ofDNA.
For each well, 5pg of either circular (transient transfection) or linear (stable
transfection) DNA was diluted in OPTI-MEM (Invitrogen) to give a final volume of
250pl. Similarly, 12pl of LF2000 reagent was also diluted in OPTI-MEM to a final
volume of 250pl. The diluted DNA and LF2000 were then combined (500pl total
volume) and incubated for 30 minutes at room temperature to allow DNA-LF2000
reagent complexes to form. The culture media from the proliferating human ES cells
was then replaced with 2.5ml of normal CM+hbFGF plus 500pl of DNA-LF2000
reagent complexes. The cells were incubated with these complexes for not more
than 16 hours at 37°C in a humidified incubator with 5% CO2.
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2.7.2 Electroporation
The conditions for a successful electroporation vary between cell types. Table 2.7.1
provides details of the specific conditions for each of the cell lines used in this thesis.
Monolayer and suspension cultures were harvested as described in section 2.4,
counted and resuspended at the required cell density in 750pl of the appropriate







Volts pF/pS Buffer Reference
H7&
H9
lxlO6 50pg 300 lOOpS Hyposmolarity buffer(eppendorf)
K562 lxlO7 20pg 250 960pF PBS
Nakano et
al, 2003






8xl05 25pg 225 750pF
Electroporation buffer
(50mM K2HP04, 20mM




Table 2.7.1 Cell Line Specific Electroporation Conditions. Electroporation of human ES cells
used the Eppendorf multiporator with conditions defined within the McWhir Group. All other
cell types were electroporated using the BioRad Pulse electroporator.
Human ES cells were electroporated using the Eppendorf multiporation system,
which involved incubating the cells in hyposmolarity buffer at room temperature for
exactly 20mins to swell the cells prior to delivery of the DNA. 50pg of DNA
(circular for transient or linear for stable transfection), solublised in 50pl sterile
dHiO, was gently mixed with the cell suspension and placed into a 0.4cm cuvette.
The cells were electroporated as described (Table 2.7.1) and left to stand at room
temperature for 10 minutes before being plated at 2xl04/ml.
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All other cell lines were electroporated using the BioRad pulse electroporator. In
this system, cells were resuspended in the appropriate buffer and immediately mixed
with the desired quantity of DNA in a 0.4cm cuvette (Table 2.7.1). Following
electroporation, cells were left to stand at room temperature for 10 minutes before
being plated (section 2.4).
2.7.3 Production ofExperimental Cell Lines
In the case of transient expression, integrated genes were usually reporter proteins,
i.e. green fluorescent protein (GFP). In these cases cells were analysed directly 48
hours after transfection. However, in the case of stable integrated transgenes, cells
were left for 48 hours after transfection before applying drug selection at the desired
concentration (Table 2.7.2) previously determined by performing a killing curve.
Each transfection experiment included a non-selection control and a no DNA control,
to indicate a) that the integration of the DNA had not resulted in promotion of cell
death, and b) that the selection regime was working, respectively.
Generally, after two weeks in drug selection, discrete colonies of cells had formed
and were large enough to pick, if a clonal cell line was required. To pick individual
colonies, the media was removed and ~10pl of TEG was taken up into a 200pl sterile
filter-tip. This was then used to collect and gently disaggregate each individual
colony, which was then transferred to an individual well of a 48-well plate. The
clones were then expanded in culture as previously described (section 2.4) into 1
well of a 6-well plate and frozen into two 0.5ml samples, to form the basis of an
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individual cell line. If a pooled population was the desired outcome, after drug
selection had killed all of the cells on the no-DNA control plate, the whole plate was
TEG treated and passaged together to be expanded before freezing (section 2.6).
Cell
Line Species Selection Features/Comments Source
M2 Human 200pg/ml
G418
Originally H9 cells. Have hTERT driven al,3gal
transgene randomly integrated. Strong expressing





Originally H9 cells. Have hTERT driven al,3gal
transgene randomly integrated. Weakly expressing




Originally H9 cells. Have EFla driven al,3gal





Originally HEK 293 cells. Have EFla driven






Originally H7 cells. Pooled cell population which








Originally H7 cells. Co-electroporated the hTERT-
H2-Kk construct with one carrying a constitutive
mouse p-2 Microglobulin gene (Prof. S Ono,







Originally H9 cells. Have 8.5Kb mouse Oct-4
driven GFP transgene randomly integrated. Strong




Table 2.7.2: Stable Transgenic Cell Lines Produced and Used in this Study.
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2.8 Characterisation of Normality and Pluripotentiality of Human ES
cells
2.8.1 Cytogenetic Analysis
2.8.1.1 Preparation ofMitotic Spreads
To prepare chromosomes from human ES cells a confluent 25cm flask was split
between three 25cm2 flasks and allowed to proliferate for 25 hours. At 25-hours
colcemid (Gibco) was added to the cell culture media at lOpl/ml, to destroy the
mitotic spindle, and cells were incubated under normal growth conditions for 2
hours. At 27-hours the cells were harvested, cell culture media was decanted and the
cells were washed with PBS, which was decanted into the culture supernatant and
saved. TEG was used to disaggregate the cells, 4 minutes at 37°C, before adding
back the decanted culture supernatant to inactivate it. The cells were collected by
centrifugation at 260g for 5 minutes, after which, the supernatant was discarded and
cell pellet re-suspended, by vortexing, in 8mls of hypotonic solution. Incubation in
hypotonic solution was exactly 10 minutes at room temperature, to prevent over
swelling of cells, after which the cells were pelleted as above.
Cells were resuspended in fixative (3:1 ratio of methanol/acetic acid) by vortexing at
room temperature. It was essential that the first 2-3mls of the first fixation only, be
added drop-by-drop down the side of a tilted tube slowly. The final volume was 8ml.
After the first fixation, the cells were then re-pelleted as before, and a further two
rounds of fixation were applied. After the final centrifugation, the supernatant was
discarded and the cells re-suspended by gently tapping the side of the tube. A small
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amount of fix was then added to thin the cell suspension; the aim was to get a slightly
cloudy solution to give the best cell density.
A single drop of the chromosome preparation was then placed onto an ethanol
cleaned and polished microscope slide; the slide was moved in a circular manner
whilst tilted, to encourage spreading, and allowed to air dry. The mitotic index was
assessed by phase contrast microscopy, prior to performing chromosome banding.
2.8.1.2 G-Bandine and Karyotype Analysis
Giemsa-banding was performed 72 to 96 hours after the preparation of mitotic
spreads. The slide preparations were incubated in 40ml 2X SSC at 65°C for 2-4
hours. Subsequently, the slides were rinsed gently in cold running tap water and then
placed in 0.25% Bacto-trypsin (Biotrace Fred Baker ltd) for between 10 and 20
seconds. The period of exposure with trypsin is critical, over exposure results in
"fluffy" chromosomes which cannot be karyotyped. Following treatment with
trypsin, the cold-water wash was repeated, before placing slides in Giemsa, diluted
1:20 in Gurrs R66 phosphate buffer (Gibco) pH6.8, for 10 minutes at room
temperature. Slides were then rinsed gently in running cold water, blotted dry and
placed in xylene (within a fume cupboard) for 5 minutes, before mounting in
PERTEX mounting medium (CellPath).
The chromosome-banding pattern was then visualised under a xlOO oil objective,
photographed and the karyotype analysed by Judith Fletcher (Roslin Institute,
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Edinburgh) in accordance with the International Standard for Cytogenetic
Nomenclature (ISCN).
2.8.2 Flow Cytometry Analysis ofCharacteristic ES Cell Surface Markers
Human ES cells were harvested as appropriate, and disaggregated into a single cell
suspension in KO-DMEM. The cells were counted (section 2.5) and used at a
density of lxl06 per ml. The cell suspension was dispensed into 1ml aliquots across
9 pre-labelled 5ml polystyrene tubes (Falcon). The tubes were centrifuged at 260g
for 5minutes and the supernatant was discarded. The cells were then blocked by re-
suspending the cell pellet in 50pl of 40% heat inactivated rabbit serum (blocking
buffer), to prevent any non-specific binding of the antibody, for 15minutes on ice.
Primary antibodies were diluted as appropriate (Table 2.8.1) in PBS plus 10% FBS
and 2mM EDTA (staining buffer) and antibody or staining buffer added to the
appropriate tube (final volume lOOpl). Cells were incubated in the presence of the
primary antibody for 30 minutes on ice, after which the unbound antibody was
removed by washing twice with 3ml of staining buffer followed by centrifugation at
260g for 5 minutes.
Following washing, the cell pellet was resuspended in lOOpl of appropriately diluted
secondary antibody or pre-conjugated primary antibody, in staining buffer (Table
2.8.1). The cells were incubated in the presence of the fluorescent conjugated
antibody for 30 minutes on ice in the dark. The unbound antibody was removed as
before, except that the wash was performed with lxPBS alone. The wash
supernatant was discarded and the cell pellet resuspended in 0.5-lml PBS or 0.1%
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paraformaldehyde (PFA) in PBS if the samples were to be stored. Stored samples












































Table 2.8.1 Specific antibody conditions for the analysis of characteristic cell surface markers of
undifferentiated human ES cells (Reubinoff et al., 2000; Thomson et al., 1998)
Samples were analysed with a FACScan flow cytometer (Beckton Dickenson
Immunocytometry Systems (BD), UK) equipped with an air-cooled argon ion laser
emitting 15mW of blue light at 488nm and with standard filter setup. Detection of
undifferentiated human ES cells used the parameter settings outlined in Table 2.8.2.
Simultaneous measurements of forward light scatter (FSC, relative size), 90 degree
light scatter (SSC, internal complexity), and green fluorescence from FITC-stained
cells or red fluorescence from R-PE-stained cells, (detected through a 530-nm,
30nm-bandwidth band-pass filter (FL1 channel) or 585-nm, 42-nm bandwidth band¬
pass filter (FL2 channel)) were collected. The FSC parameter was used as the
threshold and set at a value of 52. All cell analyses were performed using single
colour staining, at the high rate setting (60pl +/- 7pl/min), using FACSFlow solution
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(BD) as the sheath fluid, recording at least 40,000 events. Data were collected in list
mode as pulse height signals (4 decades each on a logarithmic scale) and analysed
using CellQuest Pro software (BD).
Human ES HEK 293 K562 Cells U937 Cells
Detector cells Cells Mode
Volt Amp Volt Amp Volt Amp Volt Amp
Gain Gain Gain Gain
FSC E00 1.50 E-l 6.06 E-l 7.00 E-l 7.00 Linear
SSC 340 1.00 350 1.00 370 1.00 370 1.00 Linear
FL1 600 1.00 570 1.00 600 1.00 640 1.00 Logarithmic
FL2 435 1.00 460 1.00 480 1.00 430 1.00 Logarithmic
Table 2.8.2: BD FACScan acquisition parameters for human ES, HEK 293, K562 and U937
cells.
Using the same protocol, flow cytometry was used further in Chapter 3 to determine
the level of expression and variegation of clones containing the a(l,3)Gal transgene
and also to determine their ability to bind natural anti-a-gal antibodies from human
serum (Table 2.8.3). In Chapter 4, flow cytometry was use to assess the levels of
complement inhibitor proteins (Table 2.8.3) on a number of cell types (for parameter
settings see Table 2.8.2), and also as a method of titrating blocking antibodies for use
in inhibition complement-mediated lysis. Finally, in Chapter 7, regulation of the ES
cell surface markers (Table 2.8.1) excluding CD9 but including the a-gal epitope and
GD2 (Table 2.8.3), were assessed longitudinally following differentiation (section
2.10.2.2).
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Table 2.8.3: Antibodies and their conditions for use in flow cytometry experiments described in
Chapters 3, 4 and 7.
2.8.3 Alkaline Phosphatase Staining ofHuman ES Cells
The presence of alkaline phosphatase was determined using the BCIP/NBT alkaline
phosphatase substrate kit IV, supplied by Vector Labs in accordance with the
instructions provided. Culture medium was removed and the cells were washed with
PBS before being fixed with 4% PFA for 20 minutes at room temperature. The
fixative was then removed and the cells washed twice with PBS. The BCIP/NBT
working solution was prepared immediately prior to use, by mixing 2 drops of each
of the reagents 1, 2 and 3 in 5mls of 100mM Tris-HCl buffer at pH 9.5. Enough of
the working stock to cover the surface of the cells (0.5-1.0ml) was added and they
were then incubated in the dark for 1 hour, after which the stain was removed and the
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cells were washed with distilled water. Presence of alkaline phosphatase produced a
blue stain, which was visualised by eye, or using differential interference contrast
microscopy (DIC) and photographed.
2.8.4 In vitro Differentiation ofHuman ES Cells - Undirected
The first stage of in vitro differentiation was the formation of 3-D cellular structures
known as embryoid bodies (EB). ES cells culture with a TEG passaging regime
were disaggregated into a single cell suspension and reseeded onto non-adherent
culture plastic in CM. The cells were maintained in this way for 2 days, and
spontaneously clumped together to form small cell aggregates. After 2 days, the cell
aggregates were transferred to basic differentiation medium (basic human ES
medium, un-conditioned, minus hbFGF with 10% FBS replacing the 20% KO-Serum
Replacement) and maintained in suspension for a further 5 days before being plated
on 0.1% gelatin-coated SonicSeal Bucket Slides (NUNC), at a density of 5-10 EB's
per well. During the five days suspended in basic differentiation medium, the EB's
first became very dense, and showed signs of a defined membrane before becoming
vacuolated immediately prior to plating. Once the EB's had been transferred to
gelatin-coated plates, they grew out very quickly and began to differentiate into
numerous cell types. Cultures were maintained in this way for 14-21 days with
medium changed every 48-72 hours.
2.8.4.1 Analysis ofDifferentiated Cell Types by Immunohistochemistry
Cells that had been differentiated for 14 - 21 days were washed with PBS and fixed
in 4% PFA for 20 minutes at room temperature. After fixation the cells were washed
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twice in PBS and permeabilised with absolute ethanol for 2 minutes at room
temperature. The PBS wash was repeated following permeablisation and the cells
incubated with 10% normal goat serum at room temperature for 1 hour to block non¬
specific binding of the antibodies. Primary antibodies were diluted as required
(Table 2.8.4) in 1% normal goat serum. Blocking serum was removed and cells were
incubated with 200pl of primary antibody for 2 hours at room temperature, while
shaking slowly. After 2 hours the primary antibodies were removed and the cells
washed three times for 5 minutes in PBS.











Table 2.8.4: Antibody conditions for markers routinely used to assess the in vitro differentiation
ability of undifferentiated human ES cells.
The secondary antibody (FITC labelled Goat anti-mouse-IgG (l.Omg/ml, Sigma))
was diluted 1/200 in 1% normal goat serum and the cells were incubated with 200pl
for 30 minutes at room temperature, shaking gently in the dark. After incubation
with the secondary antibody, the cells were washed three times for 5 minutes in PBS.
The wells were then mounted in Vectashield plus Dapi (Vecta Labs) and sealed with
pang (Truflex) and allowed to dry. Slides were stored at 4°C in the dark until viewed
with a fluorescent microscope.
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2.8.5 In vitro Osteogenic Differentiation ofHuman ES cells
Directed differentiation of human ES cells towards the osteogenic lineage was
performed using an adaptation of the protocol published by Sottile et al., (2003).
Briefly, differentiation was initiated by the formation of EB's (section 2.8.3),
maintained in suspension for a total of 4 days, 2 days in CM and 2 days in basic
differentiation media. After 4 days in suspension the EB's were disaggregated with
TEG into a single cell suspension, counted (section 2.5) and plated onto 0.1% gelatin
coated tissue culture plastic (NUNC) at a density of lxl05/ml in basic differentiation
medium, in a humidified incubator with 5% CO2, overnight at 37°C. The following
day, cells were either maintained in basic differentiation medium (OS-), or
transferred to differentiation medium supplemented with lOmM ^-glycerophosphate
50pM ascorbic acid, and 0.1 pM dexamethasone as osteogenic factors (OS+) for a
total of 20 days. Culture medium was replenished every 48-72 hours, and the
progress of osteogenic differentiation assessed at 0, 3, 6, 9, 13, 16 and 20 days post
induction, by Alizarin Red S staining and calcium deposition.
2.8.5.1 Analysis ofOsteogenic differentiation
Alizarin-red S Staining
Alizarin-red S combines with calcium atoms to form a bright red stain, commonly
used in the detection of mineralising nodules (Sottile et al., 2003). Cells were fixed
at the desired time point (2.8.5) by removing the culture medium, washing twice with
PBS and incubating with 4% PFA at 4°C for 10 minutes. Following fixation the PFA
was removed and the cells were washed once with distilled water. Care was taken
not to dislodge the monolayer. Alizarin-red S (Sigma) stock solution was prepared
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as a 1% solution in distilled water and fdtered through 3MM Whatman filter paper
before use. The fixed cells were incubated with sufficient Alizarin-red S solution to
cover the cells (0.5-lml) at room temperature for 10 minutes. Following the
staining, the cells were washed, carefully, three times with distilled water and
photographed immediately.
Calcium Deposition
The purpose of this assay was to determine the matrix-associated mineralization
following treatment with osteogenic factors. Cells were fixed at the desired time
point (see section 2.8.5) by removing the culture medium and washing three times
with 0.9% sodium chloride. The cells were left to dry completely at 37°C, before
lysing them with 50pl 0.1M sodium hydroxide for 2-3 hours. The lysis buffer was
neutralised by incubation with 20pl of 2M hydrochloric acid and the plates dried in a
60°C incubator. Once completely dry, the plates were assessed for calcium
deposition, using a calcium colorimetic kit obtained from Randox, using the
manufacturer's instructions as guidelines. Briefly, matrix associated calcium
deposition from differentiated human ES cells was established against a standard
curve produced by diluting the standard calcium solution (2.5mM/l) provided in the
Randox kit. To 25pl of each diluted standard, ranging from 0-100pM in distilled
water, and to each sample well, 200pl of assay buffer was added and incubated at
room temperature for 10 minutes. During this time calcium ions form violet
complexes with O-Cresolphthalein complexone (the active component of the kit) in
the alkaline medium. The absorbance of the sample and the standard were measured
immediately using a spectrophotometer at a wavelength of 570nm.
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2.8.6 In vivo Differentiation ofHuman ES Cells
For human ES cells, evidence of continued pluripotentiality can only be achieved in
vivo by the formation of teratomas. To this end, lxlO7 undifferentiated human ES
cells suspended in PBS were injected intramuscularly, (under license by Dr J.
McWhir, Roslin Institute, Edinburgh) into the hind thigh of severe combined
immunodeficient (SCID) mice strain C.B-17/Icr (Harlan UK Ltd). Generally,
tumours took between 3 and 5 months to develop, after which the mice were
sacrificed and the tumours removed. Tumours were fixed whole, or cut into
segments if very large, with 4% PFA for 20 minutes at room temperature and
subsequently stored at 4°C in sterile PBS before being analysed.
2.8.6.1 Analysis ofTumour Sections
Paraffin wax embedding
Tumours were embedded in paraffin wax in an automated system using a Shandon
Hypercentre XP processor (Shandon Scientific UK Ltd). Details of the process are
detailed in Table 2.8.5. Once embedded, tumours were cut into 10pm sections using
a Microm HM325 rotary microtome (MICROM international GmbH).
The whole tumour was sectioned, with 3 sections every 10 being transferred to
polylysine coated microscope slides. The slides were allowed to dry at least
overnight at room temperature before being stained.
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1 Ethanol 70 90 Room Temp
2 Ethanol 96 90 Room Temp
3 Ethanol 96 90 Room Temp
4 Ethanol 100 90 Room Temp
5 Ethanol 100 90 Room Temp
6 Ethanol/Paraffin clearing agent 50/50 90 Room Temp
7 Ethanol/Paraffin clearing agent 50/50 60 Room Temp
8 Paraffin clearing agent 100 60 Room Temp
9 Paraffin clearing agent 100 60 Room Temp
10 Paraffin clearing agent 100 60 Room Temp
11 Paraffin clearing agent 100 60 Room Temp
12 Paraffin Wax 100 60 60
13 Paraffin Wax 100 60 60
Table 2.8.5: Automated process for the paraffin wax embedding of tumours using a Shandon
Hypercentre XP processor (Shandon Scientific UK Ltd)
Haematoxylin and Eosin (H&E) Staining
Before staining, the dried slides were de-waxed in xylene (BHD) for 5 minutes
before being slowly rehydrated in serial ethanol incubations, at successively reduced
concentrations (2 minutes at 75% followed by 2 minutes at 65%) before being
incubate in water for a further 2 minutes. Sections were then stained with
haematoxylin (Sigma) for 5 minutes and washed under running water for
approximately 5 minutes, until the sections were blue rather than deep purple in
colour. Sections were further stained with eosin (Sigma) for 2-5 minutes and excess
stain removed by washing in water for 2 minutes. Sections were then dehydrated in
successively increasing concentrations of ethanol (1 minute at 65% followed by 1
minute at 75%). Slides were then incubated in xylene (in a fume cupboard) for 5
minutes to remove traces of ethanol and allowed to dry slightly before mounting the
slides with PERTEX mounting medium (CellPath). For the best results, slides were
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left overnight to dry completely. Histological analysis, by light microscopy, of the
tumour sections was performed by Dr David Brownstein (Research Animal
Pathology Core Laboratory, University of Edinburgh, UK).
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2.9 Analysis of Gene Expression
2.9.1 Preparation ofRNA
RNA was prepared using the RNAeasy system from Qiagen, in accordance with the
manufacturers protocol. Cells grown as monolayers on tissue culture plastic (25cm )
were directly lysed with 600pl of buffer RLT. The viscous cell lysate was
homogenised on a QIAshredder column held in a 2ml collection tube, and
microcentrifuging it at 10,000g for 2 minutes. To the flow-through, an equal volume
of ethanol (70% made in RNase-free water) was added and subsequently transferred
in two 600pl quantities to an RNAeasy column (Qiagen) and microcentrifuged at
8000g, to bind the RNA. The flow-through was subsequently discarded and the
column washed with 700pl of buffer RW1 (spun 8000g for 15 seconds). The
RNAeasy column was then transferred to a fresh collection tube and washed a further
2 times with 500pl of buffer RPE. Following the third wash, the flow-through was
discarded and the column microcentrifuged for 1 minute to dry the silica-gel
membrane and remove carry-over of buffer RPE. The RNA sample was then eluted
into a fresh 1.5ml collection tube by adding 30-50pl of RNase-free water to the
membrane and microcentrifuging at 8000g for 1 minute. The elution step was
repeated twice to improve the RNA yield. Typically the final volume was 80pl.
2.9.1.1 Assessing the Quality and Quantity on RNA
Spectrophotometric measurements were used to determine the quantity and quality of
the RNA preparations. Typically an RNA sample was diluted 1:50 with DECP-
treated water (Sigma) and the absorbance read at 260nm to give the concentration of
nucleic acid in the sample. An OD of 1 corresponds to approximately 40pg/ml of
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RNA. The ratio between readings at 260nm and 280nm provided an estimation of
the purity of the RNA preparation. Pure RNA has an OD260/OD280 ratio of between
1.9 and 2.1.
RNA integrity was also examined crudely by agarose gel electrophoresis. The
presence of 2 ribosomal bands representing the 18S (1.9kb) and 28S (5.0kb)
components of RNA should appear as discrete sharp bands, with the intensity of the
28S band being twice that of the 18S band. If the ribosomal bands produced a smear
of smaller sized RNAs, it was considered likely that the RNA had undergone major
degradation during preparation and was discarded.
2.9.2 cDNA synthesis and Reverse Transcriptase (RT) PCR
First strand cDNA synthesis and PCR were performed simultaneously using the
Superscript One-Step RT-PCR system from Invitrogen and gene specific primers
(Table 2.9.1). This system contains both Superscript II reverse transcriptase, a
modified version of Moloney Murine Leukemia Virus (M-MLV) RT, engineered to
reduce RNase H activity and increase thermal stability, and Platinum Taq DNA
polymerase complexed with a proprietary antibody that inhibits polymerase activity
at ambient temperatures. Together these enzymes permit both cDNA synthesis and
PCR in a single reaction, due to the inactivation of superscript II RT and activation
of Platinum Taq during the 94°C denaturation step in PCR cycling, providing a "hot
start" for PCR resulting in increased primer specificity.
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A typical RT-PCR reaction consisted of 125ng of sample RNA, mixed with 0.2pM
of both the sense and anti-sense primers, 6.25pl of 2X reaction mix, containing
0.4mM of each dNTP and 2.4mM MgS04, and 0.25pl of RT/Platinum Taq Mix,

























Rev: CATTCAGACTTGTCTTTCAGC 224bp 4033bp 59°C
Table 2.9.1 Species specific RT-PCR primers for the p-actin, H2-Kk and p-2 microglobulin
genes. Primers (MWG) were designed to cross introns so that genomic contamination was easily
detected. The table provides the product sizes for both cDNA and gDNA and the annealing
temperature of the specific primers.
A standard set ofPCR cycling conditions were used for each of the primer sets, on an
MJ Gradient 4 block PCR machine. cDNA synthesis was achieved in a single cycle
of incubation at 50°C for 30 minutes followed by pre-denaturation (inactivation of
Superscript II and activation of Platinum Taq) at 94°C for 2 minutes. PCR
amplification started immediately, with 40 cycles of denaturation at 94°C for 15
seconds, primer annealing at optimal temperature (Table 2.9.1) for 60 seconds,
followed by a 1 minute extension time at 72°C. A final extension period of 10
minutes at 72°C was incorporated before holding at 4°C.
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PCR products were resolved by horizontal gel electrophoresis on 2% (w/v) agarose
gels, run at 80V for 2 hours (section 2.3.2).
2.9.3 Western Blotting
Expression of the H2-Kk protein was assessed in Chapter 3 by Western blot.
2.9.3.1 Protein Isolation
Cells grown (see section 2.4) to confluence in a 25cm tissue culture flask were used
as a source of protein. Culture medium was removed and the cells washed once with
sterile PBS. Cells were then harvested from the tissue culture plastic (NUNC)
mechanically using sterile cell scrapers (Greiner Bio-one) into PBS and collected by
centrifugation at 260g for 5 minutes. The cell pellet was then resuspended in 200pl
of protein lysis buffer containing 1% Triton-X 100 and protease inhibitors (Complete
mini cocktail, Roche) on ice for 30 minutes. Following incubation on ice, the lysate
was centrifuged at 10,000g in a microcentrifuge at 4°C for 5 minutes. The
supernatant was then collected and dispensed into 20pl ampoules and snap frozen on
dry ice before being transferred to -80°C for long term storage.
2.9.3.2 SDS Polvacrvlamide Gel Electroporesis
Protein lysates were thawed on ice and mixed with an equal volume of 2x SDS
loading buffer before being loaded (10-20pl) onto a pre-cast Tris-glycine gel
(Invitrogen) using the XCell SureLock mini-cell apparatus (Invitrogen). Normally
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the proteins were run under reducing condition, 200mM DTT was present in the
loading buffer and samples were denatured at 99.9°C for 5 minutes prior to loading.
In Chapter 3, the detection of H2-Kk, was attempted using non-reducing conditions
which involved leaving out DTT from the loading buffer. The samples were
separated by electrophoresis at 100V for 2 hours using lx Tris-glycine running
buffer.
2.9.3.3 Western Transfer
Using the XCell SureLock blotting module (Invitrogen) a sandwich consisting of two
blotting pads, one piece of 3MM paper, a piece of polyvinylidene difluoride
membrane (PVDF: Hypond-P, Amersham Pharmacia) the Tris-glycine gel, a second
piece of 3MM paper and two further blotting pads was constructed. All components
were pre-soaked in IX western transfer buffer, with the exception of the hydrophobic
PVDF membrane which was first immersed in methanol and equilibrated in distilled
water prior to exposure to transfer buffer. The sandwich was then placed into the
blot module and transfer was allowed to proceed for 1 hour 30 minutes at 100mA.
Following transfer the sandwich was disassembled and the PDVF membranes
blocked with 5% milk protein for 2 hours at room temperature with agitation.
Membranes were then either immunoblotted immediately or transferred to PBS
containing 0.1% Tween20 (wash solution) and stored at 4°C.
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2.9.3.4 Immunoblotting
Primary antibodies were diluted (Table 2.9.2) in freshly made blocking solution and
incubated overnight at 4°C with gentle agitation. Membranes were then washed 6
times for 10 minutes each in wash solution at room temperature. HRP-conjugated
secondary antibody was then diluted appropriately (Table 2.9.2) in fresh blocking
solution, applied to the membrane and incubated at room temperature for 2 hours
with gentle agitation. Following incubation with the secondary antibody, the wash
step was repeated, (6 washes of 10 minutes). Membranes were then exposed to pre-
mixed ECL western agents (Amersham Pharmacia), wrapped in Saranwrap (Saran)
and exposed to film (Amersham Pharmacia) for 30 seconds to 15 minutes. Film was
developed in a Konica SRX-101A X-ograph machine.
Primary Dilution Source Secondary dilution Source
Antibody
Anti-P-Actin 1:250 Santa Cruz HRP-anti-goat Autogen Bioclear
(0.2mg/ml) (2.0mg/ml) 1:500
H2-Kk 1:50- Southern HRP-anti-mouse Amersham
(0.5mg/ml) 1:250 Biotechnology (0.73mg/ml) 1:500 Pharmacia
Table 2.9.2 Antibody dilutions for the detection of H2-Kk and p-actin by Western Blot.
2.9.4 Immunochemistry
2.9.4.1 Antibody Stainins
Cells were plated on a relevant extracellular matrix in 4-welled SonicSealed Bucket
slides (NUNC) or on glass cover slips and grown under normal conditions (2.4) until
they reached a suitable level of confluence (60-70%). Culture medium was removed
and the wells washed with PBS. If pre-fixation was necessary, (Table 2.9.3) cells
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were fixed in 4% PFA at room temperature for 20 minutes. After fixation, PFA was
removed and the cells were then washed twice with PBS. For internal epitopes,
permeablisation of the cell membrane is required, this if necessary (Table 2.8.1) was
achieved through incubation with absolute ethanol for 2 minutes at room
temperature. Ethanol was promptly removed and the cells washed twice with PBS.
Whether fixed, permeablised or stained live, non-specific binding of the primary
antibody was blocked by incubation in normal serum, specific to the species that the
secondary antibody was raised in, typically 5-10% normal goat serum (Table 2.9.3),
for 30 minutes at room temperature. After blocking non-specific activity, the
blocking agent was removed and cells were incubated with primary antibody, diluted
as specified (Table 2.9.3) in 1% blocking agent, for 1 hour at room temperature.
Cells were then washed with PBS at room temperature three times for 5 minutes
each, before being incubated with 200pl of secondary antibody diluted appropriately
as indicated in Table 2.9.3, for 1 hour in the dark. If the primary antibody was pre-
conjugated, the cells were incubated with this diluted appropriately for 1 hour (Table
2.9.3). Following incubation with the secondary antibody, the cells were washed
again with PBS three times for 5 minutes each at room temperature, in the dark.
After the final wash the cells were blotted dry and mounted with 1 drop of
Vectashield with Dapi (Vecta Labs), to stain the nuclei, with a glass cover slip on top
and sealed with Pang (Truflex). The slides were allowed to dry completely overnight
at 4°C before being viewed with fluorescence microscopy.
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Table 2.9.3: Specific conditions required for the detection of epitopes by antibody-mediated
immunochemistry.
2.9.4.2 Bandeiraea simplicifolia isolectin B4 (BS-IB4,) Staining
Cell surface expression of the a-gal epitope was assessed using a fluorescein
isothiocyanate (FITC)-conjugated Bandeiraea simplicifolia isolectin B4 (BS-IB4,
Sigma) specific for a-gal epitope with an adapted protocol from Xing et al (2001).
Briefly, after removing the culture medium, cells were washed in sterile complete
PBS (containing Mg2+/Ca2+) supplemented with 1% BSA (Gibco) three times for 5
minutes each. The cells were then incubated with the 5pg/ml BS-IB4 lectin,
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dissolved in complete PBS plus 10% newborn calf serum (NCS), at 4°C for 90
minutes in the dark. For flow cytometry, BS-IB4 was dissolved in normal PBS
(without Mg2+/Ca2+) to encourage a single cell suspension, for immunochemistry,
Mg2+/Ca2+ was added to prevent the cells from detaching. The wash step described
above was repeated a further 3 times, and the cells post-fixed in 1% formaldehyde at
room temperature for 20 minutes. The fix was removed and the cells washed and
store, if necessary, in PBS at 4°C.
2.9.4.3 Giemsa Staining
Giemsa is a deposit stain that stains DNA. Culture media was removed and cells
washed once with PBS. Cells were then fixed with 100% methanol for 20 minutes at
room temperature. The methanol fix was then removed and the cells incubated with
5% Giemsa, diluted in either Gurrs buffer pH6.5 or PBS pH7, for between 15 and 30
minutes at room temperature. After the stain had been removed, cells were washed
3-5 times with slow-running water. When Giemsa was being used to provide images
with morphology, the cells were placed in water and the images taken immediately,
after which the plates were dried and kept in the dark before whole plate
photography was undertaken.
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2.10 Strategies for the Selective Elimination of Human ES Cells
2.10.1 Complement Mediated Cell Lysis
2.10.1.1 The Calcein-Release Assay
Complement-mediated lysis was determined using the Calcein-release assay as a
fluorescent equivalent to the 51Cr-release assay, described by B. Spiller in
Complement Methods and Protocols (2000). Calcein is an organic, polyanionic
fluorochrome derived from fluorescein. In its acetoxymethyl ester form
(Calcein.AM) Calcein is only weakly fluorescent and its non-polar nature allows it to
freely diffuse across membranes. However, once inside a living cell, the
acetoxymethyl group is cleaved by ubiquitous, non-specific cytoplasmic esterases,
changing the nature of the molecule from non-polar to polar and thus trapping it
inside the cell until the cell membrane is breached. By measuring the fluorescence of
the supernatant after exposure to complement and calculating it as a percentage of
the total fluorescence of the original cell aliquot, it is possible to determine the level
of cell lysis as a result of complement exposure in terms of % Calcein-release.
Specific lysis can be calculated by subtracting the % spontaneous Calcein-released
from control cells that were not exposed to complement.
2.10.1.1.1 Pre-loading with Calcein.AM
To determine the optimal concentration of Calcein.AM for labelling, cells lines were
harvested with TEG (section 2.4), counted (section 2.5) and re-suspended at a
concentration of 2xl06/ml in 50pl of culture medium containing 0, 2, 5, 10, 20, 40,
80 and 160pM Calcein.AM. The cell suspensions were then incubated at 37°C with
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5% CO2 in a humidified incubator for 1, 2 or 4 hours in the dark. Excess
Calcein.AM was removed by washing the loaded cells twice with KO-DMEM
followed by centrifugation at 200g for 5mins. Calcein.AM uptake and Calcein-
release were assessed using a 0.1% Triton-X 100 solution to totally lyse the cells,
referred to as total release (TR) and normal culture medium to assess the level of
spontaneous release (SR). The concentration of Calcein.AM and incubation time at
which there was the greatest difference in fluorescence intensity between TR and SR
were determined to be the optimal conditions for Calcein.AM labelling (section
2.10.1.1.2 for details of quantifying Calcein-release). For all subsequent experiments
cells were loaded with 40pM of Calcein.AM for 2 hours at 37°C with 5% CO2.
2.10.1.1.2 Quantification ofCalcein-Release
Following exposure to complement, cells were pelleted at 200g for 5 minutes. Using
the method of Iwanowicz et al (2004), a 50pl sample of the supernatant was
collected without disturbing the cell pellet, mixed with 50pl of 2x Triton-X 100 and
transferred to a black, round bottom 96-well plate. This is referred to as the lysis
fraction. Excess supernatant was then discarded and the remaining cells were lysed
by re-suspension in lOOpl of 0.1% Triton-X 100 and incubated at 37°C with 5% CO2
in a humidified chamber for 15 minutes. Likewise a 50pl sample of this fraction was
collected mixed with 50pl of 2X Triton-X 100 and transferred to a second black,
round bottom 96-well plate and is referred to as the detergent fraction. The method
of Spiller (2000) differs subtly from that of Iwanowicz et al., (2004) in that Spiller
suggested the use of 250pl of both serum and detergent, and the collection of all
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250pl to the 96 well-plate, without mixing with 2X Triton-X 100 for the detection of
Calcein-release.
The fluorescence in both fractions was then measured using a fluorimeter (Wallac
1420 VICTOR ) at 530nm emission and 480nm excitation wavelengths and the level
of Calcein-release calculated (Figure 2.10.1).
Intensity of lysis fraction
% Calcein Release = X 100
Intensities of the lysis + the detergent fractions
Specific % Release = % Calcein Release — % Calcein Release from the Controls
Figure 2.10.1: Equations for calculating level of lysis in terms of Calcein-release levels
2.10.1.2 Complement-Mediated Lysis through Incubation with Whole Human Serum
2.10.1.2.1 Acquiring Human Serum
Human serum from healthy screened volunteers of blood group-A was either
purchased from Harlen Sera Labs (Loughbourgh, UK) as a pooled sample, or
collected fresh and pooled from blood group-A healthy volunteers from the Roslin
Institute (Edinburgh, UK).
Briefly, 50-100ml of blood was collected from each volunteer by Dr Tim King
(Roslin Institute, Edinburgh), separated into 10ml aliquots and allowed to clot at
room temperature for 2 hours. The clot was then cut, using a sterile pipette, to
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release the serum, and dislodged from the side of the plastic. The clot was then
incubated overnight at 4°C to retract and release its serum content. The following
day the clot was discarded and the sample was centrifuged at 3220g for 20 minutes at
4°C to remove free red cells. The straw coloured supernatant was collected and
either used directly or frozen immediately at -80°C for future use.
2.10.1.2.2 Complement-Mediated Lysis with Endogenous Antibodies
To minimise the effects of plating efficiency, complement-mediated lysis was
performed as a suspension assay. Target cells were harvested (see section 2.4),
counted (section 2.5) and washed twice with KO-DMEM before being used directly
in a lysis experiment or preloaded with Calcein.AM (section 2.10.1.1.1) before use.
Cells were collected by centrifugation and resuspended at a density of lxl06/ml in
lOOpl (105) of either active or heat inactivated (HIA) human serum, 0.1% Triton-X
100 or culture medium. Heat inactivation was achieved by incubating the serum in a
56°C water-bath for 30 minutes, mixing regularly to ensure complete inactivation. In
an attempt to reduce intra-experimental variation, each data point was represented by
6 replicates and each experiment was repeated independently in triplicate.
The cells were incubated in suspension at 37°C with 5% CO2 in a humidified
incubator for 1 hour, and agitated every 15mins to prevent cells settling. After
exposure to complement, the remaining cells were pelleted at 200g for 5 minutes and
the supernatant transferred for analysis (section 2.10.1.1.2). Where appropriate the
remaining supernatant was removed and the cells resuspended in 0.1% Triton-X 100
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to determine the specific % of Calcein released due to complement (section
2.10.1.1.2).
To determine the serum concentration required to achieve the greatest level of lysis,
a titration experiment was performed using control PDFF cells, and 0, 2, 5, 10, 20, 50
and 100% serum diluted in appropriate culture medium (section 2.4).
2.10.1.2.3 Complement-Mediated Lysis with Exogenous Antibodies
Complement-mediated lysis using antibodies from an exogenous source was
performed using the same approach as for endogenous antibodies (section
2.10.1.2.2), except that the desired antibody was diluted, at its optimal concentration
(Table 2.10.1), in the lOOpl of human serum in which the cells were resuspended.
Incubation with both antibody and serum was then carried out together for 1 hour at
37°C in a humidified incubator with 5% CO2.
The exception to this method was when blocking antibodies to CD55 and CD59 were
used. In this instance, the cells were incubated in the presence of blocking
antibodies, diluted to their optimal concentration (Table 2.10.1) in staining buffer
(2% FBS in PBS plus 2mM EDTA), for 15 minutes at room temperature. Excess
antibody was then removed by washing the cells twice with KO-DMEM followed by
centrifugation at 200g for 5 minutes. At this point the cells were treated as
previously outlined (section 2.10.1.2.2).
-121 -
Chapter 2 - Materials and Methods
Antibody Name Epitope Dilution Source
MAB4381 (1.51mg/ml) Tra-1-81 1/20 Chemicon
HD3 (1.5mg/ml) CD55 1/250 Kind Gift from Professor Paul Morgan
(University of Wales)MEM 43 (0.6mg/ml) CD59 1/250
Table 2.10.1 Exogenous Antibodies used in Complement-Mediated Lysis. TRA-1-81 is
endogenously expressed by undifferentiated human ES cells and was used to initiate a
complement-mediated attack. CD55 & CD59 are complement regulatory proteins and
antibodies were used to inhibit their effects.
2.10.1.3 M2 and HEK 293 Mixed Culture Complement-Mediated Lysis
To determine the sensitivity of the complement-mediated lysis assay,
undifferentiated M2 cells were diluted with HEK 293 cells to give a total of lxlO5
cells. M2's were spiked into the HEK 293 cultures at 50%, 25%, 12.5%, 6.3%,
3.15%, 1.6%, 0.8% and 0% of the total, in suspension. The serum lysis assay was
then performed as previously described (section 2.10.1.2.2), PDFF and H9 pure
population respectively were included as positive and negative controls.
Following exposure to active and heat inactivated serum; surviving cells were
collected by centrifugation (200g for 5 minutes) and resuspended in KO-DMEM.
Cells were seeded in duplicate wells of a 12-well plate, in both ES and HEK 293
culture conditions (section 2.4). Cultures in ES conditions were placed in G418
selection at 500pl/ml so that even rare incidences of ES cell survival could be easily
identified. For PDFF, H9, 100% M2 and 100% HEK 293 conditions, a further two
duplicate wells of a 12-well plate (active and heat inactivated) were set up so that the
initial level of cell lysis could be determined 24 hours after plating by either FITC
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conjugated BS-IB4 (section 2.9.4.2) or 5% Giemsa staining (section 2.9.4.3). All
other wells were cultured appropriately for at least 7 days, or until wells were
confluent, after which they were stained with FITC conjugate BS-IB4 (section
2.9.4.2) for the evaluation of the a-gal epitope and 5% Giemsa (section 2.9.4.3) to
give an estimation of surviving cell number.
2.10.2 Fluorescence Activated Cell Sorting (FACS)
FACS was evaluated as an alternative method for the selective removal of
contaminating undifferentiated human ES cells. Before this could be achieved, the
FACSAria was first assessed for its ability to successfully sort human ES cells,
whilst maintaining their viability, pluripotentiality and sterility.
The FACSAria cell sorter (BD, UK) was equipped with an air-cooled argon ion laser
emitting 15mW of blue light at 488nm and with standard filter setup. Detection of
undifferentiated human ES cells used the parameter settings outlined in Table 2.10.2,
using simultaneous measurements as previously described (Section 2.8.2). All cell
analyses/sorting were performed using single colour staining, passed through a 70um
nozzle using aseptically prepared PBS as sheath fluid and 70psi. At least 10,000
events were recorded for analysis, data were collected in list mode as pulse area
signals (5 decades each on a logarithmic scale) and analysed using BD FACSDiva
software.
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2.10.2.1 Assessment ofthe viability ofsorted human ES cells
Human ES cells were harvested into a single cell suspension as previously described
(section 2.4), resuspended in 5mls of KO-DMEM. This suspension was left at room
temperature for 10 minutes to allow any cell clumps to settle out. The supernatant
from this was then collected by centrifugation at 260g for 5 minutes and resuspended
in 0.2-lml of culture medium containing lx penicillin/streptomycin (lOOU/ml
penicillin and 100pg/ml streptomycin). Data were acquired on a BD FACSAria by
Dr Martin Waterfall (Roslin Institute, Edinburgh). The parameter settings for data
acquisition were determined using unlabelled human ES cells and were maintained
throughout all experiments (Table 2.10.2).
Detector FSC ssc FL1 FL2
Voltage 250 225 335 300
Mode Linear Linear Logarithmic Logarithmic
Table 2.10.2: BD FACSAria acquisition parameters for human ES cells
Initially, cells were sorted according to their forward and side scatter profdes into
5ml polystyrene sterile tubes (Falcon), primed with 1ml CM, before being transferred
back to cell culture plastic (NUNC) coated with an appropriate extracellular matrix,
substituted with lx penicillin/streptomycin (lOOU/ml penicillin and lOOpg/ml
streptomycin) for the first 24 hours. These cells were monitored for appropriate
growth and morphology, normal karyotype (section 2.8.1) and continued
pluripotentiality, including expression of ES specific cell surface markers (section
2.8.2), expression of alkaline phosphatase (section 2.8.3) and Oct-4 (section 2.9.4.1),
differentiation into cell types representative of the 3 germ layers (section 2.8.4) and
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directed differentiation into the osteogenic lineage (section 2.8.5), following 5
passages in culture.
2.10.2.2 Establishing the regulation kinetics ofES cell surface markers
H9 wild type and transgenic M2 ES cells were differentiated in an undirected
manner, as monolayer cultures by the removal of conditioned medium and hbFGF
and the addition of 10% FBS. The differentiation time course spanned a 3-week
period, after which cells from a 75cm2 tissue culture flask (for each time point) were
harvested (section 2.4) and stained as previously described (section 2.8.2) for SSEA-
4, TRA-1-81 and a-gal as markers of undifferentiated ES cell status, and SSEA-1
and GD2 as markers of differentiation. Data was acquired using the parameters
previously determined (Table 2.10.2) for 0, 2, 4, 6, 9, 11, 13, 16 and 18 days in
differentiation medium. This information was then used to determine the time point
at which discrete cell populations could be isolated and subsequently sorted based on
the presence or absence of a specific cell surface marker.
2.10.2.2 Sortine Positive and Negative cells from a mixed population
Cells from 6 and 8 days of differentiation were prepared (section 2.10.2.1) and
stained (section 2.8.2) for sorting at previously described. Sorting was performed on
M2 cells according to their expression of either a-gal or TRA-1-81, using the same
defined parameters (Table 2.10.2), gated so that positively stained cells were directed
right and unstained (negative) cells were directed left into 5ml polystyrene FACS
tubes (Falcon). Sorted cells were then cultured along side unsorted cells
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(differentiated and undifferentiated) in either ES cell culture (CM plus hbFGF)
medium or differentiation cell culture (No hbFGF plus 10% FBS) medium at a cell
density of 104 and 105 per well of a 12-welled plate (NUNC). Initially cell cultures
were supplemented with lx penicillin/streptomycin (lOOU/ml penicillin and
100pg/ml streptomycin) to reduce opportunistic bacterial infections, but this was
removed in the first media change at 24 hours post-sort. Medium was routinely
changed every 24hrs for ES and 48hrs for differentiation.
2.10.2.4 Assessing the purity ofsorted cells.
Sorting purity was initially assessed through immunochemistry to determine the
occurrence of false negative events. The negatively gated populations were stained
as monolayers 48 hours post-sort with FITC conjugated BS-IB4 or TRA-1-81 as
previously described (section 2.9.4).
The persistence of contaminating ES cells was determined following 7-10 days in ES
specific culture conditions. This assessment was based on cell morphology, Oct-4
expression (section 2.9.4.1), the presence of alkaline phosphatase (section 2.8.3), and
the live/dead stain (Acridine Orange (AO)/ Ethidium Bromide (EtBr)).
Briefly, acridine orange (Sigma) and ethidium bromide (Sigma) lOmg/ml stock
solutions were diluted in complete PBS (plus Mg2+/Ca2+) to give a working stock of
lmg/ml. Culture media was removed and the cells were washed twice with PBS
plus. The AO/EtBr working stock was subsequently diluted 1:50 (0.2mg/ml) and
used immediately. Cells were incubated with sufficient stain to cover the cells (0.5-
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lml), for 40 seconds, at room temperature in the dark. The stain was then removed
and the cells washed twice with complete PBS, and finally resuspended in complete
PBS after which the cells were photographed immediately. The stain and all washes
were disposed of appropriately, filtered through charcoal to safely remove the
ethidium bromide.
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3.2.1 The Adaptation ofExisting Cell Culture Techniques for Established Human
ES Cell Lines.
3.2.2 Engineering Human ES Cells to Express Lysis Epitopes on Their Cell
Surface.
3.3 Discussion
3.3.1 The Use ofH2-Kk as an Epitope for Complement-Mediated Lysis




As discussed in section 1.8, human ES cells, first derived by James Thomson and
colleagues in 1998 were isolated using a combination of mechanical and collagenase
IV or dispase disaggregation agents and initially cultured on mouse embryonic
fibroblast (MEF) feeder-cells, in the presence of serum and leukaemia inhibitory
factor (LIF) (Reubinoff et al., 2000; Thomson et al., 1998). Publication of the
feeder-free culture for human ES cells in 2000, had significant implications for the
scalability of human ES cell culture, growing cells on a synthetic extracellular matrix
(matrigel) in medium pre-conditioned by MEFs and supplemented with recombinant
human basic fibroblast growth factor (hbFGF) (Xu et al., 2000). However, passage
of human ES cells using the feeder-free technique continued to rely on dissociation
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with collagenase IV, a consequence of which was that the ES cell colonies remained
in small clumps at each passage (Xu et al., 2000). Since 1999, the McWhir group
has been investigating a method for the disaggregation of human ES cells using a
trypsin/EGTA solution referred to as TEG (Thomson et al., manuscript in
preparation). Use of TEG promotes dissociation into single cells and resulted in
monolayer cell growth, both of which were important properties for a number of the
techniques used in this investigation.
The ability of human ES cells to grow indefinitely in culture has provided an
opportunity to manipulate their fate, through genetic engineering. As discussed in
Section 1.8.4, a number of different methods of transfection have been used for
genetic manipulation of human ES cells, namely cationic lipids (lipofection) such as
FuGene 6 (Park et al., 2003; Zwaka and Thomson 2003; Lebkowski et al., 2001;
Eiges et al 2001) and Lipofectamine 2000 (Hay et al., 2004; Eiges at al., 2001),
polyethylenimine, ExGen 500 (Schuldiner et al., 2003; Zwaka and Thomson 2003;
Eiges et al., 2001), viral transduction using both lentivirus (Martin et al., 2005;
Gropp et al., 2003; Ma et al., 2003) and adeno-associated virus (AAV) (Smith-Arica
et al., 2003) and more recently using electroporation (Zwaka and Thomson, 2003).
Electroporation, which has been widely used to engineer mouse ES cells (Kim et al.,
2002; Thomas & Capecchi 1987; Doetschman et al., 1986, 1988), providing
transfection efficiencies in the region of 2.1xl0"5 to 5.9xl0"3 (Lakshmipathy et al.,
2004; Piedrahita et al., 1992), has proven problematic for human ES cells, due in part
to high levels of cell death using standard mouse electroporation conditions. Zwaka
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and Thomson (2003) reported that following optimisation of the standard mouse
conditions the transfection efficiency of human ES cells was at best 2.33xl0~5 using
the BioRad Gene Pulse II system (Zwaka and Thomson, 2003). However,
optimisation of electroporation for human ES cells, within the McWhir group
(Priddle, H. unpublished data) using the Eppendorf Multiporator system and human
ES cells dissociated with TEG, have shown a significant increase in the transfection
efficiency of human ES cells in excess of 20-fold (5.58xl0~4).
The aim of this investigation is to engineer human ES cells so that they express cell
surface markers specifically in their undifferentiated state. These markers will then
be used to selectively eliminate undifferentiated human ES cells from differentiated
populations using complement-mediated lysis or fluorescence activated cell sorting.
Both of these processes, successful manipulation of the human ES cells and exposure
of the transgenic cells to the elimination strategy, rely heavily upon processing
human ES cells as a single cell suspension. This chapter will look at adapting the
established in vitro culture conditions to improve growth of human ES cells as single
cell cultures and at manipulating their genome to express cell surface epitopes of
foreign origin.
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3.1.1 Chapter A ims
1. To optimise the culture of established human ES cells lines, to support
monolayer growth and disaggregation into single cell suspension.
2. To build expression vectors that would confer expression of cell surface
markers under the control of ES cell specific promoters.
3. To use electroporation, established during the course of this investigation to
integrate foreign genes into human ES cells.
4. To provide evidence ofDNA integration, protein expression and functionality
of the transgenes.
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3.2 Results
3.2.1 The Adaptation of Existing Cell Culture Techniques for Established
Human ES Cell Lines.
3.2.1.1 The Method of Disaggregation Impacts on How Human ES Cells Grow.
As previously mentioned, the expansion of human ES cells using the feeder-free
technique relied on dissociation with collagenase IV (Xu et al., 2000), which resulted
in the ES cell colonies being maintained as small clumps at each passage.
Furthermore, human ES cells cultured in this way were often associated with
spontaneous differentiation into fibroblast-like cells (Figure 3.2.1a), and in sub-
optimal conditions, the fibroblastic population would take over the culture, resulting
in loss of the human ES cell component. Cell dissociation with EDTA is an
alternative to collagenase IV. EDTA acts by chelating calcium and magnesium ions
from the intercellular bridges and desmosomes, which results in cells then
dissociating from each other and from the support matrix. However, like collagenase
IV, disaggregation with EDTA resulted in small clumps of ES cells at passage and
the presence of a fibroblast cell type within the culture (Figure 3.2.1b).
Trypsin/EGTA solution (TEG) is a method of disaggregation that has been piloted by
the group since 1999, for passaging human ES cells (Thomson et al., manuscript in
preparation) as an alternative to both EDTA and collagenase IV dissociation.
Trypsin is a pancreatic serine protease, which specifically acts on positively charged
lysine and arginine side chains, leading to dissociation from extra cellular matrices.
EGTA, like EDTA, is also a chelator of calcium ions, however its specificity for
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calcium is greater than EDTA and is considered more efficient in breaking calcium
dependent adhesion mediated by cadherins and selectins. Together, trypsin/EGTA
(TEG) encouraged disaggregation into single cells and promoted monolayer cell
growth instead of discrete colonies (Figure 3.2.1c), while significantly reducing
levels of spontaneous differentiation to little if any at all (Figure 3.2.1c).
Figure 3.2.1: Disaggregation techniques for the passage of human ES cells (HI) impact on their
growth pattern. Disaggregation with Collagenase IV (a) and O.SmM EDTA (b) results in the
formation of discrete colonies between which differentiated (fibroblast) cell types are observed.
TEG disaggregation (c) on the other hand produces a monolayer of ES cells, with little if any
evidence of differentiated cells types. Scale bars represent lOOum
To determine the efficiency of the TEG system as a method for disaggregating
human ES cells, the group compared it with collagenase IV and EDTA
disaggregation, in terms of plating efficiency following passage, expression of cell
surface markers and continued pluripotentiality for the established H9 cell line
(Thomson et al., manuscript in preparation). The results were very encouraging with
an increased plating efficiency following TEG passage, continued pluripotentiality
and expression of the characteristic cell surface markers (positive for SSEA-4, TRA-
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1-60 and TRA-1-81 and negative for SSEA-1) (Thomson et al., manuscript in
preparation).
Consequently, the remaining cell lines (HI and H7) available to the group were
converted to the TEG passaging regime for use within this thesis. To substantiate the
data for the H9 cell line, the plating efficiency of the HI cell line was also assessed.
The morphology of both HI and H7 cell lines were monitored, as was the expression
of characteristic cell surface marker following 10 passages.
3.2.1.2 Plating Efficiency
To determine the plating efficiency of human ES cells following disaggregation with
either collagenase IV, EDTA or TEG, lxl05 HI human ES cells were plated in
duplicate wells, of a 6-well plate, in triplicate. Twenty-four hours after plating, one
well from each duplicate was harvested and counted. The second well was grown to
confluence and then passaged appropriately, seeding duplicate wells at 1x10s cells
per well repeating the process. The plating efficiency of HI human ES cells was
monitored in this way for 10 passages using each of the disaggregation agents.
The results of the passaging regime experiment did not demonstrate an obvious
advantage of one treatment over the others. Each of the passaging regimes produced
high and low counts, with the exception of collagenase IV, which remained fairly
constant with an average plating efficiency of 70.91% (+/- 5.99%: Figure 3.2.2). The
average plating efficiency using EDTA disaggregation was almost identical although
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highly variable (69.29% +/- 13.50%), TEG disaggregation was again very variable,



















Figure 3.2.2: The estimated plating efficiency of the established human ES cell line, HI, using
collagenase IV, EDTA and TEG as methods of disaggregation. Triplicate wells for each
dissociation agent were counted 24 hours after re-plating using a standard haemocytometer, and
the mean used as an estimate of the plating efficiency of that agent. Error bars represent the
standard error of the mean.
The estimation of plating efficiencies for collagenase IV and EDTA were heavily
over estimated, since for both passaging regimes the cell counts could not distinguish
between undifferentiated human ES cells and the differentiated human ES cells or
fibroblasts (Figure 3.2.1). Since the use of TEG, as a disaggregation agent, was not
associated with cellular differentiation, it appeared that these data agreed with those
obtained for the H9 cell line (data not shown); the plating efficiency ofHI cells was
increased following continued disaggregation with TEG (Figure 3.2.2). A similar
trend was also observed for the H7 human ES cell line dissociated using TEG instead
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of collagenase IV, however, the plating efficiency was not calculated for this cell
line.
3.2.1.3 Maintenance of ES Cell Characteristics
Expression of the cell surface markers, SSEA-4, SSEA-1, TRA-1-60 and TRA-1-81
has been used extensively to identify undifferentiated human ES cells (Reubinoff et
al., 2000; Thomson et al., 1998). Figure 3.2.3, shows analysis by flow cytometry of
this panel of cell surface markers for undifferentiated H7 cells cultured following
collagenase IV dissociation (Figure 3.2.3a-e) or TEG dissociation (Figure 3.2.3f-j).
These data clearly show a reduced level of differentiation within the population
disaggregated using TEG, only 15% of the cells expressed SSEA-1, a marker
associated with differentiation, compared to 63% when collagenase IV
disaggregation was used. Furthermore, in every other case, the histogram profiles for
TEG passaged cells show more discrete populations with much cleaner distinction
between those which were positive and the isotype controls, indicating a more
uniform population. This difference in the expression of the cell surface markers
was also observed for both the HI and the H9 cell lines when converted to passage
using TEG dissociation instead of collagenase IV (data not shown).
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Figure 3.2.3: Expression of characteristic cell surface markers of human ES cells change slightly
using TEG disaggregation instead of collagenase IV as a result of removing the differentiated
population the histogram peaks are much better defined and the level of the differentiated
marker (SSEA-1) markedly reduced. Images a-e represent H7 cells disaggregated with
collagenase IV, while images f-j, show the same population transitioned to disaggregation with
TEG showing cell surface expression of SSEA-4 (a&f), SSEA-1 (b&g), TRA-1-60 (c&h), TRA-1-
81 (d&I) and CD9 (e&j). Percentages represent the proportion of positive cells within the gated
(live) cell population.
Along with the expression of characteristic cell surface markers, human ES cells
dissociated with TEG also expressed the transcription factor Oct-4 and alkaline
phosphatase (Figure 3.2.4). Oct-4 staining is nuclear and in undifferentiated human
ES cell cultures it was shown to co-localise with the nuclear specific stain, Dapi. All
nuclei in the TEG passaged cultures which were positive for Dapi, were also shown
to express Oct-4, confirming the absence of the differentiated ES or fibroblast cell
types observed in collagenase IV disaggregated ES cells (Figure 3.2.4a and b).
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Figure 3.2.4: Undifferentiated human ES cells cultured using TEG dissociation, express Oct-4
(a) and alkaline phosphatase (c). The whole of the TEG culture express Oct-4 with no evidence
of nuclei from differentiated cells as indicated in panel b, which shows non-specific nuclear
staining with dapi. All scale bars represent lOOum.
3.2.1.4 Fluman ES Cells in Long-Term Culture using TEG Dissociation Possess a
Stable Karyotype.
During the initial passage regime, culture of H9 cells using TEG as a method of
disaggregation resulted in the occurrence of a specific chromosomal abnormality, a
complete duplication of the short arm of chromosome 7 and loss of the long arm (an
isochromosome 7p) (Thomson et al., manuscript in preparation). Since this
observation, a number of other laboratories have described the occurrence of
karyotypic abnormalities following different types of enzymatic disaggregation,
including collagenase IV (Thomson et al., in preparation; Mitalipova et al., 2005;
Brimble et al., 2004; Inzunza et al., 2004; Rosier et al., 2004; Draper et al., 2004).
To determine if this abnormality was a random event or a consequence of TEG
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disaggregation, HI, H7 and H9 cells were assessed for their continued karyotypic
stability following prolonged TEG disaggregation.
It proved difficult to obtain sufficient mitotic spreads to perform karyotype analysis
on both the HI and H7 cell lines (and due to the time constraints of this thesis it was
decided that time would be better spent on engineering the cells first and then
determining their karyotype if time permitted). However, mitotic spreads were
successfully prepared from derivatives of the H9 cell line, the clonal cell line M2
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Figure 3.2.5: A representative example of a mitotic spread from the clonal cell line M2 following
49 passages post-transfection at passage 56. Karyotype profile is 46XX normal, with no obvious
chromosomal abnormalities. Images produced in collaboration with J. Fletcher Roslin Institute.
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A total of 30 spreads were counted, 15 of which were fully analysed (Fletcher, J.
Roslin Institute) showing a stable 46 XX karyotype (Figure 3.2.5). These data
suggested that the initial finding of the abnormal chromosome 7 was probably not a
result of the enzymatic dissociation, but more likely to be that the cells had at some
point been stressed, placing them under selective pressure, where survival was
dependent upon the presence of the isochromosome 7p. Since the report of
chromosomal abnormalities by Draper et al. (2004) a number of reports have been
published that contradict the speculation that human ES cells have unstable
karyotypes over time in culture (Sjogren-Jansson et al., 2005; reviewed by Hoffan &
Carpenter 2005). One might suggest that perhaps the culture conditions currently
employed for the propagation of human ES cells are sub-optimal and that further
refinement might address the occurrence of chromosomal abnormalities.
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3.2.2 Engineering Human ES Cells to Express Lysis Epitopes on Their Cell
Surface.
The ability of human ES cells to grow indefinitely in culture provides an opportunity
to manipulate their fate, through genetic engineering. The selective ablation
strategies in this thesis rely on achieving cell surface expression of foreign "lysis" or
"selection" epitopes.
3.2.2.1 H2-Kk - A Murine Major Histocompatibility Complex Antigen
Genetic Manipulation
To determine the potential of the murine major Histocompatibility complex (MHC)
antigen, H2-Kk, to initiate a complement mediated attack, a preliminary experiment
to engineer cell surface expression on the human ES cell line H7 was attempted.
Initially there were two H2-Kk transfection strategies, one based on the use of the
Oct-4 promoter and the other based on the hTERT promoter. A schematic
representation of the two expression vectors can be seen in Figure 3.2.6 while
specific details of the cloning strategy can be found in Appendix 1.1.
In the first instance phTH2-KkpAPN was stably transfected into 106 wild type H7
human ES cells by electroporation (Multiporator, Eppendorf). Following
electroporation, half of the cells were plated under 200pg/ml G418 selection, a
concentration previously determined by Dr A Thomson (Roslin Institute, Edinburgh)
as being optimal for the removal of non-resistant human ES cells, in a time period
suitable for deriving clones, 7 to 10 days. The resistant colonies (>300) were
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subsequently pooled and the resulting cell line referred to as H7-K.k. The rationale
for pooling the colonies for this preliminary experiment was to balance the effects of
site-specific gene integration to provide a global picture of H2-Kk expression,
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Figure 3.2.6: A schematic representation of the H2-Kk expression constructs. A) H2-Kk was
cloned by PCR from pMAC.Kkll (Milteny Biotech) and TA cloned into pGEM TEasy (Promega)
before being subcloned as an Eco Rl fragment into phTpAPN (Priddle H). Psil was used as a
site for linearising the construct. B] using an Agel : Hpal digest the eGFP minigene was
removed from phOCT-4-eGFP (Zhao D) and the H2-Kk PCR product subcloned in as a blunted
EcoRl fragment. Apa LI was used as a linearisation site.
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Analysis of H2-Kk Protein Expression
Immunochemistry, using commercially available monoclonal anti-mouse H2-Kk
antibody and adult CBA mouse lung-fibroblasts, was used to optimise staining
before assessing expression ofH2-Kk on the transgenic cell line. Wild type H7 cells
were used as a negative control. Optimal conditions for H2-Kk immunochemistry
were determined following several attempts with different methods of fixation, and
antibodies from different suppliers using a range of dilutions (Table 3.2.1).
Fixative














































































Table 3.2.1: Conditions used in the optimisation of H2-Kk immunochemistry showing a range of
fixatives, and concentrations of different primary and secondary antibodies. The conditions in
bold type were determined to be optimal. FITC - Fluorescein Isothiocyanate, PFA -
Paraformaldehyde
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The most convincing cell surface staining was achieved when cells were stained
before fixation using primary antibody diluted 1:100 (BD Pharmingen) with a
fluorescein isothiocyanate (FITC) conjugated secondary antibody (Sigma) diluted
1:200. However, staining using the same antibodies and dilutions was also observed
when cells were permeablised and fixed for 2 minutes in absolute ethanol, although
the pattern of expression altered slightly, showing more internal staining than cell
surface (Figure 3.2.7 a and b).
To determine that the staining for H2-Kk was specific, the expression pattern of p-2
microglobulin (P-2M), an MHC class I associated protein, was also performed by
immunochemistry using a commercially available monoclonal goat anti-p-2M
antibody, which cross reacts with both human and mouse P-2M (Santa Cruz
Biotechnologies, UK) with a R-phycoerythrin (R-PE) conjugated secondary antibody
(Autogen Bioclear, UK) (Table 3.2.2).
Fixative Primary P-2M antibody dilution
Santa Cruz Biotechnologies, UK
Secondary Antibody dilution
Autogen Bioclear, UK
Absolute Ethanol 0.2mg/ml diluted 1/100 IgG2b-R-PE 0.4mg/mldiluted 1/200
Live staining post -fixed
with 4% PFA 0.2mg/ml diluted 1/100
IgG2b-R-PE 0.4mg/ml
diluted 1/200
Table 3.2.2: Conditions used in the optimisation of p-2 microglobulin (P-2M) immunochemistry
showing a range of fixatives, and concentrations of different primary and secondary antibodies.
The conditions in bold type were determined to be optimal. R-PE - R-phycoerythrin.
An identical staining pattern was observed for expression of P-2M in both live and
ethanol permeabilsed adult CBA lung fibroblasts to that previously observed for H2-
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Kk (Figure 3.2.7 d and e). Furthermore, double staining for p-2M and H2-Kk (using
a FITC conjugated H2-Kk antibody, Southern Biotech, USA) showed that these two
proteins co-localised both with live and ethanol fixed cells (Figure 3.2.7 g and h).
CBA Lung fibroblasts
Live Stain
CBA Lung fibroblasts CBA Lung fibroblasts 2i"y Ab only

























Figure 3.2.7: Immunochemistry for H2-Kk and p-2 microglobulin (P-2M) shows positive
expression in CBA adult fibroblasts, but not in transgenic human ES cell lines. Cell surface
expression of both H2-Kk (a and b FITC) and P-2M (d and e R-PE) were observed when CBA
lung Fibroblasts were stained live (a, d and g) or permeablised with absolute ethanol (b, e and h).
Double staining with H2-Kk (FITC) and P-2M (R-PE) showed co-localised expression of these
two genes (g and h). However, transgenic H7-Kk-ES cells were negative for both H2-Kk and
endogenous P-2M (i). Images c and f show that H2-Kk and P-2M staining are specific to the
presence of the respective primary antibody. Scale bars represent lOOum.
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However, when the transgenic H7-Kk cell line was assessed for its level of cell
surface H2-Kk expression, no specific staining was observed under any of the
conditions tried (Figure 3.2.7i is a representative image). Furthermore, positive cell
surface staining for the endogenous MHC class I associated protein (P-2M) was also
absent (data not shown). Lack of cell surface P-2M suggested that human ES cells
either lack MHC expression or express at levels below those detectable by
immunochemistry, a hypothesis that was confirmed by Drukker et al (2002).
Integration ofH2-Kk cDNA was confirmed by RT-PCR.
To determine if the integrity of the H2-Kk transgene had been compromised during
subcloning, RT-PCR was performed to confirm successful subcloning and
integration of the H2-Kk gene into the H7 human ES cell genome.
Mouse and human specific trans-intronic primers had been designed to detect p-
Actin mRNA (a kind gift from Dr S. Pells and Dr N. Forsyth, Roslin Institute
respectively) and were used to generate loading controls (Figure 3.2.8 lanes 1 and 3-
4 respectively). Lane 2 represents RT-PCR in the absence of reverse transcriptase
indicating the specificity of PCR to cDNA and not genomic DNA contamination.
RT-PCR for the presence of H2-Kk mRNA showed positive expression in both the
adult CBA lung fibroblasts (lane 5) and a weaker band in the transgenic H7-Kk cell
line (lane 7), but an absence of expression in the H7 parental population (lane 6) as
expected (Figure 3.2.8). These RT-PCR data show that integration and transcription
of the H2-Kk transgene had successfully been achieved in the H7-Kk cell line,
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suggesting that there may be an issue with appropriate translation and transportation
of the protein.
Figure 3.2.8: RT-PCR for 0-Actin (1-4) and H2-Kk (5-7). CBA adult lung fibroblasts RNA (1),
wild type H7 RNA (3) and H7-Kk cell line (4) positively expressed species-specific P-Actin. Lane
2 represents a minus reverse transcriptase control. Positive II2-Kk expression was observed in
both the CBA positive control RNA (5) and the H7-Kk transgenic cell line (7), but was not
expressed in the H7 parental cell line (6).
Several unsuccessful attempts to determine the expression of the H2-Kk protein by
Western Blot were made. Simultaneously, the expression of p-actin was assessed,
using the same protein lysates as for the H2-Kk western blot, with success (Figure
3.2.9 A). The presence of P-actin indicated intact protein in the protein lysates in
sufficient quantity for detection by western blot. Furthermore, it provided evidence
that the solutions and technique were not responsible for the lack of H2-Kk
expression, leaving only the F12-Kk antibody and conditions.
H2-Kk antibody, from different suppliers, was tried using a range of dilutions, in
reducing and non-reducing conditions without success (Table 3.2.3). Under reducing
conditions, plus DTT in the loading buffer, F12-Kk western blots were blank (data not
shown) even with high concentrations (1:25) of antibody. It was hypothesised that
since immunochemistry of H2-Kk was dependent upon the method of fixation, that
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perhaps under reducing conditions the antibody was no longer capable of detecting
its epitope, thus non-reducing conditions, minus DTT, were tried.
Antibody Supplier Dilutions Reducing conditions Non-reducingconditions
BD Pharmingen
(0.5mg/ml) 1:500, 1:200 and 1:100
XXX
Southern Biotech
(0.5mg/ml) 1:100, 1:50 and 1:25
XX XXX
Table 3.2.3: Primary antibody conditions used for western blot analysis of the H2-Kk protein.
Non-reducing conditions could not be determined using the H2-Kk antibody supplied by BD
Pharmingen due to discontinuation of this product.
Under non-reducing conditions, faint bands of approximately the expected 41kDa
size, were present in the positive control. Increased antibody concentration (1:25)
strengthened these bands, but also resulted in a strong non-specific band in all of the
cell samples, including the negative control, of the same size (Figure 3.2.9 B lane 2).
1 2 3 12 3
Figure 3.2.9: Protein expression analysis by western blot for (t-Actin (A) and H2-Kk (B). Protein
exit acted from lysates of in vitro cell cultures of adult CBA lung fibroblasts (1), H7-ES cells (2)
and transgenic H7-Kk cells (3). The arrow indicates the expected 41kDa H2-Kk band.
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Since the data sheets for the commercially available H2-Kk antibodies did not
indicate successful use in western blot analysis, it was decided that thesis time-
constraints meant optimisation of this technique was inadvisable.
Co-expression of exogenous P-2M was insufficient to induce cell surface expression
ofH2-Kk
The cell surface expression ofMHC molecules requires association with (3-2M prior
to transportation from the endoplasmic reticulum to the cell surface (Paulsson et al.,
2001; Williams et al., 1989). Human ES cells are reported to have low levels of both
MHC and P-2M expression (Drukker et al., 2002). It was therefore hypothesised that
a potential explanation for the lack of H2-Kk at the cell surface was a result of either
insufficient P-2M to associate with both endogenous and transgenic MHC or perhaps
a consequence of species specificity to P-2M association.
In an attempt to overcome this issue, a pooled cell line, co-expressing the H2-Kk
construct and a constitutive mouse P-2M construct (VcP2 - Morello et al., 1982)
(kindly gifted by Prof. S. Ono, University College London, UK) was generated by
electroporation (H7-Kk/p2) and stained for H2-Kk and p-2M expression.
Unfortunately, the co-transfection of H2-Kk and P-2M in human ES cells had no
impact on the level of cell surface expression ofH2-Kk (Figure 3.2.10).
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CBA Lung Fibroblasts Human ES cell line (H7-KVB2)
a b C d
t
H2-K" B-2M H2-K" B-2M
Figure 3.2.10: The co-transfection of p-2M and H2-Kk was insufficient to encourage cell surface
expression of H2-Kk in H7-Kk/p2. Positive staining was for H2-Kk was observed in CBA lung
fibroblasts (a) but not on H7-Kk/p2 ES cells (c). Likewise P-2M positive staining was also
observed on CBA lung fibroblasts (b) but not H7-Kk/p2 ES cells (d)
An attempt was made to induce cell surface presentation of both MHC class I and P-
2M by culturing the H7-Kk and -Kk/p2 cells in the presence of interferon-gamma
(IFN-y), a known stimulant of MHC class I (Rosa et al., 1984; King & Jones 1983).
However, initial attempts failed to show any improvement and since there was no
evidence to suggest that the H2-Kk protein was present, it was decided that there was
no justification in pursing this line of investigation.
The lack of cell surface H2-Kk expression and the potential requirement for the
presence of additional genes and incubation with IFN-y, suggested that this epitope
was not suitable for its desired purpose, as a therapeutically useful lysis epitope.
Therefore, the decision was taken to focus on using the al,3galactosyltransferase
gene and a-gal epitope as an alternative.
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3.2.2.2 Galal-3Gaipi-4GlcNAc-R (a-gal) Epitope
Genetic Manipulation
The al,3galactosyltransferase (al,3Gal) expression vectors used in this study were
constructed by Dr. Helen Priddle (University of Nottingham, UK). A schematic
representation of these can be seen below (Figure 3.2.11) with specific cloning
details described in Appendix 1.2.
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Figure 3.2.11: Schematic representation of the two constructs used to express the a-gal epitope
on the cell surface of human ES cells. Both constructs were engineered by Dr Helen Priddle, a|
mouse kidney al,3galactosyltransferase cDNA under the control of a core hTERT promoter b|
the same construct containing the leader sequence of the fucosyltransferase gene.
Dr H. Priddle produced transgenic mGT and fucGT cell lines, by electroporation
using hyposmolarity buffer and an Eppendorf Multiporator (Eppendorf). Briefly,
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lxlO6 H9 human ES cells were electroporated with linear DNA, plated and selected
in the presence of 200pg/ml G418 for 10-14 days. From each transfection, yielding
558 and 585 colonies respectively, 24 colonies were picked and expanded, from
which 4 of the mGT clones and 8 of the fucGT clones expressed the a-gal epitope.
The latter clones contained both the a 1,3Gal gene and the leader sequence of the
fucosyltransferase gene (fucGT), which was developed because of the report that
native al,3Gal was out competed by fucosyltransferase for location in the Golgi
apparatus, conferring preference to fucosyltransferase processing (Osman et al.,
1996). Thus by engineering the a1,3Gal construct to contain the leader sequence of
the fucosyltransferase gene the hypothesis was that al,3Gal expression would be
elevated due to increased competition for location in the Golgi.
Analysis of Protein Expression
Expression of the a-gal epitope was determined using immunochemistry and flow
cytometry using the a-gal specific fluorescein isothiocyanate (FITC)-conjugated
Bandeiraea simplicifolia isolectin B4 (BS-IB4, Sigma) described by Wu et al.,
(1995). Based on unpublished data one mGT clone, M2, (Priddle H., unpublished
data) was selected for use in this investigation, due to its known high level of
expression. When cultured under G418 selection (200pg/ml), this cell line expressed
the a-gal epitope on 95.40% of its cell surfaces at levels slightly lower than those of
the endogenously expressing ovine (Polled Dorset) foetal fibroblast (PDFF) cell line
(with a median fluorescence intensity of 478.29 and 615.27 respectively) (Figure
3.2.12A, images a and c).
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97.92%
84.74%
Figure 3.2.12: Expression of al,3Gal was assessed using a fluorescein isothiocyanate (FITC)-
conjugated Bandeiraea simplicifolia isolectin B4 (BS-IB4, Sigma) specific for a-gal. A] Flow
cytometry analysis of BS-IB4 staining on endogenously expressing PDFF (a), negative wild type
human ES cells H9 (b) and transgenic cell lines M2 (c) and Fll (d). B| BS-IB4
immunochemistry for a-gal, on PDFF (a-b), H9 (c-d), M2 (e-f) and Fll (g-h) showing phase




As a comparison the level of a-gal expression of a second transgenic clone (Fll),
this time containing the leader sequence of the fucosyltransferase gene, was assessed.
The F11 cell line expressed lower levels of the a-gal epitope than did the M2 clone,
with a median fluorescence intensity of 395.96 and appeared to be more variegated
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with only 84.74% of the cells expressing (Figure 3.2.12A, image d), suggesting that
the inclusion of the leader sequence of the fucosyltransferase gene had not increased
the cells ability to process al,3Gal in the Golgi.
Figure 3.2.12B shows visually the pattern of FITC conjugated BS-IB4 binding for M2
(e-f) and Fll (g-h) clones in addition to PDFF cells as a positive control (a-b) and
consistent with the inactive gene in humans, H9 wild-type cells were negative for a-
gal (c-d). The immunochemistry and flow cytometry data both agreed that the M2
cell line had a higher and more uniform expression pattern than the Fll cell line,
although there remained a degree of variegation within the M2 population. Based on
these data, M2 was the cell line of choice in subsequent experiments, maintained in
200pg/ml G418 selection to help minimize the impact of position effect variegation
(PEV).
Transgenic human ES cells carrying the a 1.3Gal gene maintain a stable karyotype
and pluripotentiality.
To ensure that genetic manipulation had not been detrimental towards the ES cells in
terms of their pluripotentiality, embryoid bodies (EB's) were generated from the M2
cell line (see section 2.8.4). Following 7 days in suspension, the EB's were plated
onto gelatin and allowed to spontaneously differentiate for 14 days in basic
differentiation medium (KO-DMEM supplemented with 10% (v/v) FBS, 0.1mM
NEAA, 2mM L-glutamine and 0.1mM (3-mercaptoethanol). The resulting cells were
then analysed for markers representative of all 3 embryonic germ layers, endoderm
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(a-fetoprotein; AFP), ectoderm (P-tubulin III) and mesoderm (muscle specific-actin)
(Figure 3.2.13 a-c respectively).








Figure 3.2.13: Transgenic M2 cells maintain their ability to differentiate in vitro into all 3
embryonic germ layers, endoderm, ectoderm and mesoderm. In vitro differentiation of IV12 cells
results in cell types, which express markers of endoderm (a-fetoprotein; AFP (a and d)),
ectoderm (^-tubulin HI (b and e)) and mesoderm (muscle specific actin (c and f)). Ail scale bars
represent lOOum.
Furthermore, when undifferentiated M2 cells were injected intramuscularly into
severe combined immune deficient (SCID) mice they formed tumours. Upon
analysis, these tumours were found to contain cell types representative of all 3 germ
layers and were consequently classified as teratomas (Figure 3.2.14). For human ES
cells, these are the only methods available to determine the pluripotentiality of the
cells.
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Ectoderm Endoderm Mesoderm
Figure 3.2.14: Transgenic M2 cells maintain their ability to differentiate in vivo into all 3
embryonic germ layers, endoderm, ectoderm and mesoderm. When injected intramuscularly
into SCID mice M2 cells formed teratomas that contained a) sensory epithelium and b) neural
epithelium from the ectoderm lineage, c) secretary epithelium and d) transitional ciliated
epithelium from the endoderm lineage and e) cartilage, mesenchyme and f) smooth muscle from
the mesoderm. Images provided by Dr David Brownstein (University of Edinburgh, Scotland)
main images were taken using a x20 objective (inserts used a xlOO (except b which used a x200)
objective). Where provided scale bars represent lOOpM
As previously mentioned in section 3.2.1.4, M2 cells maintained a stable karyotype
after more than 60 passages with TEG. Together these data suggested that the
genetic manipulation had not had a detrimental impact on the normality or
pluripotentiality of the human ES cells.
Transgenic a-gal epitopes successfully bind human anti-a-gal immunoglobulins.
To elicit complement-mediated lysis, it is essential that the transgenic a-gal epitopes
have an appropriate conformation in order to bind anti-a-gal antibody. To assess this
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PDFF, M2 and H9 cells were incubated in the presence of undiluted heat inactivated
human serum, counter stained with an FITC conjugated anti-human immunoglobulin
(Ig) antibody (1:200 - Southern Biotech) and binding assessed by flow cytometry
(BD FACScan). Since human serum contains antibodies that may interact with
antigens on the ES cell surface, but which are not a-gal, binding to wild type F19 cells
was used as a baseline control. Additionally, to ensure that there was no non-specific
binding of the secondary antibody, H9 cells were incubated in FITC-conjugated
human Ig alone (Figure 3.2.15A).
Figure 3.2.15: Transgenic human ES cells (M2-red) expressing the a-gal epitope are less efficient
than endogenously expressing PDFF cells (blue) at binding human anti-a-gal antibodies. H9
(green), M2 and PDFF cells were incubated with undiluted heat inactivated (HIA) human serum
and counter-stained with FITC conjugated anti-human immunoglobulin as a method of
assessing appropriate conformation of the transgenic a-gal epitope. A) FI9 cells incubated
(green) and not incubated (black) with HIA serum, were used to determine the level of non¬
specific binding of the anti-Human Ig antibody, setting the baseline for B. B) Specific binding of
human Ig to the a-gal epitope over and above the baseline.
Transgenic a-gal epitopes expressed on M2 cells were successfully able to bind
natural anti-a-gal antibodies contained within human serum, although there was less
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binding than was observed for PDFF cells, with 73% of cells binding compared to
95% (Mean fluorescence intensity 447.48 and 913.34 respectively: Figure 3.2.15B),
suggesting that perhaps there was fewer epitopes on the M2 cells. As expected there
was non-specific binding to wild type H9 cells, possibly due to the presence of anti-
ES cell antibody contained within human serum, but most likely to be as a result of
the sheer volume of protein contained within serum. When this non-specific binding
was removed from the system, a substantial level of human Ig binding specifically to
the a-gal epitope was observed. This suggested that M2 cells were likely to initiate a
complement-mediated lysis response when in the presence of active human serum,
however, binding of an antibody is only the first stage of complement mediated lysis,
and the ability of complement to specifically lyse the M2 cells remained an essential
part of this investigation.
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3.3 Discussion
The use of TEG (trypsin/EGTA) as a method of disaggregation has been confirmed
as an efficient and robust method for passaging undifferentiated human ES cells,
facilitating monolayer growth while reducing spontaneous differentiation. Human
ES cells passaged in this way continue to express the characteristic markers of
human ES cells (SSEA-4, TRA-1-60 and TRA-1-81) and lack SSEA-1, characteristic
of differentiating human ES cells. Although initial results appeared to indicate an
increased incidence of chromosomal abnormalities, karyotypic analysis of a clonal
cell line maintained with TEG dissociation for more than 60 passages, showed no
evidence of genomic instability. Furthermore, the use of TEG has facilitated the use
of techniques, such as flow cytometry, which require cells to be in single cell
suspension. Since the group began work on optimising the culture conditions of
human ES cells, the use of dispase (Gibco), a commercially available amino-endo
peptidase produced by Bacillus polymyxa, to disaggregate human ES cells has been
reported (Reubinoff, et al., 2000). As with TEG the advantage of using dispase over
collagenase IV and EDTA is that dispase yields a single cell suspension.
Furthermore, dispase cleaves fibronectin, collagen IV, and to a lesser extent collagen
I, and is therefore, less aggressive than both trypsin and collagenase IV in its
disaggregation and does not disrupt the cell membrane, although, dispase is less
specific than collagenase IV. It would be interesting in light of the results comparing
TEG, EDTA and collagenase IV, to compare the dissociation of human ES cells
using dispase or TEG and to compare their effects on plating efficiency and
karyotypic stability.
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3.3.1 The Use ofH2-1'(* as an Epitope for Complement-Mediated Lysis
The rational for using the murine MHC class I molecule, H2-Kk, as an epitope to
initiate complement-mediated lysis stems from its successful application as a
transgenic cell surface epitope on chicken blastodermal cells selected for by
magnetic cell sorting (MACS) (Wei et al., 2001). However, to-date successful
expression of this cell surface marker on cells of a human embryonic nature has not
been reported. It is well known that MHC presentation is developmentally regulated
(Warner and Gollnick, 1993), with low, lack or modified MHC expression being one
of the suggested methods by which developing foetuses are protected from maternal
immune responses (reviewed by Gaunt & Ramin, 2001). The low level of both
MHC class I and 0-2 Microglobulin (0-2M) expression on human ES cells reported
by Drukker et ah, (2002), was consistent with these views that the cells of the early
embryo have some degree of immune privilege. It was hypothesised that since all
MHC molecules require the association of 0-2M to achieve stable transport to the
cell surface, that one possible explanation for the lack of cell surface H2-Kk
expression in transgenic H7 cells was insufficient 0-2M to associate with both
endogenous and transgenic MHC. However, over-expressing 0-2M using a
constitutive 0-2M construct, Vc02 (a kind gift by Prof S Ono (University College,
London) had no impact on the level of cell surface H2-Kk.
These data could be interpreted in a number of ways. Firstly, since there was no
direct selection for the integration of Vc02, it was possible that the transfection was
unsuccessful; selection of colonies was driven from the neomycin cassette contained
in phTH2-KkpAPN. Secondly, that low levels of endogenous 0-2M were not
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responsible for the lack of cell surface expression of H2-Kk, but that there was a
fundamental issue with translation of or transport of the H2-Kk protein, perhaps there
is a genetic "safe guard" against presentation of MHC on embryonic cells. Thirdly,
it was possible that the site of integration was silenced, although since the population
was a pool this seemed unlikely.
As cell surface expression of the H2-Kk protein could not be achieved using a single
transgene and could require co-transfection and induction to achieve expression, it
was decided that this construct would be more complicated to use in a therapeutic
setting, than a-gal.
3.3.2 The Use of Gala 1 -3Galf I-4glcnac-R (a-Gal) as an Epitope for
Complement-Mediated Lysis
By contrast to H2-Kk, engineering human ES cells to contain the
al,3galactosyltransferase (a-l,3Gal) gene was very successful. Cell surface
expression of transgenic a-gal epitopes was found, in the best case, to be comparable
with levels on endogenously expressing PDFF cells, as detected by binding of the a-
gal specific lectin BS-IB4. However, the level of a-gal expression was variable
between clones, suggesting that the transgene was subject to positional effects. To
some extent position effect variegation (PEV) was managed by maintaining the cells
under constant G418 selection. When G418 selection was removed on the clonal cell
lines, the number of cells expressing the a-gal epitope decreased. For the least
variegated clone M2, the expression level fell from 95.40% as shown here to 82.60%
(data not shown). However, for the Fll cell line, the drop in expression was more
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dramatic, from 84.74% to 42.90%, as detected by flow cytometry. If selection had
been relaxed permanently, there was the possibility that expression of the transgene
would have been lost through silencing. A solution to this problem would be to
target the al,3Gal construct into the endogenous hTERT locus, so that al,3Gal
would collect the native hTERT promoter and consequently would be regulated
appropriately avoiding silencing elements and heterochromatinisation. Alternatively,
the construct could be targeted into a neutral genomic site, where expression patterns
had been fully characterised. Such endogenous sites are being explored within the
group by gene targeting (DiDomenico, et al., manuscript in preparation) and through
the random integration and characterisation of an artificial locus (Thomson and
Wojtacha, unpublished data). Alternatively, since the al,3Gal construct is small,
lentiviral transduction could be used to stably integrate DNA into the human ES cell
genome, a technique that has been shown to be efficient and resistant to gene
silencing (Martin et al., 2005; Gropp et al., 2003; Ma et al., 2003).
Despite the issue of variegation, preliminary functional data showed that cell surface
a-gal epitopes on transgenic M2 cells were capable of binding natural anti-a-gal
antibodies, to a similar level as the PDFF cells and it was therefore, anticipated that
the epitopes would be able to initiate a complement mediated attack in line with that
observed for endogenously expressing PDFF cells.
Importantly, from a therapeutic perspective, human ES cells which had integrated
al,3Gal behaved in the same way as their untransfected parental cells. Transgene
integration did not affected their potentiality, with cell types representative of the 3
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germ layers, endoderm, ectoderm and mesoderm, observed with both in vitro
differentiation and teratoma formation in vivo when cells were injected
intramuscularly into SCID mice. Furthermore, the M2 cell line maintained a stable
46 XX karyotype after over 60 passages.
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3.4 Conclusion
The results presented in this chapter, show that the use of trypsin/EGTA (TEG) as a
method of disaggregating human ES cells for routine culture has allowed the
generation of a more homogeneous population of human ES cells, with little, if any
differentiation. That ES cells cultured in this way, dissociate into a single cell
suspension, aiding optimisation of electroporation techniques, resulting in efficient
introduction of transgenes with greater success than reported by Zwaka and
Thomson, (2003).
For reasons that are not yet clear, transgenic expression of H2-Kk was not achieved,
despite successful integration of the transgene. However, human ES cells were
engineered to express high levels of a-gal epitopes through the random integration of
a hTERT/al,3Gal transgene. Expression of a-gal epitopes as a consequence, was
similar to that observed on endogenously expressing cells (PDFF) and preliminary
data suggested that the expressed epitopes were able to bind natural anti-a-gal
antibodies found in human serum. It was therefore, hypothesised that the a-gal
epitope would successfully initiate complement-mediated lysis when cells were
exposed to active human serum.
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4.1 Introduction
Complement is a component of the innate immune system, involved in self-non-self
recognition. Activation of complement via the classical pathway (see section
1.7.1.2) is dependent upon binding of antibody to antigen, resulting in the exposure
of complement binding sites in the Fc portion of the antibody. The ovine foetal
fibroblast cell line, from the Polled Dorest breed (PDFF), like many other cells,
endogenously expresses the al,3galactosyltransferase (al,3Gal) gene, and hence
expresses the a-gal epitope on the surface of their cells (Figure 3.2.12). Through
evolutionary time humans have acquired a fixed mutation in the al,3Gal gene
resulting in loss of gene function, as previously discussed, and have developed
natural anti-a-gal antibodies as a result of the continued presence of the gut
microflora, which express a-gal (Galili et al., 1988b). Therefore, human serum not
only contains all of the components of the complement cascade required to cause cell
lysis, it also contains a high titre of natural anti-a-gal antibody, up to 1% of total
circulating immunoglobulin (Ig) (Galili et al., 1987b), to trigger it. Together, these
qualities provided an opportunity to establish optimal working conditions for
complement-mediated lysis experiments, independent of the effects of protein
expression levels and variegation from transgenic cell lines.
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4.1.1 Chapter A ims
1. To become familiar with established protocols for the detection of cytolytic
activity using the Calcein-release technique.
2. To optimise the Calcein-release assay to provide a sensitive and reproducible
method for the detection of cytolytic activity.
3. To determine the sensitivity of human ES cells to complement-mediated
lysis.
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4.2 Results
4.2.1 Using Established Methods for the Detection and Quantification of
Complement-Mediated Cell Lysis Utilizing the a-gal Epitope and
Endogenous Antibodies as a Trigger.
PDFFs were loaded with 2pM Calcein.AM in accordance with the methods of Spiller
(2000) for an hour at 37°C prior to lysis. Lysis was performed with 250pl of 50%
human or foetal bovine sera diluted in gelatin veronal buffer plus magnesium and
calcium (GVB2+), for 1 hour at 37°C, to determine the specificity and sensitivity of
the reported conditions for the Calcein-release assay. Initially, results appeared
encouraging (Figure 4.2.1), significant Calcein-release was only observed in the
presence of active human serum, suggesting that although the level of specific lysis
(Calcein-release from active serum minus that from heat inactivated serum) was
lower than expected (between 40-50%), the a-gal epitope was capable of eliciting a
complement mediated response triggered via natural anti-a-gal antibodies contained
within human serum.
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Figure 4.2.1: Preliminary data suggested that serum lysis of PDFF cells appeared to be specific
to active (blue) human serum. Incubation with active foetal bovine serum and heat inactivated
(HIA) sera (red) resulted in the same level of Calcein-release as seen spontaneously (yellow).
Data represents the mean of 6 replicates and error bars represent the standard deviation of the
individual observations.
However, when these conditions were tried on both wild type (H9) and transgenic
(M2) human ES cells, high levels of cell death were observed in the heat inactivated
serum control as well as in the H9 cells, which did not present a lysis epitope,
suggesting that the conditions of this assay were not optimal for human ES cells
(Figure 4.2.2).
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Active Serum HIA Serum
Figure 4.2.2: Human ES cells are non-speciflcally killed using established conditions. Serum
lysis experiments using reported protocols (Spiller, 2000) on H9 (a-b) and M2 (c-d) human ES
cells revealed a high level of non-specific cell death in the presence of both active (a&c) and heat
inactivated (b&d) human serum. Cells were suspensded at 1x10s in 250pl of human serum
diluted to 50% in GVB2+ buffer, and incubated at 37°C for 1 hour, before being re-plated in
standard tissue culture conditons. Cell Survival was assessed 24 hours later based on plating
density. All images were view under x40 objective, scale bar represents 20um.
4.2.2 Different Assay Buffers have a Dramatic Effect on the Level of
Spontaneously Released Calcein from Cells in the Absence of
Complement.
To investigate the possibility that a component of the assay was responsible for the
high level of non-specific cell death, each element was individually assessed.
Human ES cells are cultured under strict conditions, requiring very specific medium,
in comparison to that of fibroblastic cell types, and are highly sensitive to changes in
-170-
Chapter 4 - Optimising complement-mediated lysis for human ES cells.
those conditions. Therefore, the assay buffers were the obvious components of the
complement-mediated lysis assay to be addressed.
During Calcein.AM loading the cells were incubated in culture medium. However,
during lysis, the suggested serum dilution buffer was veronal buffered saline (VBS).
The necessary component of this buffer is calcium, since initiation of the classical
complement pathway requires the presence of calcium (Kosasi, et al., 1989).
However, although VBS is a saline, the salt concentration was such that the buffer
was hypotonic, which consequently induced an osmotic pressure gradient across the
cells leading to cell swelling and eventual cell death. The addition of gelatin to VBS
(GVB ) was recommended for use with cell types that were highly sensitive to lysis
• • • • 2~hfor maintenance of osmolarity (Spiller, B. Pers. Com.). Despite the use ofGVB the
level of non-specific cell death remained high when human ES cells were exposed to
diluted serum (Figure 4.2.2). To test the hypothesis that the buffer was responsible
for high background cell death, human ES cells were loaded with Calcein.AM as
9+
previously described, and then incubated in neat GVB buffer, PBS plus magnesium
and calcium, or complete culture medium for an hour at 37°C, before recording the
level of spontaneous Calcein-release in the supernatant. Interestingly, culture in
• • 9-F 9+ a
isotonic PBS (plus Mg /Ca ) resulted in elevated levels of spontaneous Calcein-
9-i_
release (53%) compared to just 27% when cells were incubated in GVB ,
confirming that the presence of gelatin reduces the susceptibility of cells to lysis in a
hypotonic environment. As expected, however, the incubation of cells in culture
medium reduced the level of spontaneous release to just 15%, suggesting that the
cells were less stressed (Figure 4.2.3).
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Figure 4.2.3: Serum dilution buffer contributed significantly to the observed spontaneous
Calcein-release. Background Calcein-release resulting from incubation with the suggested
serum dilution buffer, GVB2+ buffer (blue), was 27%. When cells were incubated with PBS
(red) was this background increased, as expected, to 53%. The use of culture medium (yellow)
reduced the background to 15%, without increasing the level of auto-fluorescence. Data
represent the mean of triplicate results and error bars represent the standard deviation of the
individual observations.
While incubation in GVB2+ alone produced considerably higher levels of
spontaneous release than incubation in culture medium, these levels were not as high
as anticipated, and were in fact only 7% higher than the accepted level for
spontaneous Calcein-release, reported in the literature (Phelps et al, 2003). However,
it was clear that incubation in GVB2+ was sufficient to compromise the ability of H9
cells to re-plate (Figure 4.2.4), helping to explain the high levels of non-specific lysis
observed (Figure 4.2.2).
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GVB2+ PBS CM
Figure 4.2.4: Cell survival following incubation with culture medium was significantly better
then incubation with GVB2+ or PBS plus. 10s H9 cells were incubated with GVB2+ (a), PBS (b)
or conditioned medium (c) for an hour before being re-plated. Cells were allowed to attach and
were assessed for cell survival based on plating density. Images a-c are representative examples
of cell density 24 hours later.
Complement is a series of proteins with short half-lives, which are rapidly degraded
as a mechanism of self-regulation (Liszewski et al., 1996), so it was essential to
determine that initiation of a complement cascade could and would still occur if the
9+
serum was diluted in culture medium and not GVB . PDFF, M2 and H9 cells were
loaded with Calcein.AM (2pM for 1 hrs at 37°C) and incubated in 250pl of active or
heat inactivated human serum, diluted to 50% in the appropriate culture medium
using a modified version of the published method (Spiller, 2000). A culture medium
alone control was included to determine the level of spontaneous Calcein-release.
Cells were incubated in suspension at 37°C in a humidified incubator plus 5% CO2,
for an hour.
• 9+ •
The dilution of serum in culture medium instead of GVB had no impact on the
initiation of a classical complement attack (Figure 4.2.5). 40% of the PDFF cells
died, specifically as a result of the active serum, as previously observed (Figure
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4.2.1), although, the level of non-specific lysis increased for the PDFFs from 21% to
37%. Furthermore, levels of spontaneous release were in excess of the accepted 20%
background. Nevertheless, a substantial increase in the level of cell survival was
observed for cells expected to survive complement-mediated cell lysis (H9) in both
active and heat-inactivated sera to approximately 70%. Unfortunately, the same
level of cell survival was also observed in the transgenic M2 cell line (Figure 4.2.5),










Active Human Serum HIA Human Serum Spontaneous Release
Figure 4.2.5: Using culture media, as serum dilution buffers, had no impact on complement
initiation. Specific PDFF lysis (blue) was observed at a level of 40% the same as when GVB2+
was used. Furthermore, there was no specific lysis observed in the H9s (yellow) as expected,
however, neither was there any lysis observed for the transgenic M2 cell line (red). Bars
represent the mean of triplicate samples and the error bars represent the standard deviation of
the individual observations.
Confirmation of these results was, however, difficult to achieve due to significant
inter-experimental variation (Figure 4.2.6). From at least four independent assay
runs, the average level of specific PDFF lysis ranged from 7% to 40%, and
- 174-
Chapter 4 - Optimising complement-mediated lysis for human ES cells.
interestingly the range of specific M2 lysis was similar, from 0% to 33%, although
unlike the PDFFs, specific M2 lysis was only observed on one occasion, giving a
value of 33%. The level of specific H9 lysis, although variable was within a much
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Figure 4.2.6: Inter-experimental variation was very high. The reported conditions for the
detection of complement-mediated lysis through Calcein-release (Spiller, 2000) were highly
variable between runs. Cells were loaded with 2pM Calcein.AM for an hour at 37°C before
incubation with active or heat inactivated (HIA) serum or culture medium (SR). The value for
SR reflects the mean of all cell types. All other values are the mean percentage Calcein-release
from triplicate experiments and error bars represent the standard deviation of the individual
observations.
The high inter-experimental variation, but absence of even low levels of reproducible
M2 lysis led to the formation of two working hypotheses, either a) the experimental
conditions for the use of the Calcein-release assay were still not optimal or b) that
because of their embryonic origin, human ES cells expressed high levels of
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complement regulatory proteins and were hence resistant to complement-mediated
attack.
4.2.3 Human ES cells Express High Levels ofComplement Regulatory Proteins
CD46, CD55 and CD59.
The initial lack of specific M2 lysis, using the published protocol, suggested that
human ES cells could be resistant to complement-mediated lysis. It was
hypothesized that this may be due to their embryonic nature, and possible over-
expression of complement-regulatory proteins (Simpson et al., 1993). Therefore, the
expression of CD46 (Membrane Co-factor protein MCP), CD55 (Decay accelerating
factor DAF) and CD59 (Membrane inhibitor of reactive lysis MIRL), the three major
membrane bound complement regulatory proteins, were assessed by flow cytometry.
Expression of complement inhibitors on human ES cells was compared to known
expression levels on cell types sensitive to complement-mediated lysis, human
multipotential erythroid progenitor (K562) cells and human promonocytic (U937)
cells (Jurianz et al., 2001; von Zons et al., 1997; Van den Berg et al., 1994) and a
second cell type of embryonic origin, human embryonic kidney, HEK 293, cells.
Pre-conjugated antibodies (Table 4.2.1) were used to stain K562, U937, HEK 293,
HI, H7 and H9 cells (106), in staining buffer (PBS with 2% FBS and 2mM EDTA),
on ice for 30 minutes in the dark. Flow cytometry was performed using a FACScan
(Becton Dickenson), and CellQuest Pro analysis software. Analysis of variance
(ANOVA) was performed (Springbett, A., Roslin Institute, Edinburgh) to determine
the significance of shifts in the mean fluorescence intensity between cell types.
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Antibody Name Fluorochrome Dilution Suppliers
CD46 (MCP) FITC 0.1mg/ml diluted 1:10 Serotech
CD55 (DAF) PE 0.2mg/ml diluted 1:10 BD Bioscience
CD59 (MIRL) FITC 0.5mg/ml diluted 1:10 BD Bioscience
Table 4.2.1: Complement regulatory antibodies, fluorochrome, dilution factors and suppliers for
the antibodies used for flow cytometry.
Human ES cells expressed statistically higher (P<0.01) levels of CD46 than K562
(Figure 4.2.7a), yet statistically lower levels than U937, with the exception of HI
cells, which express more CD46 than all of the other cell lines (Figure 4.2.7b).
Expression of CD46 on the HEK 293 cells followed that of human ES cell line H9
(Figure 4.2.7a). CD55 expression on the other hand, was significantly elevated on all
human ES cells and HEK 293 cells (p<0.01) compared to levels expressed by both
K562 and U937 (Figure 4.2.7c). CD55 expression was expressed on HI and H7 cells
in similar amounts however, H9 cells (the parental cell line to M2 cells) expressed
significantly (PO.Ol) more CD55 than both HI and H7 (Figure 4.2.7d).
It is reported in the literature, that K562 cells have high levels of complement
inhibitory protein CD59 (Jurianz et al., 2001), which was confirmed here (Figure
4.2.7e). CD59 expression on HEK 293 and human ES cells was statistically lower
than on K562 cells, but its expression was statistically higher than on U937 cells. All
three human ES cells lines expressed CD59 in equal amounts (Figure 4.2.7f).
Whilst human ES cells express significantly higher levels of complement regulatory
protein CD55 and CD59 statistically, the biological significance of these elevated
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levels remained unclear. It was decided that in order to answer this question, it was
first necessary to determine the optimal working conditions for both in vitro
complement-mediated lysis and the Calcein-release detection-assay.






Figure 4.2.7: Expression levels of complement regulatory proteins, CD46 (A&B), CD55 (C&D)
and CD59 (E&F) by flow cytometry. A, C and E compare expression levels of K562 (blue),
U937 (red) HEK 293 (yellow) and H9 (green) cells. B, D, and F compare expression levels
between different human ES cell lines HI (purple), H7 (orange) and H9 (green). In all cases the
black line represent the fluorescence from an isotype control.
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4.2.4 Assessing the Kinetics ofCalcein.AMLoading
The Calcein-release assay has been reported by many (Iwanowicz et al., 2004;
Phelps et al., 2003; Neri et al., 2001; Oral et al., 1998; Braut-Boucher et al., 1995;
Lichtenfels et al., 1994) to be a reliable and reproducible alternative to the 51Cr-
release assay. It was therefore, decided to optimise the Calcein-release assay,
specifically for assessment of complement-mediated lysis of human ES cells.
Initially, Calcein concentration and loading time were determined for PDFF's. Serial
dilutions of Calcein.AM were made in culture medium covering a range of
concentrations reported in the literature, 0, 2, 5, and lOpM (Iwanowicz et al., 2004)
and in further excess, 20, 40 and 80pM. PDFF's (1x10s) were resuspended in 50pi
of diluted Calcein.AM and incubated for 1, 2 and 4 hours at 37°C in a humidified
incubator plus 5% CO2, in an attempt to find a point of cell saturation. Following
Calcein loading, the cells were then assessed for the level of spontaneous release
(SR) through a further 1-hour incubation with lOOpl culture medium, or for the level
of total release (TR) through incubation with the same volume of 0.1% triton-X 100
(Figure 4.2.8) using the protocol described by Iwanowicz et al., (2004).
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Figure 4.2.8: Calcein.AM concentrations required for labelling 1x10s PDFF cells in suspension
far exceed those reported in the literature for other cell types. Using established protocols
(2pM) there was little difference between the level of spontaneous release (■) and total release
(A). However, at lOpM and above there is clear separation. Incubation for an hour (blue)
seems efficient at the lower concentrations but above 10pM 2 hours (red) gives a more
significant separation. 4 hours (black) in the presence of Calcein.AM appears to reduce the
level of total release, and increase slightly the level of spontaneous release, possibly due to a
toxic effect. The data represent the mean of 3 independent replications; error bars show the
standard error about the mean.
Calcein.AM Concentration
It was clear from these data that loading PDFF's with 2pM Calcein.AM was
insufficient to reliably differentiate between spontaneous (■) and total (A) release
(Figure 4.2.8). Furthermore, since the cells had not reached saturation at 80pM, a
40-fold increase in Calcein.AM, it was evident that the use of 2pM was resulting in
the majority of cells containing no label, and thus reducing the assays sensitivity as
small errors in cell counting could have accounted for the observed variation in
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fluorescence intensity readings, and consequently percentage Calcein-release
between assay runs.
Interestingly, when cells are loaded with low concentrations of Calcein.AM, up to
lOpM, a 1-hour incubation appeared to provide maximal Calcein.AM uptake, giving
the highest values of total release. However, for concentrations of 20pM and above,
a 2-hour incubation provided significantly higher levels of Calcein.AM loading.
Furthermore, the level of spontaneous release (SR) following 1- and 2-hour loading
was comparable, whereas SR was slightly elevated following 4 hours of loading.
Together with the reduced Calcein.AM uptake following a 4-hour incubation these
data suggested that prolonged incubation in Calcein.AM was detrimental to cell
survival. It was therefore decided, that a loading time of 2 hours be used to optimise
the concentration of Calcein.AM required to achieve saturation for different cell
types, without causing increased levels of background through non-specific cell
death.
4.2.5 Cell Types Vary in their Ability to Take-Up Calcein.AM and in their
Capacity to Retain the Fluorescentform ofCalcein.
To determine if Calcein.AM loading and retention varied for different cell types,
PDFF, LLC-PK1 (porcine kidney epithelial cells) and wild type H9 ES cells were
incubated with serial dilutions of Calcein.AM, extending to 160pM, for 2 hours at
37°C in a humidified incubator plus 5% CO2,
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PDFF cells were able to take up and retain the Calcein.AM label more efficiently
than either human ES cells or LLC-PK1 cells (Figure 4.2.9). At concentrations of
10pM there was already a clear difference between the level of spontaneous and total
release. Likewise for human ES cells, uptake of Calcein.AM was clearly detectable
at concentrations as low as lOpM, however, the level of spontaneous release was
significantly higher then in PDFF's reducing assay sensitivity. Therefore, in order to
achieve maximal separation of spontaneous and total released Calcein from human
ES cells it was decided that a concentration of 40-80pM Calcein.AM was necessary
(Figure 4.2.9).
Interestingly, LLC-PK1 cells were more resistant to Calcein labelling than both
PDFF and human ES cells. Calcein uptake remained low until the Calcein.AM
concentration had exceeded 40pM. However, LLC-PK1 cells were better at
retaining the Calcein label than human ES cells, but not as efficient as PDFF cells
(Figure 4.2.9).
A Calcein.AM concentration of 160pM had a negative impact on the level of total
release in both PDFF and human ES cells, and on the level of spontaneous release in
human ES cells, suggesting that at high concentrations Calcein.AM was toxic to
these cell types, preventing retention of the label during the labelling process and
hence reducing the level of Calcein released, even at the spontaneous level (Figure
4.2.9). LLC-PK1 cells however, were not adversely affected by the high
Calcein.AM concentration, suggesting that these are potentially more resilient cells.
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Calcein.AM Concentration
Figure 4.2.9: Cell types varying in their ability to take up Calcein.AM and retain Calcein.
PDFF cells (blue) were the most receptive to Calcein.AM labelling with an obvious difference
between spontaneous (SR ■) and total release (TR ▲) being observed at concentrations as low
as lOpM. Human ES cells (black) were as receptive as PDFF (blue) to Calcein.AM loading, at
concentrations of lOpM and above, however, they were the least able to retain the label, with
high levels of spontaneous release also observed at lOpM. LLC-PK1 cells (red) were the least
receptive to labelling with Calcein.AM with no distinguishable uptake observed until
concentrations exceed 40pM. Data represents the mean of duplicate experiments; error bars
represent the standard error about that mean.
PDFF cells were found to mimic more closely the human ES cells in their
receptiveness to Calcein loading, compared with the LLC-PK1 cells, and so PDFF
cells were used as the positive control cell line in all remaining experiments. The
reduced ability of human ES cells to retain the Calcein label resulted in the use of a
higher Calcein concentration (40pM) for both human ES and PDFF cell labelling
(Figure 4.2.9).
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4.2.6 Increasing the Calcein.AM Concentration Significantly Improved the
Reproducibility ofthe Calcein-Release Assay.
To determine whether insufficient Calcein loading had played a significant part in
the low sensitivity of the Calcein-release assay, PDFF cells were loaded with
Calcein.AM (105 cells in 50pl) diluted to 2pM and 40pM in culture medium (2hrs at
37°C), before being incubated with either active or heat inactivated (HIA) serum,
diluted to 50% with culture medium, culture medium alone (SR) or 0.1% Triton-X
100 (TR) and the Calcein-release recorded using the method described by Iwanowicz
et al., (2004).
By increasing the concentration of Calcein.AM used to label PDFF cells to 40pM,
the level of specific lysis increased 43% over that for the 2pM concentration, from
24% to 67% specific lysis (Figure 4.2.10). Furthermore, using the method reported
by Iwanowicz et al., (2004), the level of spontaneous release and background lysis
was also reduced, to just over 10% (Figure 4.2.10) for 2pM Calcein.AM, compared
with excess of 20% observed using the method of Spiller (2000) (Figure 4.2.5) and
concurrent reduction in the level of intra-experimental variation (Figure 4.2.11).
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Figure 4.2.10: Increased Calcein concentration significantly improves the ability to distinguish
between specific and background lysis. The method reported by Iwanowicz et al., (2004), also
reduced the level of background release for both 2pM (green) and 40pM (yellow) to less than
20%, and reduced intra-experimantal variation compared with the method of Spiller (2000).
Data is representative of three independent replicats; error bars represent the standard
deviation of the individual observations.
The methods of Iwanowicz et al. (2004) and Spiller (2000) only differed subtly but
those differences had a significant impact on the reproducibility of the Calcein-
release assay, particularly as the technique was being performed inside a laminar
flow-hood. Instead of using 250pl volumes of serum, medium or detergent, as
described by Spiller, Iwanowicz et al., reported the use of lOOpl volumes using 105
cells, instead of 106 (Iwanowicz et al., 2004; Spiller 2000). However, of greater
significance was that while Spiller suggested the collection of all 250pl of
supernatant, to record the level Calcein released, Iwanowicz et al., reported the
collection of a 50pl sample, which was then mixed with 2x Triton-X 100 and
recorded (Iwanowicz et al., 2004; Spiller, 2000). By only removing a sample of the
supernatant, after the surviving cells and cellular debris had been pelleted, there was
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a significantly reduced risk of contaminating the measurement of fluorescence in the
supernatant by bright Calcein fluorescence from any surviving cells. The risk of this
contamination with the method reported by Spiller (2000) was high, and would have
accounted for the high levels of intra-experimental variation observed (Iwanowicz et
al., 2004; Spiller, 2000). This hypothesis was confirmed when both experimental
designs were used in parallel. However, despite the reduced intra-experimental
variation, by far the most significant improvement in reliability was as a result of
increasing the concentration of Calcein.AM used to load PDFF cells. Loading of
PDFF cells with 40pM Calcein.AM considerably reduced the inter-experimental
variation, providing a clear distinction between specific and background lysis (Figure
4.2.11) improving the assays sensitivity and importantly reproducibility in
independent experiments.
-186-







































50% HIA Human Spontaneous Release
Serum
Total Release
Figure 4.2.11: Inter-experimental variation is significantly reduced with increased Calcein.AM
loading. PDFF cells were loaded with Calcein.AM at A| 2pM and B| 40pM and then cultured
appropriately. There was a significant reduction in the range of values for any one of the
treatments when 40pM were used compared to 2pM. Furthermore, there was increased
sensitivity between the level of Calcein released as a result of active and heat inactivated (HIA).
Data shows the variation across three independent replicates; error bars represent the standard
deviation of the individual observations.
However, while the reproducibility of the assay had significantly improved, there
was still a degree of variation that remained constant despite the increased
-187-
Chapter 4 - Optimising complement-mediated lysis for human ES cells.
Calcein.AM concentration. This variation was seen repeatedly following incubation
with active serum and may simply be the result of variability in the level of active
complement in the different serum aliquots since all other treatments are independent
of active lysis.
Of greater concern was the relatively low level of specific PDFF cell lysis. Based on
evidence in the literature for xenograft rejection, as a result of the presence of the a-
gal epitope (Unfer et al., 2003) the level of lysis of PDFF cells with human serum
remained noticeably lower than anticipated at best producing 60% cell lysis. For this
technique to be useful for removal of contaminating humans ES cells, it was
necessary to improve the efficiency of cell lysis.
Reports in the literature have suggested that the use of frozen or lyophilised serum
reduces cytolytic activity to approximately 60%, while fresh serum gave lysis in
excess of 90% (Phelps et al., 2003), suggesting that the current assay conditions
could be further refined by collecting fresh serum as a source of complement and
titrating the serum concentration to obtain optimal cytolytic activity.
4.2.7 Serum Concentration, Source and Storage have a Significant Influence on
its Complement Cytolytic Activity.
Previously the source of serum had been a pooled sample of blood group-A donors,
purchased from Harlan Sera Labs (Loughbourgh, UK), which arrived frozen at -20°C
and was then subsequently dispensed into small aliquots and frozen at -80°C until
required. Serum from this source will be referred to as commercial human serum.
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As a comparison, fresh serum collected from a pool of blood group-A donors (Roslin
Institute, Edinburgh), was either used directly as fresh serum, or frozen immediately
in small aliquots at -80°C for future use. Serum from this source will be referred to
as either fresh or frozen human serum respectively.
PDFF cells (105) were loaded with 40pM Calcein.AM for 2 hours at 37°C. They
were then incubated with lOOpl of undiluted active or heat inactivated (FIIA) fresh,
frozen or commercial human serum. As controls, cells were incubated with culture
medium or 0.1% triton-X 100 alone to assess the level of spontaneous (SR) and total
release (TR) respectively.
Incubation with both fresh and freshly frozen human serum significantly increased
the level of Calcein-release, compared with commercial serum, by over 30% (Figure
4.2.12), while the level of Calcein-release from heat inactivated (HIA) serum
remained constant between all the sera. Interestingly, when commercial serum was
stored as instructed, at -20°C, the cytolytic activity was even further reduced after
just 2 months (Figure 4.2.13), confirming the instability of the complement proteins.
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Figure 4.2.12: Serum frozen directly at -80°C has the same cytolytic activity as freshly acquired
serum, which is some 30% more active than commercial serum. Active (blue) fresh and frozen
serum caused over 80% specific Calcein-release, compared with 50% from active commercial
serum. Heat inactivation (red) of all serum produced levels of Calcein-release comparable with
those observed for spontaneous release (SR). Data shows the mean of two independent
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100% Active Human Serum 100% HIA Human Serum Spontaneous Release
Figure 4.2.13: The cytolytic activity of commercial serum is further reduced following
prolonged storage -20°C. PDFF cells loaded with 40pM Calcein were lysed with the same batch
of commercial serum, which had been stored at -20°C (green) or -80°C (yellow) for a period of 2-
months and clearly shows a degradation of the cytolytic active. Error bars represent standard
error of the mean of 6 replicates.
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In previous experiments, the assumption was that high concentrations of serum
would be deleterious to the cells in a non-specific manner, and therefore, the serum
was diluted to 50% in culture medium. To test this assumption, PDFF cells (105)
were loaded with Calcein.AM as previously described and then incubated with fresh
human serum diluted to 2, 5, 10, 20 and 50% in culture medium or incubated in neat
serum (100%), both active and heat inactivated, for an hour at 37°C. Included in the
experiment were culture media alone and 0.1% triton-X 100 controls to assess the
level of SR and TR respectively.
Surprisingly, when cells were incubated in serum at a concentration less than 50%,
there was no significant difference between the levels of Calcein-released due to
active or heat inactivated serum, which were not significantly different to the level of
Calcein released spontaneously (Figure 4.2.14A). At 50% serum, there was an
average of 40% specific PDFF lysis observed, which was consistent with previous
observations (Figure 4.2.11). However, multiple repeats continued to show
significant variation using serum diluted to 50% probably as a result in variation in
the level of active complement contained within each dilution (Figure 4.2.14C).
Importantly, the cytolytic activity of undiluted serum was 2-fold greater than that for
50%, producing fluorescence intensities similar to those observed from total lysis
(Figure 4.2.14A). With the assumption that 0.1% triton-X 100 is providing total cell
lysis, when Calcein-release is expressed as a percentage of the population, 100%
serum falls short of total lysis, by 6-8% (Figure 4.2.14B). However, this may simply
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be the upper-limit of the assay or representative of the number of low or non-a-gal
expressing cells (Figure 3.2.12).
The use of undiluted, freshly acquired or freshly frozen, human serum combined
with an improved assay protocol based on that described by Iwanowicz et al., (2004)
using 40pM Calcein.AM instead of 2pM, for 2 hours, has resulted in an extremely
robust method for the detection of complement-mediated lysis of PDFF cells, using
the presence of the a-gal epitope and natural human anti-a-gal antibodies. The next
objective was to evaluate the use of the optimised assay to detect complement-
mediated lysis of the transgenic M2 and Fll cell lines when exposed to human
serum.
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Figure 4.2.14: Undiluted serum significantly increases cytolytic activity, but reduced inter-
experimental variation, without increasing non-specific cell killing. A| Lysis with undiluted
serum releases similar amounts of Calcein as 0.1% triton-X 100. B] Undiluted serum doubles
the level of specific PDFF lysis compared to using serum diluted to 50%. C] Undiluted serum
(♦) significantly reduces inter-experimental variation compared to serum diluted to 50% (■)
data from three independent replicates. Active serum is represented in blue, heat inactivated
(HIA) serum in red. Error bars represent the standard deviation of the individual observations.
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4.2.8 Complement-Mediated Cytotoxicity is Specific to Cells which Express the
a-gal Epitope with High Efficiency in the Presence ofHuman Serum.
With an optimised assay, an assessment of complement-mediated cell lysis, specific
to the a-gal epitope was performed. PDFF, M2, F11 and H9 cells (105) were loaded
with 40pM Calcein.AM for 2 hours diluted in 50pl of appropriate culture medium.
Cells were then incubated with lOOpl of undiluted active or heat inactivated human
serum, or lOOpl of appropriate culture medium, for an hour at 37°C in a humidified
incubator containing 5% CO2. The culture supernatant was then assessed for the
presence of released Calcein as previously described.
As expected, PDFF cells were lysed in a specific manner resulting in excess of 80%
Calcein-release. Interestingly, the same level of specificity was also observed for the
first time in the transgenic M2-ES cell line, and as would be expected, the reduced
level of a-gal expression on the F11 cell line resulted in an increased number of cells
surviving the complement-mediated lysis (Figure 4.2.15A). Furthermore, there was
minimal lysis of the wild type ES cells (H9), just 8%, well below the accepted level
for spontaneous background release (Figure 4.2.15A).
Furthermore, the optimised assay conditions have provided a reproducible assay not
only for PDFF cells, but also for the human ES cells, clearly indicating that human
ES are susceptible to complement mediated lysis, but that in this instance it is
restricted to the presence of the a-gal epitope (Figure 4.2.15B).
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Figure 4.2.15: M2 cells are as susceptible to complement-mediated lysis as PDFFs. A] Both
PDFF (blue) and M2 (red), released ~90% of their loaded Calcein in response to human serum.
Fll (sky blue) were less susceptible to complement attack, releasing 66% Calcein. Non-specific
Calcein-release from H9 (yellow) was 13%, significantly less than the accepted background
level. B| Using the newly defined assay conditions, the level of complement-lysis has been
shown to be reproducible for both PDFF (blue) and M2 (red). The Fll clone (sky blue),
however, is more variable than the M2 clone over three independent replicates. Error bars
represent the standard deviation of the individual observations.
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4.2.9 Blocking Complement-Regulatory Proteins, CD55 and CD59, with
Monoclonal Antibodies has no Effect on the Susceptibility ofHuman ES
Cells to Complement-MediatedLysis.
The development of a reliable and reproducible assay provided an opportunity to
investigate the biological function of expressing elevated levels of complement
inhibitory proteins. To do this wild type H9-ES cells were coated with non-
complement fixing blocking antibodies, mouse IgGi, MEM-43 and HD3, anti-CD59
and anti-CD55 respectively, (a kind gift from Prof. P. Morgan, University of Wales)
and exposed to complement. To activate complement-mediated lysis, exogenous
antibody to a cell surface epitope (IgM to TRA-1-81) was diluted in active human
serum. TRA-1-81 is an endogenous cell surface marker, used as part of a panel to
characterise undifferentiated human ES cells (Reubinoff et al., 2000; Thomson et al.,
1998). It is expressed on over 90% of undifferentiated human ES cells with a mean
fluorescence intensity of 3,820 (Figure 7.2.2 and Table 7.2.1). To control against
non-specific complement activation as a result of bound blocking antibody, H9-ES
cells were incubated in the absence of the Tra-1-81 activation antibody (Figure
4.2.16).
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Figure 4.2.16: Blocking of complement inhibitors with monoclonal antibodies does not
significantly increase the level of complement-mediated lysis. H9 cells (yellow) were incubated
with active serum alone, plus activating Tra-1-81 antibody, plus blocking antibodies or plus
blocking antibodies and Tra-1-81, heat inactivated (HIA) serum and culture medium. M2 cells
(red) were incubated with active and HIA serum to compare the efficiency of the complement
mediated lysis. Data represents the mean from duplicate experiments and the error bars
represent the standard deviation of the individual observations.
□ H9 DM2
T
Active Serum Plus Tra-1-81 Plus Tra-1-81 & Plus Blocking HIA Serum Spontaneous
Blocking mAbs mAbs release
The addition of exogenous Tra-1-81 IgM produced an effective complement-
mediated lysis response, leading to 84% Calcein-release. Surprising, this was some
what lower that the lysis response to a-gal antibodies, which are mainly of IgG
isotype (95% Calcein-release; Figure 4.2.16), suggesting that there was the need
from optimisation. Pre-coating H9 cells with blocking antibodies to complement
inhibitors, before incubation with Tra-1-81 and serum, slightly increased the level of
lysis (88% Calcein-release; Figure 4.2.16). However, there was also an increase in
the level of background lysis (23%) over that observed for heat inactivated (HIA) or
active serum alone (18%; Figure 4.2.16). The working hypothesis had been that
binding antibody to the two highly expressed complement inhibitors, CD55 and
-197-
Chapter 4 - Optimising complement-mediated lysis for human ES cells.
CD59, would remove any protective capacity that they had towards undifferentiated
human ES cells. Consequently, it was hypothesised that there would be an increase
in the level of cell lysis (Calcein-release). The data presented here suggested one of
two things, either that the increased expression of complement inhibitor proteins was
insufficient to protect human ES cells from a specific complement mediated attack,
or that in both examples, natural a-gal and exogenous IgM to TRA-1-81, saturation
of the system occurred, providing no opportunity for the inhibitors to function.
Perhaps a more informative experiment would have been to expose human ES cells
to sub-optimal levels of anti-a-gal or Tra-1-81, i.e. to dilute the serum to levels
which are on the lower limit of being able to cause lysis, between 20 and 50%
(Figure 4.2.14) and then asking the question: if human ES cells have increased
complement inhibitor activity then would the level of lysis increase if this protective
action was lost (bound by antibody)?
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4.3 Discussion
4.3.1 Optimisation ofthe Calcein-release Assayfor Human ES Cells
It is clear from the results in this chapter that different cell types vary in their ability
to take up and retain the Calcein.AM label (Figure 4.2.9). The conditions reported
by Spiller (2000) using 2pM Calcein.AM to load 107 cells/ml resulted in very high
levels of intra- and inter- experimental variation. When increased levels of
Calcein.AM were investigated, it transpired that at 2pM Calcein.AM there was
insufficient discrimination between spontaneous release and specific release as a
result of either detergent or serum lysis. Furthermore, Calcein saturation was not
achieved in any cell type at 80pM, a 5-fold increase in the level of Calcein.AM, thus
when complement-mediated lysis had occurred, using the method of Spiller (2000)
the assay was not sensitive enough to detect it. Additionally, the technique reported
by Spiller, (2000) of using 250pl of serum or detergent to lyse the cells, and then
collecting all of this to measure the level of Calcein-release was difficult to achieve
inside laminar-flow hoods because of the small size of the surviving cell pellet and
the angle of the glass, adding to experimental variation through operator error. The
technique reported by Iwanowicz et al., (2004), significantly reduced this operator
error, since it did not require 100% of the lysis supernatant to calculate the
percentage Calcein-release, helping to prevent contamination of supernatant
fluorescence with cell pellet fluorescence from viable cells. Consequently, a switch
to this protocol provided more consistent results and lower standard deviations
within each experimental run (Figure 4.2.1 compared with Figure 4.2.10).
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The issue of inter-experimental variability of the Calcein-release assay was not,
however, confined to the mechanics of the assay. Sub-optimal use of serum, both
source and concentration, further exacerbated the problem. The cytolytic activity of
fresh and freshly frozen serum was some 30% higher than that achieved with
commercial serum. The reason for this was probably the initial storage (-20°C) and
transport thawing of commercial serum, which resulted in degradation of
complement proteins. Storing commercial serum at -80°C upon arrival prevented
further degradation (Figure 4.2.13), confirming the observation that complement
proteins are unstable when stored above -80°C (Spiller B. Pers. Com.) and providing
an explanation for the low level of complement-mediated lysis observed in the early
experiments and some of the inter-assay variation (Figure 4.2.12).
A titration of the serum concentration found that using serum diluted to 50%, as
reported by Huang et al., (2001) for the lysis of NIH/3T3 cells, resulted in 40-50%
specific Calcein-release, while using undiluted serum increased the specific lysis to
80-90%, without significantly increasing the level of non-specific cell lysis.
Furthermore, serum dilution was adding to inter experimental variation, and
therefore, it was not surprising that the use of undiluted serum significantly
decreased inter-experimental variation (Figure 4.2.14).
With the Calcein-release assay optimised for the detection of complement-mediated
lysis in PDFF cells, only a small adjustment in the concentration of Calcein.AM
(40pM instead of 20pM - Figure 4.2.9) was necessary to provide sensitive assay
conditions for detection of lysis in human ES cells. Importantly, H9 wild type ES
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cells were insensitive to complement-mediated lysis directed against the a-gal
epitope and were only sensitive to lysis when antibody against the endogenous cell
surface marker Tra-1-81 was added to the serum, showing specificity of the assay.
Transgenic M2 and Fll human ES cell clonal lines on the other hand were both
successfully lysed as a result of expressing the a-gal epitope on their cell surface. As
predicted, the F11 cell line was less efficiently lysed than the M2 (Figure 4.2.15) due
to its lower level of a-gal expression and increased variegation (see section 3.2.2.2).
However, in contrast to the expression data reported in Chapter 3, (Figure 3.2.12) the
M2 cell line was lysed as efficiently as the endogenously expressing PDFF cells
(Figure 4.2.15), despite apparently expressing less a-gal epitopes and binding lower
levels of anti-a-gal (Figure 3.2.14). A possible explanation for this result is that the
M2 cells, which have a smaller cell surface area than the PDFF cells, bound fewer
anti-a-gal antibodies per cell, (mean fluorescence intensity of 447.48 compared to
913.34 for PDFF's) but it is likely that the antibodies that did bind were in closer
proximity to each other. Initiation of the classical complement cascade requires the
binding of 2 molecules of IgG antibody to occur in close proximity, within 30-40nm
of each other, to then be able to bind to the first complement protein C1 q (Goldsby et
al., 2000). M2 cells were capable of binding very similar levels of both BS-IB4 and
anti-human Ig, to PDFF cells, despite their reduced size. It is therefore hypothesised
that since the majority of anti-a-gal is IgG, that the reduced cell size of human ES
cells meant that although there where fewer a-gal epitopes than where present on the
larger PDFF cells, those that were there were closer together increasing the chance of
2 anti-a-gal IgG antibodies binding in close enough proximity to initiate lysis. This
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would explain the observed similarities in the efficiency of complement-mediated
lysis of both PDFF and M2 cell lines and would also account for the differences a-
gal expression as observed by a higher fluorescence intensity by flow cytometry
following FITC conjugated BS-IB4 staining, and in increased levels of FITC
conjugated anti-human Ig binding.
4.3.2 Expression ofComplement Inhibitory Proteins on Human ES Cells
Complement-mediated lysis directed against an endogenous cell surface marker of
human ES cells, TRA-1-81, using the addition of exogenous antibody, was
successfully initiated, demonstrating that supra-optimal levels of exogenous antibody
can supersede any protective effects of having increased complement inhibitor
proteins. Additionally, these data suggested the possibilities of using this technique
with vaccination strategies against foreign epitopes.
Complement inhibitor proteins, are essentially involved with preventing spontaneous
activation of the complement cascade, caused either as a result of non-specific
binding of self-antibodies or through the constant "ticking-over" of the key
complement protein C3 (Atkinson & Farries, 1987). However, the frequency at
which this background binding takes place is likely to be orders of magnitude lower
than the specific binding of both natural levels of anti-a-gal antibody and supra-
optimal levels of exogenous Tra-1-81 antibody, leading to saturation of the system
and over-whelming the ability of complement inhibitor proteins to act against
complement initiation.
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In a recent report, Harrower et al (2004) produced transgenic pigs which over-
expressed human complement inhibitor proteins, CD59 (MIRL) or CD46 (MCP), in
an attempt to overcome the effects of hyperacute rejection. However, when exposed
to active human serum, embryonic neural tissue from pigs transgenic for either
human CD59 or human CD46 was not protected from the effects of activated
complement (Harrower et al., 2004), confirming the hypothesis that elevated levels
of complement inhibitory proteins are not capable of protecting against a directed
complement attack.
Complement regulatory proteins, particularly DAF, are highly expressed on
trophoblast cells from 6 weeks of gestation (Holmes et al., 1990). They are thought
to be involved in the protection of the foetus from maternal complement. Loss of
these proteins at the foeto-maternal interface has been shown to be associated with
foetal loss in mice and has been associated with spontaneous abortion (Xu et al.,
2000; Holmes et al., 1990, 1992). It comes as little surprise therefore, that these
proteins are highly expressed in human ES cells to the same extent as they are
expressed in the human embryonic kidney cell line (HEK 293) (Figure 4.2.7).
However, with the development of a reliable Calcein-release assay to detect
complement-mediated lysis in human ES cells, it is clear that the increase in
complement inhibitors was insufficient to protect against a directed attack.
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4.4 Conclusion
The Calcein-release assay, once optimised, has proven to be a very reliable method
for the detection of complement-mediated lysis. Using these optimised conditions
human ES cells, expressing the al,3Gal transgene, have been repeatedly shown to be
highly susceptible to complement-mediated lysis, to the same extent as a 1,3Gal
endogenously expressing PDFF cells, in the case of the M2 human ES cell line.
Furthermore, the addition of supra-optimal levels of exogenous antibody to an
endogenous cell surface epitope was also capable of eliciting a complement-
mediated attack, providing the opportunity to develop this technique in conjunction
with vaccination strategies.
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5.1.1 Chapter 5 Aims
5.2 Results
5.2.1 Complement-Mediated Lysis is Underestimated Using the Calcein-Release
Assay.
5.2.2 Surviving Cells Remain BS-IB4 Positive, Suggesting a-Gal Positive Cells
had Avoided Cell Lysis.
5.2.3 M2 ES-Cells can be Removed as a Minority Group from Populations of a-
Gal Negative HEK 293 Cells by Complement-Mediated Lysis.
5.2.4 Expression of a-Gal is Down-Regulated Following Differentiation, but is
Persistent in a Small Sub-Population
5.2.5 Differentiated M2 Cells Become Insensitive to Complement-Mediated





The persistence of undifferentiated human ES cells within a potentially therapeutic
population poses a serious risk of tumorigenicity to the graft recipient. Critical to the
success of the selective ablation strategy presented in Chapter 4, is the absence of a-
gal epitopes on differentiated derivatives of the M2 human ES cell line. The
expression of the al,3Gal transgene from the hTERT promoter should provide a
method for identifying such cells, through specific expression of the a-gal epitope on
undifferentiated human ES cells, which can then be removed or ablated. As
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discussed in Chapter 1, Tzukerman et al, (2000) have shown that there is a time-
dependent decline of telomerase activity, associated with a decline in promoter
activity, upon induction of differentiation in human ES cells. The authors observed
disappearance of hTERT activity after 14 days of differentiation (Tzukerman et al,
2000). This chapter will demonstrate the specificity of complement-mediated lysis,
as an elimination strategy, to distinguish between cells that do and do not express the
a-gal epitope. It will assess the expression of al,3Gal on differentiated derivatives
of M2 cells, and determine their sensitivity to complement-mediated attack.
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5.1.1 Chapter 5 Aims
1. To qualify the level of complement-mediated lysis indicated by the Calcein-
release assay, to determine the level and nature of surviving cells.
2. To determine whether minority populations of undifferentiated M2 cells can
be selectively eliminated from a population of a-gal negative cells.
3. To differentiate M2 ES-cells and assess the expression of a-gal on
differentiated derivative.
4. To determine the level of susceptibility in differentiated derivatives of M2 to
complement-mediated lysis.
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5.2 Results
5.2.1 Complement Mediated Lysis is Underestimated Using the Calcein-Release
Assay.
In an attempt to qualify the Calcein-release assay as a method of determining
complement-mediated lysis, unlabelled PDFF, M2 and H9 cells were exposed to
complement (105 cells in lOOpl of undiluted active and heat inactivated serum) for 1
hour at 37°C. Surviving cells were then pelleted at 200g for 5 minutes and
resuspended in lOOpl of culture medium. In duplicate wells of a 12-welled plate
(NUNC), coated with an appropriate extra-cellular matrix, 50pl of cell suspension
(maximum of 5x104) were re-plated and cultured overnight at 37°C in a humidified
incubator plus 5% CO2.
Twenty-four hours post treatment the survival of PDFFs, M2 and H9 cells was
assessed by 5% Giemsa staining (Figure 5.2.1). Surprisingly, the lysis of both PDFF
and M2 was more acute than expected from the results of the Calcein-release assay
reported in Chapter 4. Figure 5.2.1 shows representative images, from three
independent experiments, indicating the almost complete elimination of a-gal
expressing cells as a result of incubation with active human serum (Figure 5.2.1 a
and c), while a-gal negative cells were unaffected by incubation in active serum
(Figure 5.2.1b).
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Figure 5.2.1: Giemsa staining of cells following a 1-hour incubation in active (upper panel) and
heat inactivated (lower panel) human serum, shows specificity of serum lysis to the presence of
the a-gal epitope. H9 (b and e) cells are unaffected by incubation with active (b) while PDFF (a
and d) and M2 (c and 0 cells are highly sensitive to serum lysis with active (a and c) human
serum but not heat inactivated (d and f) human serum. Survival of cells assessed 24 hours post
lysis with 5% Giemsa staining, scale bar represents lOOum.
In parallel experiments, duplicate wells containing cells exposed to active and heat
inactivated human serum were set up to determine if lysis, while specific, was also
complete. These wells were allowed to grow under normal culture conditions
following treatment to induce lysis, for 7-10 days. Interestingly, in all cases, small
ES colonies did appear after a 10-day period from the M2 population treated with
active human serum (Figure 5.2.2). Cell survival suggests that a single one-hour
incubation was not sufficient to kill all a-gal expressing cells within a large
population, possibly due the presence of small cell aggregates within the cell
suspension. The presences of cell aggregates would prevent cells in the centre of the
aggregate from being exposed to active complement and consequently when the cells
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were washed, removing the dead cells, this would allow the viable cells from within
the aggregates to adhere and proliferate. Alternatively, it is possible that there was
simply insufficient complement within the serum to lyse the whole population within
an hour and that by either increasing the amount of serum or the duration of exposure
would result in total cell lysis.
Active Serum HIA Serum
Figure 5.2.2: Small colonies of human ES cells do occur 7-10 days after incubation with active
human serum (a), suggesting that a single 1-hour incubation is not sufficient to kill all a-gal
expressing cells in a large population. Panel b shows the level of growth after 7-10days of cells
incubated with heat inactivated human serum. Scale bars represent 100pm.
5.2.2 Surviving Cells Remain BS-IB4 Positive, Suggesting a-Gal Positive Cells
hadAvoided Cell Lysis.
Another hypothesis for the persistence ofM2 cells following complement attack was
that the remaining cells did not survive complement attack; they simply avoided
death because they had no a-gal epitope to initiate a complement-mediated attack. In
Chapter 3 the level of a-gal expression on the cell surface of the M2 cell line was
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reported as 95% (Figure 3.2.12), suggesting the presence of a-gal negative cells
within the population, which could account for the persistence of cells after
complement attack.
Consequently, surviving M2 colonies were assessed for expression of a-gal by
staining with FITC conjugated BS-IB4 lectin. Without exception, all surviving M2-
ES cell colonies stained positive for a-gal (Figure 5.2.3), suggesting that either these
cells had escaped complement-mediated lysis despite the presence of the a-gal
epitope, or that as a result of variegation within the clone, these cells did not express
the epitope at the time of complement attack, but up-regulated it during the





Figure 5.2.3: Surviving PDFF and M2 cells remain positive for a-gal by BS-IB4 staining. PDFF
(a and b) and surviving M2 (e - h) cells were cultured for 10 days post-incubation with active
serum and then staining with BS-IB4 for presence of the a-gal epitope. H9 (c and d) surviving
cells cultured for 10 days at low density (105/ml) did not stain positive with BS-IB4. Scale bars
represent 100pm.
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5.2.3 M2 ES-Cells can be Removed as a Minority Group from Populations ofa-
Gal Negative HEK 293 Cells by Complement-Mediated Lysis.
The data for elimination of a-gal positive cells by complement-mediated lysis
reported thus far have concentrated on eliminating a whole population of a-gal
expressing cells. However, in a clinical setting, it is likely that the contamination of
therapeutic populations with undifferentiated human ES cells will be low. Therefore,
in an attempt to mimic this clinical setting, a-gal positive M2 cells, were mixed in
serial dilutions with a-gal negative HEK 293 (Figure 5.2.4) at ratios of 50, 25, 12.5,
6.3, 3.15, 1.6 and 0.8% and then exposed to complement-mediated lysis. To ensure
specific lysis, pure populations of both M2 cells and HEK 293 cells were also















Figure 5.2.4: BSIB4 staining of transgenic M2 cells, positive for a-gal expression (a-c) and HEK
293 cells negative for a-gal (d-f). Images a and d show phase contrast microscopy, b and e show
FITC fluorescence microscopy and images c and f overlay the two. Scale bars represent 100pm.
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Cells were harvested, counted and resuspended at lxl05/ml in culture medium.
Population mixing was then carried out to give a final concentration of 105/ml of
mixed cells. The mixed populations were then pelleted at 200g for 5 minutes, and
finally resuspended in lOOpl of undiluted active or heat inactivated human serum.
After a 1-hour incubation in the presence of serum, the populations were collected,
following centrifugation at 200g for 5 minutes and resuspended in lOOpl of culture
medium. 50pl of cell suspension (maximum of 5xl04 cells) per well were re-plated
into duplicate wells of a 12-welled plate (NUNC), coated with an appropriate extra¬
cellular matrix, and cultured overnight at 37°C in a humidified incubator plus 5%
CO2. To confirm the level of population mixing, cells exposed to heat inactivated
serum were stained 24 hours post-incubation for the ES specific marker Oct-4,
(Figure 5.2.5). Oct-4 staining in Figure 5.2.5 clearly shows a gradual decline in the
number of undifferentiated ES cells within the HEK 293 cell population, indicating
that at each dilution, Oct-4 positive ES cells were present prior to treatment with
human serum (Figure 5.2.5).
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Figure 5.2.5: HEK 293 and M2 mixed populations 24 hours post-incubation with heat
inactivated human serum. M2 ES cells mixed with HEK 293 cells at ratios of 100% (a & b at
xlO and x40 respectively), 50%, 25, 12.5, 6.3, 3.15, 1.6 and 0.8% (c to I respectively) and 0% (j
& k at xlO and x40 respectively). Oct-4 staining (FITC) stains the nuclei of undifferentiated
human ES cells, background cytoplasmic staining can be seen in HEK 293 cells (k), however,
their nuclei remain blue with DAPI. Image 1 shows incubation of that undifferentiated human
ES cells with the secondary FITC antibody and DAPI, clearly demonstrating that Oct-4 staining
was specific. Scale bars represent lOOum.
After plating, all mixed populations were placed in selective medium (lmg/ml G418,
as determined by a HEK 293 and M2 kill curve, data not shown) to remove the HEK
293 cells while allowing the proliferation of the transgenic M2 cells that had escaped
lysis. Populations were cultured in this way until total cell death had occurred in the
pure HEK 293 population, 7-10 days at lmg/ml G418 (data not shown), signifying
that any remaining G418 resistant cells in the mixed populations were probably of
M2 origin. Cell survival was assessed by colony counting from duplicate wells in
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three independent experiments (Table 5.2.1) based on morphology and by 5%










A HIA A HIA A HIA
100.00% 34 >500 11 >500 12 >500 <3.80%
50.00% 6 >500 8 >500 25 >500 <2.60%
25.00% 1 >500 6 >500 13 >500 <1.33%
12.50% 0 >500 0 >500 4 >500 <0.27%
6.30% 0 >500 0 >500 3 >500 <0.20%
3.15% 1 >500 0 >500 0 >500 <0.07%
1.60% 0 480 0 435 1 >500 <0.07%
0.80% 0 242 0 216 0 466 0.00%
Table 5.2.1: The frequency of proliferating ES colonies post-lysis, after 7-10 days in selective
culture. The number of colonies surviving complement-mediated lysis in each replicate are
denoted A, for active serum, columns headed HIA represent the number of colonies expected for
the proportion of ES cells included in the mixed population, i.e. the same population mixes
incubated with heat-inactivated serum. Counts were based on morphology using phase contrast
microscopy at xlO magnification, colonies in heat-inactivated serum were too confluent to count
in most cases resulting in an under estimation of colony number and consequently, the reported
frequencies are an over estimation.
Table 5.2.1 clearly indicates that as the ratio between sera to cells increases, there is
a significant reduction in the number of surviving ES cells. In populations
containing less than 25% M2 cells, only a single colony from duplicate wells, from 3
independent experiments, was ever observed, and no colonies were ever observed
when the proportion ofM2 cells was 0.8% (Table 5.2.1 and Figure 5.2.6). However,
as previously observed, at higher concentrations of M2 cells, colonies were
occasionally observed, albeit at low frequency. It was estimated that a confluent well
of a 12-well plate contains some 3.3xl05 undifferentiated human ES cells, if this was
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taken to be the case in the above experiments, the frequency of surviving ES cells in
100 and 50% population mixes would have been in the region of 0.0057% and
0.0033% respectively. Perhaps a criticism of this result is that a total cell count,
instead of a colony count, would have provided a more accurate frequency of cells
surviving complement mediated lysis. Nevertheless, these results further indicate
that at high cell concentrations, a single 1-hour incubation in active human serum
kills most but not all a-gal expressing cells, probably as a result of cell aggregating
together when at high densities (Figure 5.2.6).
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Figure 5.2.6: Visual representation of the number of proliferating M2 ES cell colonies from a
mixed population surviving exposure to complement, stained with 5% Giemsa. Mixed HEK 293
and M2 populations (containing pure, 50, 25, 12.5, 6.3, 3.15, 1.6, and 0.8% M2 cells, images b-i
respectively) were cultured in 12-well plates in the presence of lmg/ml G418 for 7 days following
incubation with undiluted active and heat inactivated (HIA) human serum. Image a, represents
5xl04 H9 cells cultured for the same 7 day period without G418 selection.
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5.2.4 Expression of a-Gal is Down-Regulated Following Differentiation, but is
Persistent in a Small Sub-Population
As previously mentioned, for this strategy to be useful therapeutically, down-
regulation of the a-gal epitope is essential in differentiated populations.
Characterisation of a-gal down-regulation will be described fully in Chapter 7
(Figure 7.2.3). Shown here are fluorescence microscopy images demonstrating
moderate down regulation of a-gal expression following ten days in basic
differentiation medium (KO-DMEM supplemented with 10% FBS (v/v), 0.1mM
NEAA, 2mM L-glutamine and O.lmM P-mercaptoethanol, Figure 5.2.7 (images a-c))
and for comparison the expression level of TRA-1-81, a reported marker of ES and
EC cells, which is down-regulated on differentiation, at the same time point (Figure
5.2.7 (images d-f)).
As shown in Figure 5.2.7, M2 cells had begun to down-regulate TRA-1-81,
indicating that the cells were differentiating. The corresponding reduction in BS-IB4
staining supports the assumption that the al,3Gal transgene was being appropriately
regulated. Visually, it appeared that M2 cells had down-regulated the expression of
a-gal more than TRA-1-81, perhaps indicating tighter regulation of the hTERT
promoter. Furthermore, those cells which had retained a-gal expression either had an
ES phenotype or were located near to nests of ES like cells, suggesting a transient
persistence of the epitope, following down-regulation of transcription (Figure 5.2.7
(images a-c)).
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Phase Contrast Fluoresence Microscopy Merged Images
Diff M2
a-gal
Figure 5.2.7: M2 cells differentiated for 10 days begin to down regulate a-gal (FITC-green)
expression in a similar manner to TRA-1-81 (R-PE-red), a reported marker of ES and EC cells.
M2 cells, differentiated in basic differentiation medium for 10 days, were assessed for the
presence of a-gal by BS-IB4 staining and TRA-1-81. Images a and d show that the morphologies
of the differentiated cells are similar by phase contrast micrscopy. The level of continued a-gal
(BS-IB4 staining (FITC) b and overlay c), and TRA-1-81 expression (R-PE staining e and
overlay f) were determined by fluoresence microscopy showing down-regulation of both TRA-1-
81 and a-gal after 10 days of differentiation. Scale bars represent 100pm.
5.2.5 Differentiated M2 Cells Become Insensitive to Complement-Mediated
Attack Initiated by a-Gal Epitopes, with Increased Time in Differentiation
Medium.
To determine that a loss of BS-IB4 staining corresponded to a loss of the a-gal
epitope and consequently protection from complement-mediated lysis, differentiated
M2 cells were exposed to active human serum at increasing time points following
induction of differentiation.
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Differentiation of M2 cells, cultured as monolayers, was induced for 7, 14 and 21
days by replacing conditioned medium and hbFGF with basic differentiation medium
containing 10% FBS. Undifferentiated M2 cells and PDFF cells were used as
positive controls, and equally differentiated and undifferentiated H9 wild type cells
as negative controls. Cells were loaded with Calcein as previously described (105
cells with 40pM for 2 hours) and then exposed to active and heat inactivated human
serum for one hour at 37°C.
The level of specific complement-mediated lysis, percentage Calcein-release minus
spontaneous release following incubation with heat inactive serum, significantly
decreased as the differentiation time increased: 85, 62, 25 and 8% at 0, 7, 14 and 21
days respectively (Figure 5.2.8). This suggested that with increasing time in
differentiation M2 cells become less susceptible to a-gal induced complement-
mediated lysis.
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Figure 5.2.8: Differentiated M2 cells become less susceptible to a-gal induced complement-
mediated lysis with increasing time in differentiation. M2 (red) and H9 (yellow) cells were
differentiated (green and purple respectively) in basic differentiation medium for, 7 days [A], 14
days [B] and 21 days [C], for being exposed to complement mediated cell lysis. PDFF cells
(blue) were included as a positive control. Each graph represents a single experiment
containing six replicates. Error bars represent the standard deviation of the individual
observations.
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5.3 Discussion
As predicted, by the well-characterised properties of germ line- and epiblast-specific
telomerase expression (Wright et al., 1996), the hTERT/al,3Gal transgene has been
successfully expressed and regulated in M2 cells. The transgene provided strong
expression in undifferentiated human ES cells, which was consequently down-
regulated upon differentiation, mimicking expression at the endogenous hTERT
locus (Wright et al., 1996). The results presented here and in Chapter 4, provide
clear evidence that M2 cells are susceptible to complement-mediated lysis
specifically when undifferentiated, and that they lose this susceptibility with time in
differentiation, as a consequence of a loss in al,3Gal expression. In the context of
regenerative medicine this could provide a powerful tool for protection against
contamination of therapeutic cell types with undifferentiated human ES cells, by
exposing differentiated populations to active human serum prior to engraftment.
The treatment of high-level M2 contamination with a single 1-hour exposure to
active human serum, showed low level evasion of M2 cells from complement-
mediated attack. This result was anticipated in a variegated population (see Chapter
3, Figure 3.2.12), where subsets of cells were not expressing the a-gal epitope at the
time of incubation. However, it may be possible to overcome this issue, by using
multiple exposures to active serum and complement to completely eliminate such
cells prior to engraftment. Low-level contamination, on the other hand, where
minority populations of M2 cells were mixed with a-gal negative HEK 293 cells
were efficiently eliminated by a single 1-hour exposure to active human serum.
When M2 cells constituted just 0.8% of the total population, an average of 308
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colonies were observed following treatment with heat inactivated serum. By contrast
the same cell populations exposed to active human serum, resulted in no ES colonies
being detected after 7-10 days of ES specific culture (Figure 5.2.6 and Table 5.2.1).
Similar results were also observed with mixed populations including up to 12.5% M2
contamination. From three independent experiments, only a single colony from all
experiments was ever observed for populations containing, 1.6, 3.15, 6.3 and 12.5%
M2 contamination, compared to an uncountable number of colonies (>500) for each
replicate population exposed to heat inactivated serum (Figure 5.2.6 and Table
5.2.1). These data show that in practice M2 cells that avoid complement-mediated
attack due to loss of a-gal expression, appear at low frequency, suggesting further
that it was probably either the ratio of serum to target cell number or the occurrence
of cell aggregates that prevented the complete lysis ofM2 human ES cells, and that a
second exposure to active serum would be likely to be fully effective.
The advantage of using a-gal in a clinical setting as an epitope to mediate
complement attack is that humans possess high titres of naturally circulating anti-a-
gal antibodies (Galili et al., 1984, 1985). This could provide constant surveillance
against not only cells that have evaded the initial treatment, but also against cells that
dedifferentiated, or became cancerous, switching on the hTERT promoter and
reactivating the al,3Gal transgene. Furthermore, targeting the al,3Gal transgene to
acquire the endogenous hTERT promoter or targeting the construct into a
characterised "neutral" site, using homologous recombination could eliminate the
risk of cells evading complement-mediated lysis as a result of variegation.
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A criticism of this research is that all of the data provided are based on the use of
serum from blood group A individuals. Dr H. Priddle made an early attempt to lyse
a-gal positive cells with serum from blood group -A and -B volunteers. In these
preliminary experiments it was observed that blood group-A serum provided
elevated levels of lysis as compared to blood group-B serum. This was not an
unexpected result based on evidence that the anti-blood group-B antibody, contained
within blood group-A serum, cross reacts with the a-gal epitope, thereby enhancing
any complement-mediated response (Galili et al., 1987a). It is hypothesised that
blood group-B serum would initiate a complement-mediated attack, but a longer
exposure time (or multiple exposures) would be necessary. Further studies are
required to evaluate the use of all blood types to initiate an a-gal-mediated
complement attack, using the optimised Calcein-release assay as a method of
detection.
A further criticism of this work reflects the use of a single human ES cell line, H9.
Although the effects of the hTERT/al,3Gal transgene have been studied in two
independent clonal cell lines, both cell lines were derived from the H9 cell line. To
support the potential of this strategy for clinical development, the transfection of
other parental human ES cell lines, such as HI and H7, would be required, to
determine if the effects of complement-mediated lysis against the a-gal epitope vary.
As discussed, a critical aspect of this elimination strategy was the regulation of the
al,3Gal transgene in differentiated M2 cells. This chapter provides evidence that the
a-gal epitope is down-regulated as differentiation progresses, and that loss of a-gal
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epitopes at the cell surface corresponds with evasion of complement-mediated lysis.
A report by Tzukerman et al, (2000), demonstrated that loss of hTERT promoter
activity would occur after 14-days of differentiation. The data provided here shows
that after 14 days of non-specific differentiation, 25% of cells continued to express a-
gal epitopes from the hTERT promoter. By 21 days this population had decreased
further, constituting just 8%. One hypothesis for the persistence of a-gal expressing
cells following differentiation, as an alternative to residual ES cell contamination,
was the presence of hTERT expressing cells within the differentiated population.
Although telomerase expression is considered a characteristic of embryonic, germ-
line or malignant tissues, there is a growing body of evidence that shows expression
of telomerase in some somatic cell types including, hematopoietic progenitors,
particularly lymphoid lineage committed progenitors, normal peripheral blood
leukocytes (Hohaus, et al., 1997; Weng, et al., 1996) and in the continuously
proliferating epidermis basal layer (Harle-Bachor et al., 1996). Non-specific
differentiation protocols were employed in this investigation to determine a global
picture of a-gal regulation with differentiation. However, it would be interesting to
determine the level of a-gal expression following specific differentiation into
osteogenic or neural lineages for example. If the persistence of hTERT expression
by progenitor or mature cells was responsible for the continued a-gal expression
observed with non-specific differentiation, than in populations known to lack
telomerase expression, a more rapid down-regulation of a-gal would be anticipated.
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Additionally, now that proof of principle has been demonstrated, a number of
a1,3Gal constructs, utilising different ES specific promoters, require evaluation. One
candidate promoter would be the Oct-4 promoter, which is strongly expressed in
undifferentiated human ES cells and has been reported to be effectively down-
regulated with differentiation (Zaehres et al., 2005; Matin et al., 2004; Hay et al.,
2004; Reubinoff et al., 2000). Another candidate promoter for this comparison study
would be Rexl, used by Eiges et al., (2001) in a reporter construct to mark
undifferentiated human ES cells. The authors demonstrated that when human ES
cells were differentiated as EB's in suspension for 20 days, GFP expression, driven
by the Rex 1, promoter was practically eliminated. They also demonstrated that
monolayers of Rexl/GFP human ES cells significantly reduced GFP expression
when partially differentiated, although the time of differentiation was not specified
(Eiges et al., 2001).
In a recent report Martin et al., (2005) have expressed caution regarding the use of
human ES cells, which have been grown in current culture conditions, for human
therapy. The authors demonstrated that human ES cells grown in medium containing
serum replacement, acquire expression of an immunogenic, non-human sialic acid
(Neu5Gc) on their cell surface (Martin et al., 2005). They claim that when such cells
were exposed to human serum in vitro, there was an increase in both C3b deposition
(from 1% to 37%) and complement-mediated cell death (from 40% background to
60-70% specific) as detected by propidium iodide uptake (Martin et al., 2005).
However, the report indicated difficulties in determining the level of complement-
mediated lysis of human ES cells, with high levels of non-specific cell death (40%)
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in untreated cells, the optimised Calcein-release assay reported here shows less than
20% background. Based on the evidence in Chapter 4, the high background cell
J • • 2"bdeath was likely to have been caused by the dilution of human serum in GVB
buffer, see Chapter 4 (Figures 4.2.2 & 4.2.3) leading to increase human ES cell
death. When complement-mediated lysis was performed on monolayer cultures, the
report indicated only a 4% increase in the level of PI uptake between background and
specific lysis using serum containing high natural titre Neu5Gc antibody (Martin et
al., 2005). This increase could be explained by intra-experimental variation due to
the use of diluted serum (25% in GVB2+) as indicated in Chapter 4 (Figures 4.2.6 &
4.2.14). By contrast to Martin et al (2005), wild type H9 ES cells used in this
investigation, grown under similar conditions (in the presence of serum
replacement), were not observed to be sensitive to complement-mediated lysis.
Levels of Calcein-release from H9 cells exposed to active human serum were
comparable to the levels observed when exposed to heat inactivated serum and a
result of spontaneous release. Furthermore, when cells were exposed to a 10-fold
increase in the amount of Neu5Gc reported to be present in serum replacement
(0.3mM), by incubation with 3.0mM recombinant Neu5Gc, there was no increase in
the observed level of calcein-release compared to untreated H9 cells (data not
shown). This result suggests two possible conclusions, either that the levels of
complement-mediated lysis attributed to the presence of Neu5Gc were over
estimated as a result of a sub-optimal method of detection, or that the natural
Neu5Gc antibody titre of the serum used in this study was insufficient to mediate
complement attack. However, in the absence of commercial sources of anti-Neu5Gc
antiserum a definitive conclusion could not be reached.
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5.4 Conclusion
In conclusion, the data presented here and in Chapter 4, provide early
exemplification of a new approach for the protection of patients against the
associated risk of tumorigenicity from differentiated human ES cells, contaminated
with a minority undifferentiated population. The approach could be further
improved using homologous recombination, to target the transgene into a site free
from position effect variegation. The production of homozygous cells, containing
two copies of the transgene, would guard against gene mutation and chromosomal
loss. However, it is necessary to evaluate this approach on a number of other human
ES cell lines, to determine that the results are reproducible between cell lines, and to
prove its worth as a widely applicable approach for the removal of contaminating
undifferentiated human ES cells.
The obvious advantage of using al,3Gal to provide unique epitopes on the cell
surface of undifferentiated ES cells, is the potential for continued surveillance once
engrafted. Natural immunity to a-gal in humans provides a safe-guard not only
against the accidental transplantation of undifferentiated ES cells, but also against
cells which dedifferentiate, or which become malignant in vivo, with reactivation of
the hTERT promoter, which occurs in over 80% of studied malignancies (Tzukerman
et al., 2000), resulting in re-expression of al,3Gal by these cells.
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6.2.1 The Mechanics of Cell Sorting does not Affect the Proliferation or
Differentiation ofHuman ES Cells





Fluorescence activated cell sorting (FACS) has the potential to enhance many
applications in the field of stem cells research. One such area is in directed
differentiation where sorting for markers of differentiated human ES cell derivatives
could lead to the isolation of a minority population which could subsequently be
expanded and used in therapy. Similarly, FACS could be used to deplete
undifferentiated human ES cells, with tumourigenic potential, from mixed
populations, as an alternative to complement-mediated lysis described in Chapters 4
and 5.
Successful application of FACS with human ES cells has been reported. Eiges et
al., (2001), demonstrated the identification of pure populations of undifferentiated
human ES cells transfected with a GFP reporter gene, using the Rex-1 promoter to
Zoe Hewitt
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drive expression specifically ill undifferentiated and not in differentiated derivatives
of human ES cells (Eiges et al., 2001). The authors indicated that the use of FACS
had not affected the morphology and growth of the human ES cells, but they had not
assessed the pluripotentiality and karyotypic stability of the sorted population, nor
had they attempted to single cell clone the sorted cells.
In this chapter the effects of FACS on undifferentiated human ES cells and their
differentiated derivatives, in terms of the effects on their proliferative capacity,
differentiation potential and karyotypic stability have been investigated. The
rationale for doing this work was through necessity, since the BD FACSAria was a
new piece of equipment, and consequently there was limited knowledge as to how
human ES cells and their derivatives would respond to the process of cell sorting.
Also presented within this chapter are data to support the use of FACS to
successfully isolate single-cell clones of human ES like-cells, at relatively high
frequency, contradicting current perception (Amit et al., 2000; Thomson et al.,
1995).
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6.1.1 Chapter A ims
1. To become familiar with and optimise the mechanics of cell sorting for
human ES cells using the BD FACSAria.
2. To calibrate the FACSAria to determine the reliability and reproducibility of
the data produced by comparing them with data sets acquired by flow
cytometry using the BD FACScan.
3. To determine whether the process of cell sorting affects the proliferation,
karyotypic stability and pluripotentiality of human ES cells.
4. To investigate the potential of FACS to isolate single human ES cell clones,
using H9-ES cells carrying a GFP reporter under the control of the Oct-4
promoter.
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6.2 Results
The Becton Dickinson (BD) FACSAria cell sorter was a new piece of equipment
acquired during the course of this investigation and thus, before it was used
experimentally the machine was assessed for stability and calibrated against data
sets acquired for human ES cells using the BD FACScan cell analyser. To do this
data for forward (FSC) and side (SSC) scatter and fluorescence levels from the
expression of the endogenous cell surface markers, TRA-1-81 and SSEA-1, from
undifferentiated human ES cells were collected on multiple occasions on both
cytometers and compared.
The data presented in Table 6.2.1 and Figure 6.2.1, are representative of three
independent experiments, and show that the data observed using the BD FACScan
cell analyser (Figure 6.2.1 A) were comparable to the data produced by the BD
FACSAria cell sorter (Figure 6.2.IB). Results from both machines showed a
transient increase in forward scatter (FSC), following 5 days in differentiation
medium, which was lost when cells have been differentiated for 10 days.
Furthermore, TRA-1-81 expression, a characteristic marker of ES and EC cells, was
highly expressed in undifferentiated human ES cells, but as expected this expression
was lost with increased time in differentiation (Figure 6.2.1 and Table 6.2.1.)
Conversely, SSEA-1 expression, which is associated with differentiation, was up
regulated after 5 days of differentiation. However, following 10 days in
differentiation medium, expression appeared to drop off (Figure 6.2.1 and Table
6.2.1). This result was consistent with the transient expression reported by Draper et
al., 2002.
-232-
Chapter 6- Optimising fluorescence activated cell sorting for human ES cells













1" " 1" ■ ■ 1" •» 1 •







lin^ i 11 nnq 1uq lllllfff
io' IO1 10' 10"
Tra-1-81 PE-A
VT















10 10 10 10
Tra-1-81 PE-A
10 10 10 10
SSEA-1 PE-A
Figure 6.2.1: A comparison of the acquisition parameters for the Becton Dickinson FACScan
(A) and FACSAria (B), using FSC, SSC and expression of TRA-1-81 and SSEA-1 on
undifferentiated human ES cells. Images are representative of 3 independent experiments,
indicating similar expression patterns from both cytometers; a transient increase in FSC after 5
days of differentiation which is lost by 10 days, progressive loss of TRA-1-81 with increased
differentiation and a transient increase in SSEA-1 expression following 5 days of differentiation
which appeared to be decreasing after 10 days. Contour lines represent a 70% log decrease in
cell number. Faded histograms represent staining from secondary antibody controls, and all
graphs represent a minium of 10,000 live events.
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FACScan 95.4% 91.6% 22.3%









FACScan 25.2% 75.4% 67.4%
FACSAria 31.1% 80.8% 71.2%
Table 6.2.1: Data acquired for the level of cell surface marker expression on undifferentiated
ES cells and ES cells differentiated for 5 and 10 days are comparable when collected on the
FACSAria with data collected on the FACScan. Figures represent the proportion of positive
events from a total of 10,000 live events.
It is interesting to note that the BD FACScan appears, visually, to provide clearer
separation between positive and negative peaks than the BD FACSAria (Figure
6.2.1), providing greater clarity. However, when the statistics were analysed, it is
clear that although the BD FACScan provides visually clearer results, statistically
the two cytometers were recording similar data. A possible explanation for this is
that the BD FACScan records using a logarithmic scale based on 1024 channels, as a
consequence small differences appear greater. The BD FACSAria on the other
hand, actually records on a linear scale based on 256,000 channels, so small
differences don't appear so great, providing more accurate data. Furthermore, the
BD FACSAria measures events based on the height of the electronic pulse and its
duration to provide a measurement of area, the BD FACScan, only records the
height of the pulse. Together with the use of a 5-log axis this makes the BD
FACSAria a more sensitive machine than the BD FACScan.
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6.2.1 The Mechanics of Cell Sorting does not Affect the Proliferation or
Differentiation ofHuman ES Cells
The use of flow cytometry as an alternative method for the elimination of
undifferentiated human ES cells from a mixed population first required an
assessment of the ability of human ES cells and their derivatives, to survive the
process of cell sorting. The rationale behind this assessment was that if
undifferentiated human ES cells were efficiently removed from a mixed population,
there would be confidence that the result arose because human ES cells had been
specifically removed, and not because human ES cells simply had not survive the
sorting process.
Differentiated and undifferentiated human ES cells were harvested as previously
described (see section 2.4) using TEG solution to achieve a single cell suspension.
After the initial centrifugation the cells were resuspended in culture medium and left
at room temperature for 10 minutes, to allow small clumps of cells to settle out. The
supernatant was then collected, pelleted and re-suspended in 200-500pl of culture
medium supplemented with antibiotic (lOOU/ml penicillin and 1 OOpg/ml
streptomycin) to prevent growth of any opportunistic bacteria. Viable cells were
then sorted based on their FSC and SSC profiles, using a gate defined as "live" to
exclude dead cells and debris (Figure 6.2.2). The sorting process was designed to
collect 2x106 viable cells into each of two 5ml polystyrene tubes (Falcon) containing
lml of culture medium supplemented with antibiotic. After sorting, data for a small
sample (2-5,000) of cells was reacquired back through the cytometer to determine
the profile of sorted cells as a way of assessing the success of a sort (Figure 6.2.2).
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Undifferentiated human ES cells
Pre-Sort Post-Sort
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Figure 6.2.2: Undifferentiated human ES cells (A) and their differentiated derivatives (B) were
sorted based on their forward (FSC) and Side (SSC) scatter, using a gate to exclude dead cells
and debris - "live gate". The acquisition of post-sort data showed profiles similar to those of
pre-sorted cells. In all cases the post-sort profiles display a drop in FSC and continue to show
signs of cellular debris. Plots are representative of duplicate experiments for each cell state.
Contour lines represent a 70% log decrease in cell number.
In all cases, the sorted undifferentiated ES cells (Figure 6.2.2A) and differentiated
ES cells (Figure 6.2.2B) had a lower FSC than pre-sorted cells. The exact reason for
this drop in FSC is currently unknown, although it is thought to be a consequence of
changes in osmolarity, as a result of sorting cells from culture medium into a
minimal volume of culture medium, which was subsequently diluted during the
course of the sorting with sheath fluid, composed mainly of PBS.
From this initial data, undifferentiated human ES cells appeared to be more
amenable to cell sorting than their differentiated counterparts (Figure 6.2.2). A
typical pre-sort preparation of undifferentiated human ES cells contained an average
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of 68% viable cells which, despite a drop in FSC, increased to 87% on average in
the post-sort analysis (Table 6.2.2 and Figure 6.2.2A). The pre-sort preparations of
differentiated human ES cells on the other hand contained a greater percentage of
viable cells to begin with, on average 78%, although a proportion of these cells were
very large and could not be represented on the dot and contour plots using the same
acquisition settings. It is probably that these larger cells represented doublets or
small aggregates of differentiated cells that had not been fully disaggregated, since
trypsin is unable to disrupt tight junctions that form between differentiated cells.
The characteristic drop in FSC as a consequence of cell sorting allowed the
inclusion of these "larger" cells into the viable post-sort cell population. However,
despite this, the post-sort population contained on average only 73% viable cells,
suggesting that an increased level of cell death had occurred in the differentiated
population compared with the undifferentiated population. It is possible that
changes in osmolarity, responsible for the reduction in FSC, had a more influential
effect on the differentiated ES cells as a consequence of the increased level of
mechanical stress that is exerted on them as compared to undifferentiated human ES
cells. The pressurised environment of the sorter may have assisted in the separation
of cell aggregates but as a result could have increased the friability of the cells
leading to an increased level of cellular debris (Table 6.2.2 and Figure 6.2.2B).
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Table 6.2.2: Undifferentiated human ES cells, survive the process of cell sorting more efficiently
than their differentiated derivatives. Figures represent the average proportion of cells present
in the "live" gate pre- and post-sorting.
Following the sort process, the cells were pelleted to remove traces of sheath fluid
and resuspended in KO-DMEM for counting. Triplicate counts, using 0.5% trypan
blue, from each tube were made before the cells were plated under normal culture
conditions. Cell recovery was very much lower than expected with an average of
46.72% discrepancy between the digital count provided by the BD FACSAria and
the manual cell counts (Table 6.2.3).
Initially it was considered that the loss of cells might have been as a consequence of
the yield and purity settings being used on the FACSAria. When set for purity, the
BD FACSAria looks at the position of a cell within each drop of sheath fluid. If the
cell appears close to the edge of a drop the cytometer includes the drop that precedes
or follows it, depending on its position, to ensure purity. If this were the case it
would mean that for every cell, two events would have to be counted by the BD
FACSAria, which could have accounted for the discrepancy in cell recovery.
However, when the purity setting was inactivated, cell recovery did not improve
(data not shown), suggesting that the machine settings were not responsible for the
poor cell recovery.
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ES Rep 1 4.5 xlO6 1.71 xlO6 38.00 91.50
ES Rep 2 4.5 xlO6 2.47 xlO6 54.89 94.60
ES Rep 3 2.0 xlO6 1.41 xlO6 70.50 nd
ES Rep 4 3.0 xlO6 1.87 xlO6 62.33 nd
Average 56.43% 93.05%
DiffRep 1 3.0 xlO6 0.94 xlO6 31.33 86.00
Diff Rep 2 4.0 xlO6 1.08 xlO6 27.00 91.00
DiffRep 3 5.0 xlO6 2.21 xlO6 44.20 nd
DiffRep 4 2.0 xlO6 0.92 xlO6 46.00 nd
Average 37.13% 88.50%
Table 6.2.3: Cell recovery following sorting for cell viability (BD FACSAria) was significantly
lower than expected. Expected values were based on the BD FACSAria's internal digital
counter. Following sorting, a manual cell count using 0.5% trypan blue staining and a
standard haemocytometer revealed a value significantly lower than expected level of cell
recovery. Triplicate counts were made for each sample, the top portion of the table refers to
undifferentiated human ES cells, while the bottom refers to differentiated human ES cells,
indicating a significant difference (p=0.02) between the two cell states, nd denotes no-data.
It is possible that poor cell recovery was a consequence of cell shearing when the
cells hit the surface of the medium within the collection tube, or through the
adhesion of cells to the polystyrene collection tubes, used in these experiments.
Alternatively, the pressure exerted by the BD FACSAria, could have had a
detrimental effect on cell survival and could reflect inherent difference between
different cell types. Undifferentiated human ES cells had a significantly higher
(p=0.02) level of cell recovery than their differentiated counter parts (Table 6.2.3)
suggesting that perhaps the pressure exerted on the cell aggregates or larger
differentiated cells was more detrimental. It would be interesting to repeat these
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experiments using medium- or low-pressure settings and polypropylene collection
tubes in an attempt to improve the level of cell recovery.
Interestingly, the viability of those cells recovered, assessed by trypan blue staining,
was observed to be very high, on average >90% cell viability (Table 6.2.3),
suggesting further that it was an aspect of the sorting process that was resulting in
cell loss.
6.2.1.1 Plating efficiency and morphology are comparable
Following cell sorting, both differentiated and undifferentiated human ES cells were
re-plated at 4.5x10 and 8.5x10 respectively in duplicate 25cm flasks. Twenty-
four hours after plating, cells were recovered from one flask for counting to assess
plating efficiency (Table 6.2.4). The difference in plating density between the two
cell populations was a consequence of recovered cell numbers, recovery of far fewer
differentiated cells than undifferentiated cells meant that it was not possible to plate
the cells at the same density. The assumption was that the differentiated cells would
be able to grow at this low density while current opinion suggests that
undifferentiated human ES cells plated at low density would have spontaneously
differentiated (Thomson et al., 1998; Thomson et al., 1995).
The cell counts presented in Table 6.2.4 and Figure 6.2.3, indicated little difference
in the plating efficiency of sorted and unsorted cells, for both differentiated and
undifferentiated human ES cells. However, there was a significant difference
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between the percentage plating efficiency of undifferentiated and differentiated
human ES cells, whether sorted or not. Initially it was thought that the seeding
density of differentiated ES cells was too low, at 4.5x105 per 25cm3 flask, however,
when undifferentiated human ES cells were plated at densities as low as 3x105, the
plating efficiency remained significantly higher than that of differentiated cells (over
83% compared to 25-30% for differentiated cells).
Undifferentiated human ES Differentiated human ES
cells cells
Unsorted Sorted Unsorted Sorted
Average cells plated at pi 8.50 xlO5 8.50 xlO5 4.50 xlO5 4.50 xlO5
Average cell count (pi) 7.18 xlO5 6.90 xlO5 1.33 xlO' 1.08x10'
Average plating efficiency 84.40% 81.25% 29.35% 23.90%
Average cells plated at p2 5.00 xlO5 3.00 xlO5 nd nd
Average cell count (p2) 4.74 xlO5 2.58 xlO5 nd nd
Average plating efficiency 94.70% 83.00% nd nd
Average 89.55% 82.12% 29.35% 23.9%
S.D. 11.08% 4.95% 3.25% 1.1%
Table 6.2.4: Plating efficiency for both differentiated and undifferentiated human ES cells were
not significantly affected by cell sorting. No data (nd) can be provided for differentiated cells at
passage 2 (p2), as the cells never reached confluence they were discarded before passage.
Values represent the mean of triplicate cell counts for each duplicate. Data coloured grey
indicates a loss of a substantial amount of the cell pellet during passaging of one of the
replicates, hence the significant reduction in cell number plated (in this instance cells were
plated in a well of a 6-well plate not in a 25cm2 flask).
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Figure 6.2.3: Plating efficiency of undifferentiated (red) and differentiated (blue) human ES
cells following passage (sorted) through the FACSAria cell sorter. Cells from the same
preparation were reseeded at the same density following the same period of time in suspension
but without passing through the sorter (unsorted). Differentiation of human ES cells was as a
monolayer in the absence of CM and bFGF for at least 14 days. Data represents the mean of
triplicate cell counts from two independent experiments at two passages; error bars represent
one standard deviation of the mean.
Interestingly, cultures of sorted and unsorted differentiated human ES cells
contained a large proportion of dead cells. Furthermore, those cells that survived
didn't proliferate extensively in the days after plating and following 8 days in
continuous culture the cells had changed in morphology and were senescent (Figure
6.2.4A). Consequently they were discarded and it was decided that in future
experiments the plating density for differentiated cells would need to be increased,
or the surface area onto which they were plated would be decreased.
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A 24 hrs post-sort 24 hrs post-sort 5 days post-sort 8 days post-sort
x4 x10 x10 x10
Unsorted
Sorted
d 24 hrs post-sort 24 hrs post-sort Passage 2 Passage 5
x4 x10 x10 x10
Unsorted
Sorted
Figure 6.2.4: Differentiated (A) and undifferentiated (B) human ES cells sorted using a live
gate, behave in a similar manner to their unsorted counterparts after re-plating. Images a, b, e,
f, i, j, m and n represent 24 hours after plating (a, e, i and m at x4 and b, f, j and n at xlO
magnification). Images c and g follow 5 and d and h follow 8 days in differentiation culture
show continued differentiation, but loss of proliferation. Images k and o, and I and p, represent
continued proliferation of undifferentiated human ES following 2 and 5 passages respectively.
Scale bars represent 100pm.
By comparison, in excess of 89% of sorted undifferentiated human ES cells were
adherent (Table 6.2.4), containing only small numbers of dead cells. Furthermore,
the proliferative capacity of the cells was not impeded, with confluence being
reached two-three days after plating (Figure 6.2.4B). Sorted and unsorted human ES
cells were maintained in culture for a further five passages in their undifferentiated
state, before being assessed for continued normality and pluripotentiality.
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6.2.1.2 Karyotypic normality is maintained following the sorting process
Mitotic spreads where made from both unsorted (A) and sorted (B) human ES cells
following 8 passages in culture (p99+8). A total of 30 spreads were counted from
each population, 10 of which were fully analysed (Fletcher, J., Roslin Institute,
Edinburgh), showing a normal 46XX karyotype (Figure 6.2.5)
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Figure 6.2.5: Representative mitotic spreads from unsorted (A) and Sorted (B) M2 cells, 8
passages after they were sorted (or mock sorted). Both cell populations have a normal 46 XX
karyotype with no obvious chromosomal abnormalities. Images produced in collaboration with
J. Fletcher, Roslin Institute.
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6.2.1.3 Expression of ES specific markers are maintained on sorted
undifferentiated human ES cells
Human ES cells have been characterised extensively in the literature by the
expression of a number of markers; positive expression of the cell surface epitopes
SSEA-4, TRA-1-60 and TRA-1-81, expression of Oct-4 and alkaline phosphatase
and the lack of SSEA-1 expression (Reubinoff et al., 2000; Thomson et al., 1998).
Consequently, to assess the normality of the human ES cells, following cell sorting,
both sorted and unsorted human ES cells were assessed for expression of the above
panel of characteristic markers.
Expression of cell surface markers was assessed by flow cytometry (BD FACScan)
and showed positive staining for SSEA-4, TRA-1-60 and TRA-1-81 to the same
extent in both sorted and unsorted populations (Figure 6.2.6a, c and d respectively).
As expected, both populations lacked expression of SSEA-1 (Figure 6.2.6b),
indicating that sorted undifferentiated human ES cells maintained their
undifferentiated state and that there had been no adverse effects on cell surface
marker expression as a consequence of cell sorting.
-245-
Chapter 6- Optimising fluorescence activated cell sorting for human ES cells
Figure 6.2.6: Cell surface expression of the markers SSEA-4 (a), SSEA-1 (b) TRA-1-60 (c) and
TRA-1-81 (d) remained constant on cells subjected to the process of sorting (blue) as compared
to the same cells which had not been sorted (red), after 5 passages in culture. Each data set
consists of 10,000 events. The black line represents the level of non-specific binding of the
secondary antibodies. FL1 - 530/30nm bandwidth filter detects FITC-stained cells, while FL2 -
585/42nm bandwidth fdter detects R-PE-stained cells.
Immunochemistry for the nuclear expression of the transcription factor Oct-4
showed clear and strong co-localisation with the nuclear stain dapi in both sorted (a)
and unsorted (b) human ES cells (Figure 6.2.7). Furthermore, all human ES cells
expressed alkaline phosphatase as determined using the BCIP/NBT substrate IV kit
(Vector Labs.) to the same extent, whether sorted (a and b) or not (c and d; Figure
6.2.8)
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Oct-4 + dapi Oct-4 + dapi Secondary only
Sorted
Unsorted
Figure 6.2.7: Cells exposed to the process of cell sorting (a) expressed Oct-4 at a level
comparable to cells not exposed to the sorting process (b). Oct-4 (FITC, green) co-localises with
the nuclear stain dapi (blue) to give a turquoise positive stain. In dividing cells (indicated with
arrows) Oct-4 leaks from the nucleus into the cytoplasm producing a diffuse green stain.
Columns 1 and 2 show positive staining at xlO and x40 magnification respectively. Column 3
shows the negative control, FITC-conjugated secondary antibody with dapi. Scale bars
represent 100pm.
Sorted human ES cells Unsorted human ES cells
Figure 6.2.8: Positive alkaline phosphatase staining was observed in all cells whether exposed (a
and b) or not (c and d) to the process of cell sorting. Images are by differential interference
contrast (DIC) microscopy at x4 (a and c) and x40 (b and d) magnification. Scale bars
represent 100pm.
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6.2.1.4 Human ES cells, which have undergone the sorting process, can
differentiate into cell types representative of the three-germ layers and can
be directed to differentiate down the osteogenic pathway
In collaboration with Davina Wojtacha (Roslin Institute, Edinburgh), sorted human
ES cells were assessed for their continued pluripotentiality. Using the standard
undirected differentiation protocol, described in Chapter 3 (ref methods), sorted and
unsorted human ES cells were formed into embryoid bodies in suspension before
being plated on gelatin coated bucket slides (NUNC), and allowed to spontaneously
differentiate for a further 14 days (21 days in total). The resulting cells were then
analysed for markers representative of all 3 embryonic germ layers, endoderm (a-
fetoprotein; AFP), ectoderm (p-tubulin III) and mesoderm (muscle specific-actin).
Figure 6.2.9 demonstrates that sorted undifferentiated human ES cells, maintained
the potential to differentiate into cell types representing all 3 embryonic germ layers,
with an abundance of P-tubulin III (c) and muscle specific actin (d) staining and
clear areas of AFP staining (a and b). In the unsorted population, however, while
there was an abundance of both P-tubulin III (f) and muscle specific actin (g), there
was far less evidence of AFP staining (e) than was observed for the sorted
population. Furthermore, due to the reduced frequency of AFP positive cells and
because of the nature of AFP positive cells, often differentiating as 3-dimenstional
structures in very dense areas of cells, it was not possible to obtain clear images
showing high magnification images of AFP positive cells in the unsorted population.
It is likely that the difference in AFP staining between the sorted and unsorted
populations occurred by chance, and that with further repeats, using this undirected
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differentiation protocol, examples would be found where there was an increased
amount of AFP staining and where clearer images of AFP positive cells could be
obtained. However, it is also possible that by exerting the selection pressure of
sorting on undifferentiated human ES cells that a juvenile cell, with increased
potentiality had been isolated.

















Figure 6.2.9: Sorted human ES cells maintain their potential to differentiate into cell types
representative of all 3 germ layers. Sorted human ES cells (a-d) differentiated into cells that
express a-fetoprotein (a xlO, b x40), p-Tubulin III (c, x40), and muscle specific actin (d x40).
Unsorted human ES cells readily differentiated into identifiable cell types expressing p-Tubulin
III (f, x40), and muscle specific actin (g x40). However, do to the nature of AFP positive cells,
they differentiate in areas of dense cells, and it was not possible to obtain images in clear focus
with out background staining for the unsorted population. The area in image e, outlined by a
white box, is an area typical of AFP staining, showing the characteristic sphere (xlO). Scale
bars represent 100pm.
In addition, the sorted and unsorted human ES cells were also directed to
differentiate into bone, using the directed osteogenic protocol developed within the
group (Sottile et al., 2003). Briefly, human ES cells were harvested and aggregated
into EBs, as previously described, and were then plated on to gelatin, in basic
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differentiation medium supplemented with the osteogenic factors (3-
glycerophosphate (lOmM), ascorbic acid (50pM) and dexamethasone (0.1 pM) (see
section 2.8.5). The progress of osteogenic differentiation was assessed at 0, 3, 6, 9,
13, 16 and 20 days post induction, by Alizarin Red S staining (Figure 6.2.10 and
Figure 6.2.11) and calcium deposition (Figure 6.2.12).
Figure 6.2.10: Sorted (a) human ES cells have the same capacity as unsorted (b) human ES cells
to differentiate into bone, in the presence of osteogenic factors (a & b). Significant numbers of
bone nodules started to form after 13 days in the presence of osteogenic factors, but not in the
absence of osteogenic factors (c), at similar frequencies between the two populations. Images
produced in collaboration with Davina Wojtacha (Roslin Institute, Edinburgh).
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Figure 6.2.11: Phase contrast microscopy showing the development of bone nodules with time
in differentiation, specifically in response to osteogenic factors (a, b and c), panel d represents
no osteogenic factors. No significant difference was observed between the ability of sorted (a
xlO and b x40) and unsorted (c xlO) cells to differentiate into bone. Images produced in
collaboration with Davina Wojtacha (Roslin Institute, Edinburgh), scale bars represent 250pm.
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Alizarin Red S staining indicated an abundance of bone nodules following 16 days
in osteogenic differentiation medium in both the sorted and unsorted populations
(Figure 6.2.10). However, using phase contrast microscopy (x40), nodules were
observed as early as day 6, in the sorted population (Figure 6.2.11b). Calcium
deposition data indicated a significant increase in calcium following 3-6 days in
osteogenic differentiation medium, which precedes the development of bone nodules
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Figure 6.2.12: Calcium deposition as a result of directed osteogenic differentiation is unaffected
by the process of cell sorting. Sorted human ES cells (red) deposit calcium at levels comparable
with unsorted (blue) human ES cells, when differentiated in the presence (■) of ostegenic
factors for 20 days. Differentiation in the absence (A) of osteogenic factors resulted in minimal
calcium deposition in both sorted and unsorted cells. Data represents the average of triplicate
wells and the error bars represent one standard deviation about that mean. Data produced in
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The behaviour of both sorted and unsorted human ES cells following osteogenic
differentiation suggested that the process of cell sorting had not affected their ability
to be directed to differentiate into cell types of the mesoderm germ layer. Following
the results of the undirected differentiation, it would be interesting to determine if
there were any significant differences in the ability of sorted and unsorted human ES
cells to be directed to differentiate into cell types of the endoderm lineage.
6.2.2 FACS is an Efficient Methodfor Single Cell Cloning of Undifferentiated
Human ES Cells.
With the evidence presented here, and the indication in Chapter 5 that, possibly,
single cells can survive complement-mediated lysis, leading to the formation of a
colony, it was hypothesised that perhaps cell sorting could be used to produce single
cell clones of undifferentiated human ES cells. To test this hypothesis, H9 cell lines
containing a GFP-reporter gene, driven from the full 8.5kb murine Oct-4 promoter
were generated (see appendix 1.3), and single cells sorted into 96-welled plates.
From in excess of 50 colonies, produced by lipofection (see section 2.7.1), 9
colonies were suitably discrete to enable them to be picked as a single colony for
expansion into lines, of which only 6 survived expansion. When analysed by
fluorescence microscopy, all 6 cell-lines, named Oct-4/GFP-3 to -7 and -9, had
variegated GFP expression. Maintaining cells in the presence of 200p.g G418
reduced the level of variegation (data not shown), however, there remained
significant differences between the lines (Figure 6.2.13). Oct-4/GFP-6 showed the
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lowest level of variegation, by fluorescence microscopy, and consequently was used





Figure 6.2.13: Oct/GFP-6 human ES cell line had a more uniform GFP expression pattern from
the Oct-4 promoter, than Oct/GFP-5. Random integration of transgenes results in positional
effects. Clone 5 is an illustrative example, where despite being cultured in the presence of G418
selection, expression of GFP is minimal. Oct/GFP-6 on the other hand has almost ubiquitous
expression in the presence of G418 selection. Scale bars represent 100pm.
Oct-4/GFP-6 cells were first assessed for their ability to down-regulate the Oct-4
promoter when differentiated. Differentiation was induced, as previously described
(see section 2.8.4), by forming embryoid bodies in suspension and seeding EBs onto
gelatin coated plates in basic differentiation medium (KO-DMEM supplemented
with 10% FBS (v/v), 0.1 mM NEAA, 2mM L-Glutamine and 0.1mM p-
mercaptoethanol). Figure 6.2.14 shows representative images of a differentiation
time-course, where GFP expression was down-regulated in the majority of cells
following 6 days of differentiation (Figure 6.2.14 d-f). Those cells that maintained
GFP expression were located in dense areas of cells and in areas with a 3-
-254-
Chapter 6- Optimising fluorescence activated cell sorting for human ES cells
dimensional structure, which would often beat. This may represent continued
expression, or perhaps persistence of the GFP protein (d, e, g and h) since it was the
unmodified EGFP that was used with a reported half-life of 26 hours (Ward & Stern,
2002; Corish & Tyler-Smith, 1999). Following 14 days plated in differentiation
medium, no convincing GFP expression was observed, only auto-fluorescence from





Figure 6.2.14: Oct/GFP-6 effectively down-regulated GFP expression with time in
differentiation medium. The majority of Oct/GFP cells have lost GFP expression following 6
days in differentiation medium. Those cells that persist are located in dense areas and could
represent either continued expression or persistence of trapped GFP protein. Following 14
days in differentiation medium the only staining observed was auto-fluorescence from very
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dense areas of cells. Left panel shows merged images of the centre, GFP fluorescence and right,
phase contrast images. Scale bars represent 100pm.
Oct-4/GFP-6 cells were cultured and harvested as previously described (see section
2.4), and were sorted into 4 replicate, 96-well plates containing conditioned medium
supplemented with 100U penicillin and lOOpg streptomycin, by Martin Waterfall
(Roslin Institute, Edinburgh) using the BD FACSAria. The sort plan used for each
of the 4 replicate 96-well plates, placed the wells containing the highest numbers of
cells (50, 20 and 10 cells) around the edges of the plates (Figure 6.2.15 e). This was
a deliberate action, as it is known that the outer wells of a 96-well plate can be
affected by evaporation resulting in the loss of cells contained within.
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Figure 6.2.15: Human ES cells expressing Oct-4/GFP were single cell sorted into 96-welled
plates based on position of FSC and SSC (live gate to remove dead cells and debris) and on
positive GFP fluorescence. Dot plot (a) defines the "live" gate based on FSC and SSC and the
proportions and statistics are provided (b). GFP positive and negative populations are
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identified (c) to establish the range for the sort gates (d). The sort plan for the distribution of
cells within a 96-well plated is provided (e).
The plates were maintained without media change for 1-week, at 37°C in a
humidified incubator plus 5% CO2, and a decision was made to make an assessment
of the number of wells containing surviving cells before the medium was changed.
There were 2 reasons for this decision: a) to prevent disturbance of the colonies,
such that each colony was generated from a single cell deposited by sorting and not
from the production of satellite cells, which would have resulted in an apparent
increase in colony number, and b) to prevent any possible well-to-well
contamination in the media changing process from impacting on the efficiency of
cell survival. After a 1-week period in culture, a significant number of colonies
were visible by phase contrast microscopy (Table 6.2.5).
No of No of No of wells Frequency No with Frequency of
cells per wells with cell of cell GFP GFP expression
well seed growth survival expression in surviving cells
50 8 1 12.5% 0 0.00%
20 44 8 18.2% 1 12.5%
10 44 12 27.3% 5 41.7%
8 48 19 39.6% 12 63.2%
6 48 13 27.1% 10 76.9%
4 48 14 29.2% 11 78.6%
2 48 9 18.8% 9 100.0%
1 96 10 10.4% 9 90.0%
Table 6.2.5: Cell survival rates of single human ES cell clones are relatively high, and show
strong expression of GFP driven by the Oct-4 promoter. Survival of human ES cells in the
outer rows of the 96-wells were low as anticipated, and those cells which did proliferate,
appeared in most cases to switch off the Oct-4 GFP construct. Data represent the absolute
number of wells containing proliferating cells from 4 replicate plates.
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The cell survival data in Table 6.2.5 supported the expectation that wells on the edge
of a 96-welled plate were less amenable to cell growth than those in the centre.
From a total of 96 wells, only 21 wells (22%) containing 10 or more cells, supported
proliferating cells after a 1-week period, out of which only 6 wells (6.25%)
contained cells that continued to express the Oct-4/GFP transgene following 2
weeks in culture.
Interestingly, the frequency of wells containing proliferating cells from a single
seeded cell was very encouraging, with a 10.4% success rate. This frequency was a
significant improvement on that reported by Amit et al., (2000), who described
clonally derived human ES cell lines at a frequency of just 0.52%. Furthermore,
90% of the wells that contained proliferating cells from a single seeded cell also
continued to express the Oct-4/GFP transgene (Table 6.2.5 and Figure 6.2.16).
Flowever, there was some degree of variation in the morphology of the proliferating
cells. Out of the 9 wells, 2 contained cells with a non-ES like morphology,
suggesting that they were differentiating and perhaps in the process of down
regulating Oct-4 expression (Figure 6.2.16b). Flowever, this was not a result that
was unique to the single cell wells, there was also evidence in the 2-cell (c) 4-cell
(d), 6-cell (data not shown) and 10-cell (f) wells (Figure 6.2.16).
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Seeding GFP Phase Merged
Figure 6.2.16: Representative examples of human ES cells, which have proliferated for 2 weeks
after cell sorting and show expression of the Oct-4/GFP transgene. Cell which had been
individually seed (a and b), 2-cells seeded (c), 4-cells seeded (d) 6-cells seeded (e) and 10-cells
seeded (f) per well proliferated into visible colonies 1 week after being sorted and continued to
express the Oct-4/GFP construct. The majority of surviving colonies also maintained an ES-
like morphology, but some colonies, particularly those in wells around the edge of the plates, (b
and f) had lost their ES-like morphology, but continued to express the Oct-4/GFP transgene.
Scale bars represent 100pm
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Preliminary data for the isolation of single cell human ES cell clones using cell
sorting indicated that it was relatively efficient (10.4%), however, these results
represent a single experiment, which must be repeated in order to confirm the
observations. Furthermore, it is essential that clonal human ES cells are expanded
into cell lines and characterised for karyotypic stability and continued
pluripotentiality. Unfortunately, due to bacterial contamination, this was not
possible at the time of this first experiment, but it will be an essential result if cell
sorting is to be used to generate single cell clones of human ES cells in the future
and is currently being repeated within the group.
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6.3 Discussion
The data presented in this chapter indicated that the BD FACSAria could be used to
reproducibly sort undifferentiated human ES cells. Furthermore, when those cells
were placed back into culture, they proliferated to the same extent as those which
had not been sorted and upon further characterisation, sorted undifferentiated human
ES cells expressed markers, characteristic of undifferentiated human ES cells, to the
same extent as unsorted cells. The karyotypic stability of both sorted and unsorted
cells was confirmed, as was their continued pluripotentiality in vitro. Interestingly,
differentiation into the endoderm lineage, indicated by the expression of a-
fetoprotein (AFP), appeared to be achieved more readily with undifferentiated
human ES cells that had been sorted, based on forward (FSC) and side (SSC) scatter,
for viability, although this could simply be due to chance. Differentiation into the 3
germ layers was not performed using directed differentiation protocols and
therefore, it is possible that the wells selected for AFP staining simply did not
contain cells of the germ layer which expressed AFP. Alternatively, it is possible
that by exposing the cells to sorting, selection of a "juvenile" cell, with increased
potentiality has occurred. The directed osteogenic differentiation protocol indicated
little difference between the ability of sorted and unsorted human ES cells to
produce bone (mesoderm). However, to test the possibility that a "juvenile" cell
with increased potentiality had been selected, it would be interesting to direct
differentiation of sorted and unsorted human ES cells into cell types of the
endoderm lineage, such as hepatocytes.
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Human ES cells which had under gone differentiation were however, less amenable
to the process of cell sorting. It is appropriate to point out that cells referred to in
this chapter as differentiated, have not been directed to differentiate into a particular
lineage, and are defined as differentiated based on their non-ES like morphology.
Prior to harvesting for cell sorting these differentiating human ES cells had a steady
rate of proliferation. It is possible that this proliferative capacity was as a result of
association with small populations of undifferentiated human ES cells or progenitor
cells, which when grown as monolayers, were in close contact, possibly contained
within cell aggregates, to the differentiated cells. It is hypothesised that during cell
sorting, the pressurised environment in which the cells were place, encouraged the
breakdown of cell aggregates, which would have removed any close association the
differentiated ES cells had with undifferentiated ES or progenitor cells.
Consequently, when the single cell suspension was plated at low density, the lack of
cell-to-cell contact with highly proliferative cells perhaps induced senescence in the
differentiated population. If this explanation is correct then plating differentiated
cells at higher density on a smaller surface area could improve the level of cell
survival but it is unlikely that the proliferative capacity of differentiated cells would
improve.
The ability of human ES cells to differentiate into cells representative of the three
germ layers holds a great deal of promise for their use in regenerative medicine.
However, the majority of the published data describes the potential of populations of
human ES cells, which could contain several precursors or stem cells committed to
different lineages. Amit et al., (2000) described the first clonally derived human ES
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cell lines, providing the first evidence that each human ES cell had the capacity to
proliferate indefinitely and to develop into representative cell types of the 3 germ
layers. However, the efficiency at which clonal cell lines were derived was very
poor, a frequency of just 0.52% (Amit et al., 2000). The preliminary data presented
here indicates that undifferentiated human ES cells can be successfully and
efficiently single cell cloned using FACS, with a frequency of 10.4%, and that the
proliferating cells continued to express Oct-4. However, as previously mentioned,
these results represent a single experiment and must be repeated to confirm the
observations. It is also essential that these clonal human ES cells are expanded into
cell lines and characterised for karyotypic stability and continued pluripotentiality, if
this technique is to be used routinely to derive clonal ES cell lines. Furthermore, it
would be interesting to determine if the frequency of isolating single cell clones can
be increased through culture in low oxygen. Ezashi et al., 2005, have reported that
human ES cells grown under conditions of hypoxia (3-5% O2) undergo less
spontaneous differentiation than the same cells cultured under conditions of
normoxia (21% O2). The hypothesis therefore, is that if spontaneous differentiation
hampers the ability of human ES cells plated at low density to survive, then perhaps
culturing cells in hypoxia may help to over come this. Currently members of the
McWhir lab are under taking these experiments.
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6.4 Conclusion
As a new piece of equipment the BD FACSAria has been shown to reproducibly and
reliably sort differentiated and undifferentiated human ES cells, producing analytical
data comparable to that obtained for the BD FACScan. The data presented in this
chapter clearly indicate that undifferentiated human ES cells can be successfully
sorted using FACS and that the surviving cells continued to grow and behave as
undifferentiated human ES cells: expressing characteristic ES cells markers,
maintaining a normal karyotype and retaining the ability to differentiate into cells
representative of the three germ layers. Furthermore, presented here are preliminary
data to support the use of FACS to derive single cell clones, at relatively high
frequency (10.4%), with an ES-like morphology and continued expression of Oct-4.
Under the conditions described in this chapter, differentiated human ES cells
appeared less amenable to sorting than their undifferentiated counter-parts.
Significantly increased levels of cell death were observed when differentiated cells
were plated at low density, compared to undifferentiated human ES cells, which
consequently reduced their plating efficiency and proliferative capacity. However,
reduced cell survival could not be attributed to the process of sorting, since the same
effects were observed in the unsorted controls. Therefore, in future experiments the
plating density of differentiated cells should be increased in an attempt to improve
sustainability of the cultures.
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7.2.1 Expression Profiles of ES Cell Surface Markers are Comparable in Both
Transgenic and Wild Type Human ES Cells, with the Exception of SSEA-
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7.2.2 Nine Days in Differentiation Medium Significantly Reduces the Ability of
Human ES Cell Derivatives to Revert Back to Their Undifferentiated
State.
7.2.3 Mixed Populations of Differentiated and Undifferentiated Human ES




In Chapter 6, fluorescence activated cell sorting (FACS) was shown to reproducibly
sort undifferentiated human ES cells, with no adverse effects on their proliferative
capacity. This chapter investigates the possibility of using FACS to deplete
undifferentiated human ES cells, with tumorigenic potential, from mixed
populations, as an alternative to complement-mediated lysis, reported in Chapters 4
and 5. Endogenous cell surface markers (SSEA-4 and TRA-1-81), which have been
reported in the literature to be characteristic of undifferentiated human ES cells
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(Reubinoff et al., 2000; Thomson et al., 1998) showing rapid down-regulation with
differentiation (Draper et al., 2002), will be used to assess the appropriate regulation
of transgenic a-gal expression, with time in differentiation. In addition endogenous
cell surface markers indicative of differentiation (SSEA-1 and GD2) will also be
assessed in longitudinal studies in an attempt to identify differentiated and
undifferentiated cells in a mixed population. SSEA-1 has been discussed elsewhere
(see section 1.6.3), its expression is found on undifferentiated mouse ES cells, is
absent on undifferentiated human ES cells but shows a transient up-regulation as
human ES cells differentiate (Draper et al., 2002). The ganglioseries glyolipid,
GD2, is a marker on neuroectoderm and consequently has been shown to have no or
very low expression on undifferentiated human EC and ES cells. However, with
onset of differentiation GD2 expression is stably upregulated showing a progressive
increase in expression with time in differentiation (Draper et al., 2002; Andrews et
al., 1990).
Cell sorting experiments were designed to collect both positive and negative cell
fractions stained for the expression of either the TRA-1-81 endogenous ES cell
epitope or transgenic a-gal. Sorted populations, both negative and positive, were
subsequently cultured in conditions known to support the proliferation of
undifferentiated human ES cells, should they be present. The results presented in
Chapter 6 provide confidence that if contamination of the differentiated population
persisted, undifferentiated ES cells would be readily identified.
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7.1.1 Chapter A ims
1. To characterise the longitudinal expression of SSEA-4, TRA-1-81 and a-gal
as ES specific markers following in vitro differentiation.
2. To identify cells positive and negative for endogenous ES or a-gal epitopes
in a mixed population of undifferentiated and differentiated human ES cells.
3. To determine the potential of undifferentiated human ES cells to proliferate
following time in differentiation medium.
4. To compare endogenous ES cell and a-gal epitopes in their use as ES
specific markers for the removal of contaminating undifferentiated ES cells
from differentiated populations.
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7.2 Results
7.2.1 Expression Profiles ofES Cell Surface Markers are Comparable in Both
Transgenic and Wild Type Human ES Cells, with the Exception ofSSEA-
4.
To use either endogenous cell surface markers or a-gal expression under hTERT
control as a method for selectively removing undifferentiated human ES cells from a
mixed population, it was first necessary to establish longitudinal characterisation of
their expression. To do this, wild type H9 cells and transgenic M2 cells were
differentiated over a period of 22 days and assessed for the continued expression of
characteristic markers of undifferentiated ES cells (SSEA-4 and TRA-1-81),
markers of differentiation (SSEA-1 and GD2) and M2 cells were assessed for
expression of transgenic a-gal. Initially, the FSC and SSC profile of
undifferentiated H9 and M2 cells was analysed using the BD FACSAria to
determine if the process of genetic manipulation had affected the ES cell profile as
determined by flow cytometry. Reassuringly, the FSC and SSC profiles of H9 and
M2 cells were very similar (Figure 7.2.1), suggesting that the size and complexity of
the ES cells had not been affected by genetic engineering and selection.
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Figure 7.2.1: Transgenic and wild type human ES cells, maintain the same forward (FSC) and
side (SSC) scatter profdes. Dot (a and b) and density contour (c and d) plots indicate that the
forward (FSC) and side (SSC) scatter of wild type H9 (a and c) and transgenic M2 (b and d)
cells remain unchanged, graphs are representative of those observed throughout the
investigation and are based on 10,000 counted events within the live gate. Grey represents cells
considered to be dead or cellular debris, while blue represents viable cells, referred to as being
in the "Live" gate. Contour lines represent a 70% log decrease in cell number.
SSC-A
However, while the expression patterns of SSEA-1, GD2 and TRA-1-81 were
comparable between the undifferentiated transgenic M2 cells and the parental cell
line (H9), SSEA-4 expression was different (Figure 7.2.2A). H9 cells showed two
distinct cell populations, a large negative population, constituting 68.6% of the total,
and a minor population positive for SSEA-4 (Figure 7.2.2A H9). M2 cells, on the
other hand, which were of H9 origin, only displayed a single positive population for
SSEA-4, showing 96.3% positive staining (Figure 7.2.2Aa and Table 7.2.1).
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Figure 7.2.2: Longitudinal characterisation of the expression of the cell surface markers SSEA-
4 (A), SSEA-1 (B) and GD2 (C), on differentiating M2 human ES cells. Time course for
differentiation represented at 0, 5, 7, 9, 11, 13,17, 19 and 22 days (a-i respectively). Where M2
cells behaved differently to their H9 parental cell line, the H9 histograms are provided (H9).
Histograms are representative of three independent experiments and show a minimum
acquisition of 10,000 "live" events. The position of the negative gate was derived from time
course matched isotype control samples. Data were acquired using the BD FACSAria in
collaboration with Martin Waterfall (Roslin Institute, Edinburgh).
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Proportion (%) of cells positive for the cell surface marker
SSEA-4 TRA-1-81 a-gal SSEA-1 GD2
0 96.3 91.7 98.5 0.5 0.1
5 94.8 94.3 95.6 23.0 0.1
7 74.5 91.9 70.4 84.4 0.1
9 71.3 78.5 71.6 81.2 0.1
11 58.5 66.9 43.8 76.7 0.0
13 51.9 48.9 39.2 25.0 0.2
17 42.2 36.3 27.2 20.0 1.6
19 42.3 22.5 25.8 12.0 0.6
22 26.7 14.1 00 OO 11.7 2.9
H9 ES Cells 30.2 92.9 0.6 11.6 0.2
Table 7.2.1: Positive expression of endogenous cell surface markers (SSEA-4 and TRA-1-81) by
ES cells decrease with time in differentiation, with a corresponding increase in expression of
characteristic markers of differentiation (SSEA-1 and GD2). Expression of a-gal driven by the
hTERT promoter follows a similar pattern to SSEA-4 and TRA-1-81 in its down regulation
with time in differentiation. Data were acquired on a BD FACSAria in collaboration with
Martin Waterfall (Roslin Institute, Edinburgh) and represent 10,000 live events. These data
are representative of three independent experiments.
A possible explanation for variation in SSEA-4 expression between the parental H9
cell line and M2 transgenic clonal cell line is that the integration of DNA which led
to the establishment of the M2 cell line, integrated into the parental cell line in a cell
positive for SSEA-4. However, observations from within the group show that
expression of SSEA-4 on the H9 ES cell line is highly variable between different
preparations of cells. The H9 cells used for these experiments, although from
similar stocks, were not from the same cell preparation that the M2 cell line was
derived from. Despite the apparent differences in expression on undifferentiated
cells, SSEA-4 was down-regulated in a similar manner on the positive population in
both H9 and M2 cells (Figure 7.2.2 shows data for M2 cells only) during the process
of differentiation.
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SSEA-1 and GD2 are both markers of differentiation. SSEA-1 is reported to be an
early onset marker of differentiation, with transient expression, while GD2 is a
marker expressed in the later stages of differentiation, after SSEA-1 has switched off
again (Draper et al., 2002). A comparison of the expression of both SSEA-1 and
GD2 on H9 and M2 cells, indicated no significant difference between the two cell
lines, and confirmed that SSEA-1 was a transient marker of early stages of
differentiation, being up regulated as early as day 5 (23%) increasing to maximal
expression between days 7 and 11 (-80%) before reducing to 25% by day 13 (Figure
7.2.2B and Table 7.2.1). GD2 on the other hand showed only low expression on
differentiating human ES cells. Although there was not a significant shift of the
peak to the positive gate (only 2.9% of cells after 17-22 days in differentiation) there
was gradual shifting of the mean fluorescence intensity with time in differentiation,
from a mean fluorescence intensity of 30 to 197 (Figure 7.2.2C and Table 7.2.1)
following 17-22 days.
TRA-1-81 is one of a panel of markers used to characterise undifferentiated human
ES cells. Expression of TRA-1-81 was found to be consistent on both H9 and M2
cell lines throughout the time-course of differentiation. Down regulation of TRA-1-
81 was, however, relatively slow compared with that of SSEA-4, which initial
increased remaining positive on over 90% of cells following a week in
differentiation medium (Figure 7.2.3A and Table 7.2.1). This was followed by a
drop in expression between day 7 and 9 of differentiation reducing the positive
population to -78%. After 2 weeks of differentiation a second more substantial drop
in expression was observed resulting in TRA-1-81 expression on only -50% of the
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cells. A gradual decline of TRA-1-81 expression was then observed between 13 and
22 days resulting in just 14.1% of cells remaining positive compared to 26.7% of
cells expressing SSEA-4 at the same point of differentiation (Table 7.2.1 and Figure
7.2.3A).
To determine the potential for hTERT driven expression of a-gal epitopes to
selectively remove undifferentiated cells, instead of endogenous ES cell markers,
their expression was also characterised over time in differentiation. As expected M2
cells expressed high levels of a-gal in their undifferentiated state (Figure 7.2.3Ba
98.5%) while the H9 parental cell line was essentially negative (showing 0.6%
positive staining Figure 7.2.3B-H9 probably caused by no-specific binding of the
BS-IB4 lectin). As with SSEA-4, down regulation of a-gal was observed
immediately after the induction of differentiation, and occurred at a similar rate.
Expression of a-gal had reduced to 71.6% of the cells by 7 days, compared to 74.5%
of cells that expressed SSEA-4 at the same time point while over 90% of cells
continued to express TRA-1-81. Following 9 and 11 days of differentiation, a-gal
expression was reduced to approximately 40% of the population. This down-
regulation of a-gal expression continued with time in differentiation and after 22
days, only 8.8% of the population continued to express a-gal, compared to 26.7%
expressing SSEA-4 and 14.1% expressing TRA-1-81 (Figure 7.2.3B, Figure 7.2.2A,
Figure 7.2.3A respectively and Table 7.2.1.). Interestingly this was a similar level to
the percentage Calcein-release that was observed after M2 cells, differentiated for 21
days, were exposed to human serum (8.8% Figure 5.2.8), suggesting a residual a-gal
expressing population.
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Figure 7.2.3: Longitudinal characterisation of the expression of the cell surface markers TRA-
1-81 (A) and a-gal (B) on differentiating M2 human ES cells. Time course for differentiation
represented at 0, 5, 7, 9, 11, 13, 17, 19 and 22 days (a-i respectively). Where M2 cells behaved
differently to their H9 parental cell line, the H9 histograms are provided (H9). Histograms are
representative of three independent experiments and show a minimum acquisition of 10,000
"live" events and the position of the negative gate was derived from time course matched
isotype control samples. Data were acquired using the BD FACSAria in collaboration with
Martin Waterfall (Roslin Institute, Edinburgh).
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7.2.2 Nine Days in Differentiation Medium Significantly Reduces the Ability of
Human ES Cell Derivatives to Revert Back to Their Undifferentiated
State.
In an attempt to identify a "natural" population, which contained both
undifferentiated and differentiated derivatives of human ES cells, H9 cells were
differentiated using basic differentiation medium, but instead of making EBs, cells
were differentiated as monolayers, plated on matrigel coated plastic. The cells were
maintained, in triplicate wells, in differentiation medium for 3, 6, 9, 12, 15 and 18
days and showed clear changes in morphology (Figure 7.2.4).
3 Days 6 Days 9 Days
12 Days 15 Days 18 Days
Figure 7.2.4: Human ES cells were differentated as monolayers in basic differentiation medium
and assessed for changes in cell morphology. The time course of differentiation was 3, 6, 9, 12,
15 and 18 days (a-f respectively). Images are representative of triplicate wells. Scale bars
represent 100pm.
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At each of these differentiation time points the cells were passaged (1 in 2) and were
placed back into culture conditions that favoured growth of undifferentiated ES
cells, in conditioned medium supplemented with hbFGF (Figure 7.2.5). In every
case, when cells had been in differentiation medium for only 3 days, human ES cells
emerged at high frequency, and also proliferated well (Figure 7.2.5 a and b).
3 Days 6 Days 9 Days 12 Days
Figure 7.2.5: Human ES cell-derivatives placed back into ES culture conditions (conditioned
medium plus hbFGF) following 3, 6 and 9 days in differentiation medium (a&b, c&d and e&f
respectively) give rise to ES-like cells. By 9 days the surviving ES-like cells were few and in
most cases they didn't proliferate well. Following 12 days of differentiation, cell survival at
passage significantly improved, leading to the presence of more cells in undifferentiated ES cell
conditions (g&h). However, these cells were not observed to proliferate, they did not have an
ES-like morphology, and gradually they declined in number during the 14 days of
undifferentiated culture. Images are representative of triplicates, from duplicate experiments.
Scale bars represent 100pm.
Human ES like-cells also appeared, at increasingly lower frequencies, when cells
had been exposed to differentiation medium for 6 and 9 days (Figure 7.2.5 c and d,
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and e and f respectively). However, when human ES cells were differentiated for 12
days before being placed back into conditions for undifferentiated ES cell culture,
there was an unexpected increase in the number of cells that survived passage which
had not be seen at earlier time points. The reason for this increase in survival may
have been due to cell expansion with time in culture. At each time point, cells were
not counted prior to passage, they were split 1 in 2, with half of the cells being
placed into conditions for undifferentiated ES cell culture. Perhaps a more stringent
experimental design would have been to count cells prior to passage, maintaining a
constant seeding density. However, despite this increase in cell number, no cells
with ES-like morphology were observed in 12-day differentiated ES cells, following
10-14 days in culture conditions which would favour their growth (Figure 7.2.5 g
and h).
This lack of ES-like cell re-growth, post 9 days in differentiation medium,
corresponded with the significant increase in SSEA-1 expression and down
regulation of SSEA-4, TRA-1-81 and a-gal expression observed by flow cytometry
(Figure 7.2.2A and Figure 7.2.3 A and B). Therefore, mixed populations containing
differentiated and undifferentiated human ES cells with growth potential were likely
to occur between 6 and 9 days in differentiation medium and consequently were
used as the start population to evaluate the potential of cell sorting.
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7.2.3 Mixed Populations of Differentiated and Undifferentiated Human ES
Cells can be Sorted Using FACS
The use of cell sorting to remove minority populations of undifferentiated human ES
cells from a population of differentiated derivatives was investigated as an
alternative to complement-mediated lysis. Since the expression of SSEA-4 was
observed to be variable between different preparations of H9 cells and as there is
evidence to show that SSEA-3/4 negative human EC cells retain the ability to form
teratomas in vivo (Andrews et al., 1985), the decision was taken to use TRA-1-81 as
an endogenous cell surface marker, and compare it with the use of transgenic a-gal
epitopes, under the control of the hTERT promoter, on M2 cells.
M2 cells were differentiated for either 6 or 8 days as monolayers, in basic
differentiation medium. Undifferentiated M2 cells, stained either with BS-IB4 lectin
or Tra-1-81 antibody (Figure 7.2.6 b and e respectively), were used as positive
controls to determine the position of the positive sort gates. As negative controls,
H9 cells, labelled with BS-IB4, were used for a-gal sorts (Figure 7.2.6a) and M2
cells, labelled with an IgM isotype control antibody, were used as the negative
control for TRA-1-81 sorts (Figure 7.2.6d). These control populations were used to
define the upper limits of the negative sorting gates. To reduce contamination of the
sorted populations as a result of conflicts around the upper and lower limits of the
sort gates, an area between the upper boundary of the negative gate and the lower
boundary of the positive gate was excluded for this sort strategy (Figure 7.2.6 c and
f).
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Once the sort gates had been defined, the sort was designed to collect a minimum of
2xl06 cells from the negative and positive gates, discarding those cells that fell
between the two gates. Cells were collected in 5ml polystyrene tubes (Falcon)
containing 1ml of conditioned medium (positive sort) or 1ml of basic differentiation
medium (negative sort) supplemented with 100U penicillin and lOOpg streptomycin,
to reduce the possibility of opportunistic infection during the sorting process.
H9 ES OAL
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Figure 7.2.6: Sort profiles were established for both a-gal (a-c) and TRA-1-81 (d-f) sorting,
using negative (a and d) and positive (b and e) controls to determine the sort gates (c and f). To
reduce conflict around the upper and lower boundaries of the negative and positive sort gates
(respectively) an area between the two was left un-gated, referred to as the conflict zone.
Histograms represent 10,000 events. Data was acquired using the BD FACSAria in
collaboration with Martin Waterfall (Roslin Institute, Edinburgh).
After sorting, the collected cell populations were washed to remove traces of sheath
fluid (sterile PBS) and cellular debris, and a small sample of 2-5,000 cells was
reacquired to assess the purity of the sorts. Analysis of the post-sort profiles
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indicated that the sort had been successful: taking into account that the start
population was a mix of cells with indiscriminate expression of the respective
markers. Reacquisition data indicated a 9- and 3-fold enrichment of the negative,
potentially differentiated, population from 10.3% and 29.3% to 97.3 and 91.5% for
a-gal and TRA-1-81 sorts respectively (Figure 7.2.7). Similarly, positive sorts for a-
gal and TRA-1-81 indicated enrichment in the population of 8% and 39.8%
respectively. However, it is possible that this is an underestimate of enrichment,
since quenching of the fluorochrome and re-distribution of the live events about a
new mean, has resulted in a slight shift in the histogram peaks towards the negative
upon reacquisition of the data (Figure 7.2.7 c and f).
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Figure 7.2.7: Pre-sort and post-sort profiles of human ES cells differentiated for 6 days in basic
differentiation medium and sorted based on their continued expression of either a-gal (a-c) or
TRA-1-81 (d-f). Histograms a and d show the mixed starting population stained for either a-gal
(a) for TRA-1-81 (d), b and e show the post-sort profiles of the two negative populations and c
and f show the post sort profile of the positive populations a-gal and TRA-1-81 (c and f
respectively). Shaded histograms represent the position of the respective negative (b and e) and
positive (c and 0 populations used to define the sort gates. Histograms for post-sort profiles
represent between 2,000 and 5,000 events only, while pre-sort histograms represent 10,000
events, the axes have been adjust accordingly. Post sort gates were defined from the staining
profiles of H9 ES (negative control) and M2 ES (positive control) with BS-IB4 or Tra-1-81 and
relevant isotype control as indicated in Figure 7.2.6 a&b and d&e respectively. Data acquired
using a BD FACSAria in collaboration with Martin Waterfall (Roslin Institute, Edinburgh).
In terms of the elimination of undifferentiated human ES cells from within a mixed
population it was necessary to determine whether this percentage enrichment of the
negative population corresponded to reduced contamination by undifferentiated
human ES cells. Consequently, after sorting cells, both the positive and negative
fractions were re-plated in triplicate wells of a 12-well plate, at a density of lxlO5
per well, in both undifferentiated and differentiation culture conditions. As controls,
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undifferentiated human ES cells were plated in triplicate at densities of 1x10s and
2 21x10 ; 1x10 undifferentiated ES cells/well would be the equivalent of a 0.1%
contamination in a mixed population. These wells would therefore demonstrate that
this level of contamination could be detected in lxl05-sorted cells, should they be
present. The mixed "unsorted" population was also plated in triplicate at a density
of lxl05, to determine the extent of surviving undifferentiated human ES cells, after
6 days in differentiation medium.
Cell viability was determined using Acridine Orange/Ethidium Bromide staining,
following 7-10 days in culture. Acridine Orange (AO) permeates all cells and
makes the nuclei appear green, while Ethidium Bromide (EtBr) is excluded from
living cells, only being incorporated into cells that have lost cytoplasmic membrane
integrity, staining the nucleus orange/red. In addition AO/EtBr staining can also be
used to identify cells that are undergoing apoptosis as opposed to necrosis. Early
stage apoptosis is characterised by highly condensed chromatin that is uniformly
stained by the AO (appearing as bright green spherical beads) and possibly EtBr
uptake in the cytoplasm as a result of disruption to the cell membrane. Late
apoptotic cells display condensed and fragmented orange chromatin, again
appearing as spherical beads as apposed to the orange structured nuclei observed in
necrotic cells.
Undifferentiated human ES cells, seeded at a density of 105 per well, became
confluent within 2-3 days in medium supporting undifferentiated ES cell growth,
producing a sheet of cells that was too dense to use as a control a later time points
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(data not shown). However, the same cells plated at 102, to represent 0.1% residual
ES cell contamination, produced several large colonies following 7-10 days in
culture, which stained bright green in the presence of AO/EtBr (Figure 7.2.8a and
d).
ES cells (CM) 1x102 Unsorted D6 (CM) Unsorted D6 (EB)
Figure 7.2.8: Acridine Orange/Ethidium Bromide staining of the control populations for the a-
gal (a-c) or TRA-1-81 (d-f) sorted. Unsorted undifferentiated (a and d) or partially
differentiated for 6 days (b-c and e-f) human ES cells. A similar frequency of undifferentiated
human ES cells, was observed in the partially differentiated (6 days (D6)) start population, as
was seen in the wells containing IxlO2 ES cells (representing a 0.1% contamination) when
seeded back into culture conditions which favoured the proliferation of undifferentiated human
ES cells. No ES-like colony cells were observed when cells were grown in differentiation
medium (c and f)- Scale bars represent lOOpM. CM = conditioned medium which favours
undifferentiated growth, EB = Embryoid Body medium referred to as basic differentiation
medium, AB = Late stage apoptotic body and N = necrotic cells.
A similar frequency of undifferentiated human ES cells, was also observed in the
partially differentiated (6 days (D6)) start population when seeded back into culture
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conditions which favoured the proliferation of undifferentiated human ES cells
(Figure 7.2.8 b and e). As expected, cells with ES-like morphology were not
observed in the 6-day differentiated start population when placed back into
differentiation medium (13-16 days total differentiation Figure 7.2.8 c and f).
By contrast to the results in Chapter 6, differentiated human ES cells adhered well at
a density of 105, with less cell death; however, although there was increased survival
the cells did not proliferate well, never reaching confluence. This reduced
proliferation of differentiated human ES cells compared to undifferentiated ES cells
was also observed in the uptake of AO/EtBr. AO/EtBr both intercalate into DNA,
and therefore, uptake of this stain is dependent on the condensation status of DNA.
Highly proliferative cells (undifferentiated ES cells for example) have relaxed DNA,
which will readily incorporate AO, producing the bright green stain observed in
Figure 7.2.8a, b, d and e. Senescent or quiescent cells, on the other hand are likely
to have more condensed DNA, which is unable to incorporate AO as efficiently,
leading to a dull green stain (Figure 7.2.8 c and f). Furthermore, in the differentiated
cultures there was increased evidence of apoptotic and necrotic cells.
When assessed for the expression of a-gal (BS-IB4) and TRA-1-81 undifferentiated
controls stained strongly positive (Figure 7.2.9 a and e). The mixed populations
placed back into undifferentiated culture conditions stained positive only in areas
that either had ES-like morphology or on cells that were adjacent to such colonies
(Figure 7.2.9 images b-c and f-g respectively). Flowever, there was evidence of
persistent positive staining for a-gal and TRA-1-81 on unsorted cells placed back
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into differentiation (EB) medium (total of 13-16 days Figure 7.2.9 e and h
respectively). This level of expression was comparable to that observed in the
longitudinal expression studies of these markers (Figure 7.2.3).
ES cells in CM x4 Unsorted cells in CM x4 Unsorted cells in CM x10 Unsorted cells in EB x10
a-gal
Tra-1-81
Figure 7.2.9: BS-IB4 (a-d) and Tra-1-81 (e-h) staining of the unsorted control populations from
the a-gal and TRA-1-81 sorts indicated that the persistence of the epitopes was mainly
associated with cells of ES-like morphology or in areas that close to ES-like colonies, following
7-10 days of culture. Images are representative of triplicate wells. Scale bars represent 100pm.
CM = conditioned medium which favours undifferentiated growth and EB = Embryoid Body
medium referred to as basic differentiation medium.
As expected, populations of cells sorted for the positive expression of either a-gal or
TRA-1-81 epitopes were found to contain a high incidence of human ES-like cells
(Figure 7.2.10 a and d respectively). However, despite the high seeding density of
positively sorted cells (105/well), the frequency of ES-like cells was more
comparable to that observed when unsorted control ES cells were seeded as 102.
This suggested that partially differentiated cells may have expressed
"undifferentiated" markers at the time of the sort, but did not maintain
undifferentiated ES cell growth potential. After 7-days in medium which favours
-285-
Chapter 7- Fluorescence activated cell sorting as a method for selective elimination of undifferentiated human ES
cells.
the growth of undifferentiated human ES cells, those ES-like cells that did arise
stained strongly for either BS-IB4ox Tra-1-81 respectively (Figure 7.2.10 b-c and e-f
respectively), confirming that the sorting process did not affect ES cell survival and
proliferation.
Acridine Orange/Ethidium Bromide Epitope Staining
Positive Sort D6 (CM) Positive Sort in CM x4 Positive Sort in CM x10
Figure 7.2.10: Partially differentiated (for 6 days) cell populations sorted for the positive
expression of either a-gal (a-c) or TRA-1-81 (d-f) showed an abundance of viable cells will ES-
like morphology by Acridine Orange/Ethidium Bromide staining when placed back into to
conditions that support undifferentiated ES cell growth for 7-10 days (a and d respectively).
Furthermore, these cells were highly proliferative and stained positive for a-gal (b & c) and
TRA-1-81 (e & f) respectively. Images are representative of triplicate wells. Scale bars
represent 100pm. CM = conditioned medium which favours growth of undifferentiated cells.
Interestingly, the frequency of ES-like cells, collected in the population that was
positive for a-gal, appeared to be less than in the TRA-1-81 population (Figure
7.2.10 a compared to d) suggesting that differentiated cells with residual a-gal
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expression had been included in the positive population, diluting the presence of ES-
like cells. During acquisition of the a-gal sort, the BS-IB4 stain for a-gal appeared to
be quenched to a greater extent than the TRA-1-81 stain (Figure 7.2.7 c and f
respectively). It was hypothesised that BS-IB4 lectin may have been sub-optimally
bound by partially differentiated human ES cells, which had started to down regulate
a-gal epitopes on the cell surface, which was then lost during the sorting process.
Of greater significance however, to this investigation was the emergence of ES-like
cells in the negative populations. Following 7-10 days in culture conditions which
favour the growth of undifferentiated ES cells, an abundance of viable cells, with
ES-like morphology, were observed by AO/EtBr staining in the negative TRA-1-81
population (Figure 7.2.1 le) at a frequency comparable to that observed in the cell
population sorted as positive for TRA-1-81 expression (Figure 7.2.1 le compared to
Figure 7.2. lOd).
Initially it was considered that contamination of the negative population, as
indicated by 8.5% TRA-1-81 positive cells might have accounted for the observed
presence of ES-like cells (Figure 7.2.7e). However, as there was a significant
increase, in excess of 10-fold, in the number of TRA-1-81 positive cells (Figure
7.2.7f), it was unexpected that similar levels of ES-like cell growth would have been
observed in the two populations. These preliminary data strongly suggest that,
contrary to current belief, loss of TRA-1-81 does not necessarily indicate terminal
differentiation of human ES cells. In addition, TRA-1-81 expression, as detected by
immunochemistry with Tra-1-81 antibody, was strongly up-regulated in the
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"negative" population following 7-10 days in culture conditions that favour
undifferentiated ES cell growth (Figure 7.2.11 g and h).
Acridine Orange:Ethidium Bromide Epitope Staining
Negative Sort D6 (CM) Negative Sort D6 (EB) Negative Sort in CM x4 Negative Sort in CM x10
a-gal
Tra-1-81
Figure 7.2.11: Partially differentiated (6 days) cell populations were sorted for negative
expression of either a-gal (a-d) or TRA-1-81 (e-h) and were subsequently placed back into to
conditions that support growth of undifferentiated ES cells (CM). After 7-10 days, the
surviving cells were stained with Acridine Orange/Ethidium Bromide to identify viable cells.
Under these conditions, small ES-like colonies were occasionally observed in the a-gal negative
sort population (a). However, a significant increase in the presence of ES-like cells was
observed in the negative TRA-1-81 sort population (e), which showed comparable ES-like cell
levels to the positive sort population (Figure 7.2.10d). Furthermore, staining for a-gal (c & d)
and TRA-1-81 (g & h) indicated that the persistence of the epitopes was mainly associated with
these highly proliferative cells of ES-like morphology or in areas close to ES-like colonies. No
ES-like colony cells were observed when cells were grown in differentiation (EB) medium
(images b and f). Images are representative of triplicate wells. Scale bars represent 100pm.
By contrast, the a-gal sort demonstrated only an occasional ES-like colony (Figure
7.2.11a), which may have developed as a consequence of contamination by low
expressing positive cells in the negative population (Figure 7.2.7b indicates 2.7%
contamination) or possibly as a result of de-differentiation, resulting in up-regulation
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of hTERT and consequent expression of a-gal. BS-IB4 staining in the negative a-gal
sorted population was specifically restricted to those cells with ES-like morphology,
which suggests re-occurrence of expression rather than persistence.
Together these data might imply that down-regulation of a-gal, which lags behind
down-regulation of hTERT gene expression, more accurately characterises terminal
differentiation, as compared to TRA-1-81.
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7.3 Discussion
The preliminary experiments reported in this chapter were designed as a "proof of
principle" to determine whether fluorescence activated cell sorting (FACS) could be
used efficiently as an alternative to complement-mediated lysis to eliminate
undifferentiated human ES cells from a mixed population. In order to achieve this,
"naturally" occurring differentiated populations, which had been demonstrated to
contain detectable levels of undifferentiated human ES cells with growth potential,
were assessed for the expression of cell surface epitopes that could be used to
identify contaminating undifferentiated ES cells.
Longitudinal flow cytometry studies demonstrated that the expression of
characteristic ES cell surface markers, SSEA-4 and TRA-1-81, showed a steady
decline in expression with time in differentiation, a pattern that was also reflected in
a-gal expression under the control of hTERT on M2 cells. A significant reduction in
the expression of all cell surface markers studied (SSEA-4, TRA-1-81 and a-gal)
and up-regulation of the early differentiation marker SSEA-1 was observed between
5 and 9 days of differentiation. This change in expression of cell surface antigens
corresponded to a significant reduction in the ability of differentiated populations, at
the same time points, to give rise to ES-like colonies when placed back into culture
conditions which should favour growth of undifferentiated ES cells, suggesting that
perhaps a significant event, such as cell commitment, was taking place. Draper et
al., (2002) reported that the surface antigens of the E17 human ES cell line changed
upon differentiation. In this report the authors indicated that SSEA-4 and TRA-1-81
both progressively down-regulated with time in "un-inducted" differentiation (i.e. on
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matrigel but in the absence of conditioned medium and hbFGF), although it was to a
lesser extent than with retinoic acid induced differentiation. However, they
indicated that after 9 days of differentiation, H7 cells had down-regulated
significantly more TRA-1-81 than SSEA-4 at the same time point, and that in fact
SSEA-4 expression initially increased following induction of differentiation before
beginning to down regulate, which is the inverse of what was observed in this
investigation. Furthermore, Draper et al., indicated very little increase in SSEA-1
expression, unless retinoic acid was used to induce differentiation, yet they show
that GD2 expression was almost immediately up regulated without induction, again
the reverse of what was seen in the experiments reported here (Draper et al., 2002).
It is unclear from the report whether a longitudinal study of the expression of these
markers was performed or whether the authors picked the time points at which to
assess expression. Interestingly, the time points at which they chose to report were 9
and 16 days. Following 9 days of differentiation Draper et al., reported that a
significant number of the markers used to characterise undifferentiated human ES
cells (SSEA-3 and -4, TRA-1-60 and -1-81 and also alkaline phosphatase) had all
begun to be down-regulated, which is reflected in the experiments reported here. It
is likely that the specific differences observed in patterns of down regulation
between the Draper et al., (2002) report and this one, are related to the use of
different human ES cell lines, and it would be interesting to repeat the experiments
reported here to test this hypothesis.
Day 6-9 differentiated populations were demonstrated to produce ES-like cells when
placed back into culture conditions for undifferentiated ES cells. Furthermore,
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cultures in this period of differentiation were also shown to have begun down-
regulation of the characteristic surface markers of undifferentiated ES cells.
Therefore, these populations were selected as a target start population to represent a
differentiated population contaminated with undifferentiated ES cells which had
continued growth potential. It was not possible to detect the appearance of
undifferentiated ES cells when 8 day differentiated ES cells were sorted and
returned to undifferentiated culture conditions (data not shown). Consequently all
subsequent sorting experiments therefore used human ES cells differentiated for 6
days.
A limitation of this experimental design was that after only 6 days in differentiation
medium definitive discrimination of cells that were positive for continued
expression of the desired epitopes (a-gal and TRA-1-81) from those which were
truly negative was not possible; a large proportion of the start population had
varying degrees of epitope expression at this time point. Differentiation of ES cells
for 6 days may not reflect the period from which therapeutic cells would be isolated.
To use time points later in differentiation would have simplified the cell sorting
strategy, by providing clearer distinction between negative and positive cells,
however in order to evaluate the success of FACS at eliminating undifferentiated ES
cells, the start population had to contain significant levels of cells with
undifferentiated in vitro growth potential to allow for post sort analysis.
Despite starting with an indiscriminately stained population, cell sorting based on
the positive and negative expression of either a-gal or TRA-1-81 was very
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successful, with negatively expressing populations being enriched from 10.3% and
29.3% to 97.3% and 91.5% respectively. However, while enrichment of a
population is a good measure of the success of FACS, only re-culturing of the sorted
populations could demonstrate the efficiency of the selection marker(s) to identify
contaminating cells with undifferentiated growth potential. In the report by Draper
et al., (2002), the authors did not attempt to re-culture the "differentiated" cells that
had reduced expression of "characteristic ES markers" in conditions that favour
undifferentiated ES cell growth to determine if loss of characteristic markers of
undifferentiated ES cells was indicative of differentiation, their assessment was
made on changes in morphology only.
Positive and negative sort populations were seeded back into to culture conditions
that favoured the growth of undifferentiated ES cells and were assessed for the
presence of viable cells with ES-like morphology and growth potential. In both a-
gal and TRA-1-81 positive sort populations there were significantly fewer ES-like
colonies than in the unsorted, undifferentiated ES cell controls, seeded at the same
density (105) (data not shown). The frequency of ES-like colonies in the positive
TRA-1-81 sort was similar to that observed in the unsorted undifferentiated ES cells
seeded at 10 , suggesting that some of the TRA-1-81 positive cells were partially
differentiated. Furthermore, in the a-gal sort the frequency ofES-like cells appeared
to be less than in the TRA-1-81 population, suggesting that either differentiated cells
maintained low level a-gal expression on their cell surface, or that the BS-IB4 lectin
was sub-optimally binding to partially differentiated human ES cells that had started
to down regulate a-gal epitopes on the cell surface.
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The BS-IB4 lectin has four binding sites by which it can bind to a-gal epitopes,
however, for stable binding the lectin must be bound by at least two of these sites
(Galili 1999a). Therefore, negative staining by BS-IB4 lectin may not necessarily
mean a lack of a-gal epitopes, just that the epitopes are to far apart for the lectin to
bridge the gap and bind to at least two. It has been reported that binding via just one
of the lectins binding sites is too weak to sustain stable binding and so the lectin is
easily removed by washing (Galili 1999a). This explanation corresponds with the
staining pattern that was observed for the mixed population used for the a-gal sort.
Initially, when the sort gates were defined, immediately after staining, the
population stained strongly with BS-IB4. During the course of cell sorting, under
constant pressure and continuous mixing of the cell suspension, the BS-IB4 staining
became weaker, suggesting that loosely bound lectin was being removed. If this
was the case it would help to explain why the frequency of ES-like cells in the
positive a-gal population was lower than in the positive TRA-1-81 population.
Weak binding of BS-IB4 to a single a-gal epitope could have resulted in the
inclusion of a-gal positive cells, which were actually partially differentiated,
consequently diluting the number of high level expressing, potentially
undifferentiated ES cells.
The removal of positive, potentially tumorigenic cells from the negative, potentially
therapeutic populations was of greater importance in the experimental design of this
thesis. Negative populations, cultured for 7-10 days in medium that favours
undifferentiated ES cell growth, which had been enriched for loss of TRA-1-81
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expression were shown to contain an abundance of ES-like cells, strongly suggesting
that loss of TRA-1-81 was not indicative of a reduction in undifferentiated ES
growth potential. A comparison of the negative (91.5% cells) and positive (94.2%
cells) populations by fluorescence microscopy of acridine orange/ethidium bromide
(AO/EtBr) stained cells indicated a similar level of ES-like cell growth in both
populations, strongly suggesting that, contrary to current dogma, TRA-1-81 may be
a poor marker of ES cell differentiation.
By comparison, expression of a-gal under the control of the hTERT promoter
appeared to be significantly better at discriminating between the differentiation
status of ES cells. The negative a-gal population contained far fewer
undifferentiated ES-like cells compared to the TRA-1-81 negative population.
Furthermore, ES-like colonies that did appear in the a-gal negative population were
much smaller, suggesting that they might have arisen during the time in culture, or
that as low density contaminants from the sort process the ES cells had experienced
delayed proliferation due to their isolation from neighbouring ES cells (Amit et al.t
2000; Thomson et al., 1995). There are a number of possible explanations for the
persistence of ES cells, with undifferentiated growth potential. As shown in Chapter
3, expression of a-gal on M2 cells was affected by position effect variegation, so it
is possible that evading cells were not expressing a-gal at the time cell sorting took
place. Alternatively, it is possible that the a-gal negative sort gate was too generous,
to collect sufficient cells for analysis, which consequently allowed only partially
differentiated cells with reduced a-gal expression to be included in the negative sort.
Alternatively, it is possible that cell sorting did eliminate all a-gal expressing
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undifferentiated cells, but that during the re-culture, partially differentiated cells de¬
differentiated, switched back on hTERT, which consequently resulted in re-
expression of the al,3Gal transgene.
These arguments could be individually addressed in an attempt to optimise FACS as
a method for eliminating undifferentiated ES cells from a mixed population. For
example, the use of homologous recombination, to target the al,3Gal transgene into
a site with characterised stable expression, would remove the risk of cells evading
elimination through position effect variegation. By targeting the endogenous
hTERT locus, this would increase the potential for in vivo regulation of tumours that
arise after graft transplantation as the majority of tumours demonstrate hTERT
expression (Tzukerman et al, 2000). Concurrent expression of a-gal in such
modified ES cell derivatives, should invoke a rapid complement-mediated lysis
response, following the emergence of only a small number of cells with tumorigenic
potential, through naturally occurring anti-a-gal antibodies present in human serum.
In addition, sort purity may be addressed by using stringent negative sort gates to
prevent contamination of the negative population by partially differentiated cells
with reduced expression. Flowever, this would result in a significant reduction in
yield of the negative, potentially therapeutic population, requiring significantly
increased cell numbers to begin with, which would consequently increase cost and
processing time, which could subsequently affect the viability of the therapeutic
population.
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Undifferentiated human ES cells are currently characterised using a panel of
markers, including telomerase activity and TRA-1-81 expression. Therefore, it is
hypothesised that future elimination experiments could benefit from combinational
staining, with a number of "ES" specific markers, followed by enrichment for the
population which is negative for all of them. During the course of this
investigation, co-staining of cells partially differentiated for 6 days was performed
with BS-IB4 and Tra-1-81 (data not shown). Preliminary results from this population
indicated that from the total population, 50.1% co-expressed both the a-gal and
TRA-1-81 markers strongly suggesting that half of the population following 6 days
in differentiation had the potential to have undifferentiated growth. Of the
remaining 49.9%, 18.9% of the cells continued to express a-gal only and 5.3%
continued to express TRA-1-81, while 25.7% of the population were negative for
both markers. Using the current experimental design a single marker sort for TRA-
1-81 could have contained as many as 18.9% of TRA-1-81 negative cells with
continued undifferentiated potential, as indicated by the continued expression of
hTERT driven a-gal. However, if the sorting strategy had been designed to collect
cells that were double negative for both a-gal and TRA-1-81 it would have increased
the stringency of the negative sort, increasing the purity of the potentially
therapeutic population and thereby reducing the risk of tumorgenicity. The addition
of a third selection marker, such as SSEA-3/-4 or transgenic Oct-4-GFP for example
would further increase population purity, but as seen in the example above, cell
retrieval would be significantly reduced with greater stringency, from 44.6% of the
total population to 25.7%.
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When differentiating human ES cells for clinical application, as well as considering
the prevention of ES cell derived tumour growth, it is important to consider the
number of cells that are required for therapeutic effect. For example, it has been
suggested that in order to support liver failure in an adult, anywhere form 2-33% of
the liver's cell mass would need to be replaced, equating, in humans, to between
lxlO9 and lxlO11 cells per person (Elaghighi et al., 2004; Sundback & Vacanti
2000). Steps have been taken to improve the culture of human ES cells so that they
are less labour intensive, in the absence of feeders and using enzymatic
disaggregation, so that they would be more amenable to "bulk culture" (Thomson et
al., in preparation; Xu et al., 2001; Amit et al., 2000; Thomson et al., 1998). In
addition, a number of groups are investigating the possibility of expanding the
currently small-scale lab based differentiation protocols to enable "bulk culture" for
therapeutic use (Gerecht-Nir et al., 2004 & 2004; Magyar et al., 2001).
The implications of using multiple markers, whether they are specific for
undifferentiated, or differentiated cell types, or a combination of both, to identify
and eliminate a specific population would have significant implications for the
volume of cells that would need to be produced to enable therapeutic applications, as
already discussed. It is therefore unlikely that FACS could be extended into routine
clinical practice as a single procedure for the elimination of potentially tumorigenic
cells. A possible alternative to using multiple markers to increase the stringency of
FACS would be to use a single marker but in multiple sorts. The first round of
sorting would be used to significantly enrich the negative (or positive) population as
presented here from -10% to over 90%. This desired population would then be
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returned to appropriate culture and expanded. Upon the second round of sorting
there would be greater distinction between the two populations which would enable
greater stringency of the sort gates which would increase the purity of the desired
population without significantly effecting cell number. However, this technique
would depend on the ability to expand differentiated cells in vitro, which is currently
a limitation (Hay D. unpublished data).
Instead of using FACS as a substitute technique for the removal of undifferentiated
human ES cells from a mixed population, it could be used in combination with
complement-mediated lysis. In this chapter the potential of FACS as a strategy for
evaluating markers of terminal differentiation and its ability to significantly enrich
minority populations have been clearly demonstrated. Furthermore, a-gal under the
control of hTERT has been shown to efficiently characterise the differentiation
status of ES cells. However, despite the success of a-gal cell sorting, there appeared
to be small populations of undifferentiated ES cells that were evading selective
elimination. A similar situation was also reported when complement-mediated lysis
was attempted on populations that had high-levels of ES cell contamination in
Chapter 5. By combining the two techniques, the power of FACS would be utilised
to enrich for therapeutic populations with great success, while the sensitivity of
complement-mediated lysis to remove minority populations of contaminating
undifferentiated ES cells would a) provide the purity and b) could be utilised in vivo
as a form of immune surveillance.
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7.4 Conclusion
For fluorescence activated cell sorting to be used as an alternative technique to
complement-mediated lysis for the elimination of potentially tumorigenic
undifferentiated human ES cells, either a true marker of the undifferentiated state of
ES cells needs to be identified or else sorting should eliminate undifferentiated cells
by sorting for the positive expression of specific markers of differentiated cells
types. Preliminary data presented in this chapter indicate that expression of
common markers used for identifying undifferentiated human ES cells, the tumour
recognition/rejection antigens (TRA-), do not necessary indicate loss of
undifferentiated growth potential. However, expression of transgenic epitopes under
the transcriptional control of the human telomerase promoter (hTERT) indicated a
much closer correlation to loss of undifferentiated growth potential.
FACS as a strategy for evaluating markers of terminal differentiation and for
enriching minority populations has been clearly demonstrated but it is hypothesised
that to achieve selective elimination of undifferentiated ES cells for clinical
application, FACS may best be employed in combination with a second selective
technique, such as complement-mediated lysis.
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8.1 Summary ofResults
8.2 Critique of this Research
8.3 Potential Clinical Application of hTERT/al,3Gal Expressing Human ES
Cells.
8.4 Taking this Research Forward - Future Experiments
8.5 Conclusion
The experiments described in this thesis were aimed at investigating strategies to
eliminate undifferentiated, potentially tumorigenic, human ES cells from a mixed
population of potentially therapeutic cells. Human ES cells were engineered to
express a foreign epitope on their cell surface, which was down-regulated upon
differentiation, thereby identifying those cells with undifferentiated
growth/tumorigenic potential. This transgenic epitope was evaluated against cell
surface markers endogenously expressed by undifferentiated human ES cells,
reported to be down-regulated with differentiation, to compare their ability to
identify and aid in the elimination of contaminating undifferentiated ES cells.
8.1 Summary ofResults
Human ES cells were successfully engineered to express the
al,3galactosyltransferase (al,3Gal) gene, responsible for expression of the major
xenoantigen Gal al-3Gaipi-4GlcNAc-R (a-gal) epitope, under the transcriptional
control of the human telomerase reverse transcriptase (hTERT) promoter (Priddle,
Zoe Hewitt
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H.). Although variegated, strong a-gal expression was found on cells in their
undifferentiated state, at levels comparable to those observed on ovine (Polled-
Dorset) foetal fibroblast (PDFF) cells with endogenous al,3Gal expression. The M2
clonal cell line was identified as a strong candidate for further experiments due to its
low level of variegation compared with other clonal lines, Fll for example.
Transgenic a-gal epitopes on M2 cells were shown to bind natural anti-a-gal
antibody, present in human serum, while wild type H9 cells remained non-reactive.
Importantly, for the strategies reported in this thesis, transgenic a-gal epitopes were
efficiently down-regulated upon differentiation and preliminary investigations
indicating that loss of hTERT/al,3Gal was more closely correlated to loss of
undifferentiated growth potential than the characteristic ES cell marker, TRA-1-81.
In addition an attempt was made to engineer human ES cells to express the murine
MHC molecule (H2-Kk) under the transcriptional control of the hTERT promoter.
However, despite successful integration of the transgene (identified by RT-PCR),
H2-Kk cell surface expression was not achieved and initial attempts to show protein
translation, by Western Blot, were unsuccessful. It was suggested (Chapter 3) that
issues associated with protein translation or with assembly and/or transport of H2-Kk
from the endoplasmic reticulum were responsible for the lack of cell surface
expression. However, the potential requirement for additional genes, such as P-2
microglobulin (fi-2M) or possible stimulation with interferon-gamma (IFN-y) to
overcome this issue suggested that H2-Kk was not as suitable as a-gal as a lysis
epitope for therapeutic application.
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Results presented in Chapter 3 indicated that the use of trypsin/EGTA (TEG) as an
enzymatic method for disaggregating human ES cells in routine culture generated a
more homogeneous population of human ES cells, as compared with collagenase IV
disaggregation, with little, if any differentiation. Human ES cells cultured in this
way, dissociate into a single cell suspension, aiding both of the elimination strategies
and the optimisation of electroporation techniques. Furthermore, the ability of
engineered cells to proliferate or differentiate was unaffected and the cells
maintained a normal karyotype through over 40 passages. It is possible that previous
karyotypic abnormalities observed in the ES cells maintained by the MeWhir group
whilst using TEG dissociation (Thomson et al., in preparation), resulted from a
unique selection pressure that was exerted as part of their in vitro culture, unrelated
to the use of TEG. This suggests that perhaps the conditions in which human ES
cells are currently maintained require further optimisation.
Strategies to eliminate undifferentiated ES cells focused on the use of complement-
mediated lysis in Chapters 4 and 5. Using PDFF cells as a positive control the
Calcein-release assay was optimised for the detection of a-gal induced lysis of M2
and Fll ES cells in normal human serum. These optimisation assays clearly
indicated that different cell types respond differently to the Calcein label and that the
use of sub-optimal procedures could result in inappropriate interpretation of results.
Following optimisation, the Calcein-release assay (using 40pM Calcein labelling)
was shown to be an extremely reliable method of detecting complement-mediated
lysis. In turn complement-mediated lysis (using undiluted human serum) was shown
to be a very efficient method for repeatedly eliminating minority populations of
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undifferentiated ES cells which expressed the al,3Gal transgene. In the case ofM2-
ES cells, a-gal induced complement-mediated lysis occurred at the same level as
observed for endogenously expressing PDFF cells. Interestingly when the level of
M2-ES cell contamination was 0.8% of the total population, no residual ES cell
colonies were observed. However, with increased levels of contamination, the
number of undifferentiated M2-ES cells that avoided elimination increased steadily,
showing frequencies of <0.07% residual cells at 3% contamination, increasing to
<1.33% at 25% contamination, <2.60% at 50% contamination and <3.80% from a
pure population of undifferentiated M2 ES cells treated with human serum.
Although variegated transgene expression could have accounted for some of these
residual cells, it is considered that saturation of the experimental conditions would
explain the gradual increase in the number of surviving cells as the level of
contamination increased. It is hypothesised that if serum treatment had been
repeated, these residual cells could have been eliminated. Importantly,
differentiation of a-gal expressing ES cells (M2) resulted in a significant reduction in
their sensitivity to complement-mediated lysis. After 21-days in differentiation
medium only 8% of the cells remained sensitive to complement, which correlated to
the proportion of cells that continued to express a-gal, as determined by flow
cytometry (Chapter 7) at a similar time point.
During the optimisation of the complement-mediated lysis assay, it was hypothesised
that due to the embryonic nature of ES cells and evidence that cells of the human
blastocyst express high levels of membrane bound complement regulators (Fenichel
et al., 1995), it was possible human ES cells could be protected from complement-
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mediated lysis by the presence of complement regulatory proteins. Evidence was
provided (Chapter 4) to show that undifferentiated ES cells (HI, H7 & H9) express
high levels of the complement regulatory proteins to similar (CD59) or greater
(CD55) levels than on human multipotential erythroid progenitor cells (K562).
Furthermore, complement regulators were expressed at similar levels on Human
Embryonic Kidney (HEK) 293 cells, suggesting that this level of expression was due
to the embryonic nature of the cells and not because they were ES cells per se.
However, high expression levels of CD55 and CD59 were insufficient to inhibit
complement-mediated lysis of human ES cells, although it remains unknown if
increased levels of CD55 and CD59 could protect undifferentiated ES cells from low
level attacks as discussed in Chapter 4. In addition to serum, containing antibody,
the use of exogenous antibody to an endogenous ES cell surface epitope was also
shown to be capable of eliciting a complement-mediated attack, providing the
opportunity to develop this technique in conjunction with vaccination strategies.
In Chapters 6 and 7 the focus of elimination switched to using fluorescence activated
cell sorting (FACS) as an alternative technique to complement-mediated lysis to
remove undifferentiated ES cells from within a mixed population. Enrichment of
minority populations by FACS was clearly demonstrated and importantly the process
of sorting was shown not to affect the viability, pluripotentiality or karyotypic
stability of undifferentiated ES cells. These data confirmed the assumption made in
the report by Eiges et al., 2001. In addition preliminary results (Chapter 6)
demonstrated that FACS could be used to single cell sort undifferentiated human ES
cells and that these cells survive and proliferate at a frequency of 10.4%. However,
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although the majority of these cells maintained an undifferentiated ES cell
phenotype, further experiments are required to determine if these cells maintain the
characteristic properties of undifferentiated ES cells.
As reported in Chapter 7, under the conditions used in this thesis, FACS, using a-gal
and TRA-1-81 as markers, was unable to separate a population of cells that was free
of undifferentiated ES cell growth potential. Evidence was provided to show that
FACS could be used to greatly increase the purity of an indiscriminately stained
population. However, specifically in the case of TRA-1-81, a comparison of the
negative (91.5% cells) and positive (94.2% cells) populations indicated that a similar
level of ES-like cell growth occurred in both populations. These data strongly
suggest that, contrary to current perception, TRA-1-81 is a poor marker of ES cell
differentiation, thus highlighting the importance of verifying dogma reported in the
literature (Draper et al., 2002). By contrast, the negative a-gal population contained
far fewer undifferentiated ES-like cells compared to positive a-gal population,
suggesting that hTERT/a-gal expression was significantly better at discriminating
between the undifferentiated and differentiate status of ES cells. It is hypothesised
that small adjustments to the sort parameters in subsequent experiments would be
sufficient to eliminate these cells, however, restricting sort gates has the potential to
increase the cell number requirement and the level of cell wastage, thus increasing
cost and processing time which could affect viability. It is considered that for FACS
to be used to eliminate potentially tumorigenic undifferentiated human ES cells as a
stand alone, single use strategy either a true marker of undifferentiated ES cells
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needs to be identified or else sorting should eliminate undifferentiated cells by
sorting for the positive expression of specific markers of differentiated cells types.
8.2 Critique of this Research
The majority of the work reported in this thesis reflects the use of a clonal human ES
cell line, M2. Although other clonal cell lines were investigated, all lines were
derived from the H9 parental ES cell line. To support the potential of this strategy
for clinical development, other parental human ES cell lines, such as HI and H7,
would need to be engineered to determine if the regulation of hTERT/al,3Gal
expression is comparable and that the effects of complement-mediated lysis against
the a-gal epitope are reproducible in multiple cell lines. In addition M2 and Fll
clonal cell lines expressed hTERT/al,3Gal from random integration sites, which as
reported in Chapter 3 clearly experienced varying degrees of variegation. It has been
hypothesised that position effect variegation (PEV) may have been responsible for
some undifferentiated ES cells evading elimination under the strategies reported
here. As previously discussed (Chapters 3 & 7) targeting the a 1,3Gal construct into
the endogenous hTERT locus, for example, to acquire the native hTERT promoter
should eliminate the effects of silencing elements and heterochromatinisation.
However, there is a risk that disrupting a copy of the hTERT gene could affect the
ability to maintain ES cells indefinitely in an undifferentiated state and could
potentially increase cellular aging of the differentiated derivatives if hTERT
functions in a dose-dependent manner. Alternatively, the hTERT/al,3Gal expression
vector could be targeted into a "neutral" genomic site, un-associated with PEV, or
else the incorporation of insulator elements, to confer site-independent expression,
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could be investigated (Burgess-Beusse et al., 2002; Hasegawa & Nakatsuji 2002). In
addition there is the potential to use lenti-viral vectors, which have been reported to
be free of the effects from gene silencing (Martin et al., 2005; Gropp et al., 2003; Ma
et al., 2003), as a method of engineering the ES cells.
During the course of this work non-specific differentiation protocols have been
adopted to determine the global regulation of a-gal with differentiation. It is possible
that continued a-gal expression at the latter time points was as a consequence of
persistent hTERT expression. Although telomerase is considered a characteristic of
embryonic, germ-line (Wright et al., 1996) or malignant tissues (Tzukerman et al.,
2000), there is a growing body of evidence that shows expression of telomerase in
some somatic cell types including, haematopoietic progenitors, particularly lymphoid
lineage committed progenitors, normal peripheral blood leukocytes (Hohaus, et al.,
1997; Weng, et al., 1996) and in the continuously proliferating epidermis basal layer
(Harle-Bachor et al., 1996). In terms of regenerative medicine it is likely that
partially differentiated, progenitor cells will be the targets for engraftment to enable
the graft to proliferate in situ, to aid integration and regeneration in the host. It will
therefore be important to investigate the persistence of hTERT expression using
specific differentiation protocols, such as osteogenic or neural lineages for example,
to determine if hTERT expression is present in progenitors. It will also be important
to assess the use of alternative ES-restricted promoters, such as Oct-4 or Rex-1,
(reviewed by Ginis et al., 2004) to restrict expression of a-gal to only those cells
with undifferentiated growth/tumorigenic potential, should hTERT prove not to be
efficiently restrictive.
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For any elimination strategy to be of therapeutic relevance, it is essential that the
strategy can be widely implemented, providing significant advantage to a large
number of individuals. As discussed in Chapter 1, there is evidence to suggest that
specificity of the anti-a-gal antibody is blood group dependent (Galili et al., 1987b).
It has been reported that approximately 75% of the anti-blood group B antibody
found in sera of blood group-A and -O individuals cross reacts with the a-gal epitope
due to similarities in their structure (Galili et al., 1987). The experiments reported in
this thesis show the level of complement-mediated lysis as a result of exposure to
pooled serum from blood group-A individuals. Although there is no evidence that
serum from blood group-B individuals has lower levels of specific anti-a-gal
antibody to those found in blood group-A & -O serum, serum from blood group-B
and -AB individuals lack the additional cross reactive anti-B antibody (Oostingh et
al., 2003; McMarrow et al., 1997; Galili et al., 1984). It is therefore likely that
although complement-mediated lysis would still occur following exposure to blood
group-B serum the efficiency would be reduced, possibly requiring increased
exposure time or multiple rounds of treatment. The blood group-B antigen is the
least common of the blood group antigens, with blood types AB and B accounting
for approximately 15% of all the blood types. However, in the areas of Eastern
Europe and Central Asia the B-antigen is more common, and can account for up to
38% of the populations (www.bloodbook.com/world-abo.html, 2005). Therefore, an
assessment of different blood types must be made before such a strategy could be
considered for therapeutic use. If exposure to blood group-B or -AB serum proves
unable to eliminate undifferentiated ES cells efficently then the situation could, in
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principle, be redressed by immunisation against a-gal for in vivo strategies. In vitro
strategies are not sensitive to blood type, but it would be beneficial to use serum
from blood group-0 individuals, since blood group-0 serum has the broadest range
of anti-a-gal antibody activity due to the present of cross reactive anti-blood group-B
and -A antibodies (Galili et al., 1987b).
8.3 Potential Clinical Application of hTERT/al,3Gal Expressing Human
ES Cells.
The tumorigenic potential of undifferentiated ES cells is significant following
subcutaneous injection into SCID mice as discussed in section 1.4 (Reubinoff et al,
2000; Thomson et al, 1998; Thomson et al., 1995; Evans & Kaufman, 1981).
However, the level of ES cell contamination of a therapeutic population that would
result in tumour formation remains unknown. It has been reported that tumorigenesis
can be induced by as few as 500 undifferentiated, Oct-4 positive murine ES cells,
irrespective of the site of implantation (Erdo et al., 2003). Furthermore, pre-
differentiation of such cells into neural progenitors, containing less than 0.5% Oct-4
positive cells, resulted in 86% of the mice developing tumours within 2-weeks of
transplantation (Erdo et al., 2003).
Chapters 4 to 7 have assessed the individual merits of both complement-mediated
lysis and of fluorescence activated cell sorting (FACS) as alternative methods for the
removal of contaminating potentially tumorigenic undifferentiated human ES cells,
based on the specific expression of transgenic a-gal or endogenous TRA-1-81
epitopes. As indicated in Chapter 7, a-gal epitopes under the control of the hTERT
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promoter were efficiently down-regulated upon differentiation and displayed a closer
correlation to loss of undifferentiated growth potential than the endogenous human
ES cell marker TRA-1-81.
In addition, the use of hTERT/al,3Gal to provide unique a-gal epitopes on the cell
surface of undifferentiated ES cells has the advantage that humans have natural
immunity to a-gal; human serum contains high resting levels of anti-a-gal antibody
(30-70pg/ml; Galili et al., 1984, 1985). Naturally high levels of circulating antibody
have the potential to provide an in vivo surveillance system, not only against the
accidental transplantation of undifferentiated ES cells, but also against cells which
dedifferentiate, or which become malignant in vivo, with reactivation of the hTERT
promoter occurring in over 80% of studied malignancies (Tzukerman et al., 2000).
The development of malignancy would result in re-expression of al,3Gal by these
cells and re-presentation of the a-gal epitope on the cell surface.
The prevention of tumour growth following the use of ES-derived cell therapy is an
important safety consideration; however, in eliminating this risk, it is important that
strategies take into account the number of cells that will be required for therapeutic
application and how in vitro research can be adapted for clinical use. As discussed in
Chapter 7, cell numbers in the region of lxl09-lxl011 per person have been reported
for the treatment of adult human liver failure (Haghighi et al., 2004; Sundback &
Vacanti 2000). This thesis presents "proof of principle" data showing complement-
mediated lysis on a small scale to eliminate contaminating ES cells, requiring lOOpl
of human serum to treat 105 cells. Translated into clinical terms this would be
-311 -
Chapter 8 - Discussion & Conclusions
equivalent to 1-100 litres of serum (approximately 5-500 litres of human blood) to
eliminate undifferentiated ES cells from the 109-1011 liver cells required to treat one
liver patient. Since there is already a shortage of blood the requirement for these
quantities of human serum is unsustainable. Furthermore, the challenge of
maintaining and regulating the quality of serum to ensure good manufacturing
practice (GMP) over time for clinical application, including the necessary health and
safety issues, pathogen screening etc, suggests that this strategy would not be viable
on such a large scale. To overcome these issues it is possible that a human
monoclonal antibody could be developed, which when used together with
recombinant/purified human complement would substitute the requirement for
human serum/blood. However, this technique would require significant
optimisation, is likely to be very expensive and again could prevent large-scale
rollout on the National Health Services (NHS).
FACS, as an alternative, has the ability to handle large volumes of cells. However,
while FACS showed significant enrichment of a-gal negative populations from
10.3% to 97.3%, not all cells with undifferentiated ES growth potential were
removed. To increase the purity of therapeutic populations sorted by FACS, multiple
markers, either specific for undifferentiated or differentiated cell types or
combinations of both could be used, or else tighter sorting parameters or multiple
rounds of sorting could be tried. Whilst such strategies would improve the purity of
the resulting population, they could significantly reduce the yield of the potentially
therapeutic population, which would have a significant impact on the number of cells
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required to begin with, consequently increasing cost and processing time, the latter
subsequently affecting the viability of the therapeutic population.
It is therefore unlikely that, as with complement-mediated lysis, FACS could be
extended into routine clinical practice as a single procedure for the elimination of
potentially tumorigenic cells. A strategy that would be worth considering is the use
of magnetic activated cell sorting (MACS) in combination with either FACS or
complement-mediated lysis, or both. Miltenyi Biotec (GmbFI, Germany) has
developed CliniMACS®, which is a system that can be used to deplete or enrich for
specific sets of cells on a large scale, through magnetic labelling of cell surface
epitopes. This unique system has been used clinically to enrich for CD34+ cells from
peripheral blood, without affecting the viability of the cells (Despres et al., 2000).
The advantage of CliniMACS® over FACS is the size and cost of the equipment, and
the quantity of cells that CliniMACS® can process; it has the capacity to sort some
4x1010 cells in approximately 2 hours, within a sterile environment. It is proposed
that, by combining the enrichment power of a technique such as FACS or MACS
with the sensitivity of complement-mediated lysis to effectively eliminate low-level
contamination, this strategy would prove to be very powerful at eliminating
undifferentiated ES cell contaminants, specifically with the potential for in vivo
surveillance as a result of a-gal.
As discussed in Section 1.6.2 natural immunity to a-gal expression holds great
promise for the treatment of cancer. A number of reports have shown that different
human cancer cell lines can be efficiently eliminated by human serum following
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transfection/transduction with the al,3Gal gene and their ability to establish tumours
following treatment is reduced (Aubert et al., 2003; Unfer et al., 2003; Sawada et al.,
2002; Yoshimura et al., 2001; Jager et al., 1999; Link et al., 1998). In addition,
LaTemple et al., (1999), immunized a 1,3Gal knockout mice with irradiated tumours
cells that were engineered to express a-gal on their cell surface and were able to
show that the a-gal epitope acted as an opsonin, encouraging phagocytosis. The use
of a-gal as a mechanism to initiate cell death directly in transfected cells or to
indirectly target cells through immunization, provides evidence that the response to
the presence of a-gal epitopes is not restricted to the endothelium of vascularised
tissues and organs, underlying the potential for in vivo immune surveillance.
However, in an allograft setting, it will be important to establish that the level of
immune suppression necessary to prevent graft rejection would not entirely eliminate
circulating anti-a-gal activity.
8.4 Taking this Research Forward - Future Experiments
In addition to the experiments described above (see section 8.2) to improve the
reproducibility and potential of the techniques described in this thesis, there are a
number of interesting experiments that can be performed with the existing cell line
(M2). As discussed it will be important to use specific, directed differentiation
protocols to assess expression levels of hTERT/al,3Gal in potentially therapeutic
progenitor cells. In doing so this will determine a time point at which cells with
undifferentiated growth potential can be eliminated without eliminating those cells of
potential therapeutic value.
-314-
Chapter 8 - Discussion & Conclusions
In collaboration with labs that have optimised specific differentiation protocols for
human ES cells, and for whom the occurrence of tumours in transplantation studies
are proving to be problematic, it would be interesting to test the in vitro elimination
strategies described in this thesis. The aim of these experiments would be to
ascertain whether treatment of potentially therapeutic cells with complement or
sorting populations by FACS, affects their ability to engraft, integrate, migrate and
provide functional improvement to the same level as untreated controls.
Differentiated derivatives of M2-ES cells which have undergone either treatment
with human serum or cell sorting or a combination of both, to remove potentially
tumorigenic cells (referred to as stripped populations) would be injected into SCID
mouse models. To reflect the same environmental stresses that the stripped
populations had gone through, controls of un-stripped populations, which had been
sorted, based only on viability, or treated with heat-inactivated human serum or a
combination of both, would be used. The development of tumours would then be
used, in combination with a panel of screening assays (such as analysis or expression
markers and undifferentiated ES cell growth in vitro) as a measure of the success of
hTERT/al,3Gal, and the respective elimination strategies to prevent tumour
formation compared to the unstripped controls and an experimental standard,
untreated control.
In the long-term it would be interesting to investigate the potential of in vivo a-gal
immunity against residual ES cells which express hTERT/al,3Gal. To achieve this a
mouse model which has the a 1,3Gal knockout phenotype (Ohshima et al., 1997;
Thall et al., 1995) and also the ability to accept human cell transplants needs to be
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created. Mice that possess the SCID mutation have no acquired immunity, lacking
both B- and T- lymphocytes they are unable to produce antibody or initiate humoral
immunity (reviewed by Bancroft & Kelly, 1994). When the SCID mutation is in the
C57BL/6 or Balb/c genetic background, the mice retain a functional innate immune
system with normal levels of macrophages, natural killer (NK) cells and antigen
presenting cells (APC), in addition to normal, sometimes elevated complement
activity (JAX® Communication 2000; reviewed by Bancroft & Kelly, 1994). On the
other hand, NOD inbred mice have impaired, macrophage, APC and NK cell
function and lack haemolytic complement C5, and so NOD-SCID mice are
complement deficient (JAX® Communication 2000). Therefore, to create a model in
which to test in vivo immunity against the M2 human ES cell line SCID mice of
appropriate genetic background (C57BL/6 or Balb/c) should be crossed to the
al,3Gal knockout mouse (Ohshima et al., 1997; Thall et al., 1995) and subsequent
offspring inbred to produce a stable SCID/al,3Gal knockout mouse.
Transplantation of M2 human ES cells into this model, with sufficient quantities of
anti-a-gal antibodies (requiring repetitive immunisation over time) could be used as a
model to test the effectiveness of in vivo complement-mediated lysis against residual
undifferentiated ES cells following transplantation. Initially it would be interesting
to use the SCID/al,3Gal knockout to perform dilutions studies, to determine the
level of ES cell contamination that the in vivo immune system would be able to clear,
without tumour formation. To achieve this undifferentiated M2 (a-gal expressing)
cells would be mixed with differentiated, (non proliferative, non-a-gal expressing)
cells at serial dilutions. Pure ES and pure differentiated cell populations would be
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used as positive and negative controls respectively and the occurrence of tumours
and in vitro ES cell culture etc would be used as a measure of success. The aim of
these experiments would be to determine the minimum level of purity that would be
required from in vitro elimination strategies and would provided an insight into
levels of risk.
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8.5 Conclusion
The novel system for selective ablation reported in this thesis could potentially
provide natural immune protection to eliminate the risk of tumorgenicity associated
with ES-derived therapy. Naturally circulating antibodies to a-gal could protect
graft-recipients from the presence of, or de-differentiation of, human ES-cell
derivatives following engraftment. Combining the sensitivity of complement-
mediated lysis at eliminating minority populations with the enrichment power of
fluorescence activated cell sorting (FACS), or magnetic activated cell sorting
(MACS), would potentially overcoming issues of scalability, that could otherwise
hamper this technique in its move from research bench to widespread clinical
application.
The advantage of the hTERT/al,3Gal strategy over the use of constitutive HSV-tk
expression, report by Schuldiner et al. (2003), is that by restricting expression of
a 1,3Gal through the use of the hTERT promoter, only areas of the graft that become
tumorigenic will be eliminated in vivo. Thus preventing representation of symptoms
and the need for further intervention. However, this strategy does not address the
issue of post-transplant complications, unrelated to tumorigenicity, which might
affect the whole ES-cell derived graft. Therefore, it is likely that these two
strategies, hTERT/a-l,3Gal for tumour elimination, and constitutive HSV-tk, in case
of post-graft complications, would benefit from being combined.
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Whilst investigating the potential of complement-mediated lysis and FACS to
eliminate undifferentiated ES cells, this thesis has brought to light a number of
interesting observations.
1. It provides evidence to show that clonal ES cell lines can be cultured using
enzymatic disaggregation techniques (TEG) for many (>50) passages without
effect on their karyotypic stability;
2. Evidence has been provided that indicates that undifferentiated ES cells
express high levels of complement inhibitory proteins, in line with expression
on the human blastocyst (Fenichel et al., 1995);
3. Undifferentiated ES cells have been shown to survive and proliferate
following single cell sorted; and
4. It has challenged the use of TRA-1-81 as a characteristic marker of
undifferentiated ES cells, by showing that its down regulation is not indicative
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APPENDIX I CONSTRUCTS & CLONING STRATEGIES
1.1 H2-Kk - A Murine Major Histocompatability Complex Antigen
1.2 Galal-3Gaipi-4GlcNAc-R (a-gal) Epitope
1.3 The Undifferentiated ES Cell Reporter Construct - mOct-4-EGFP
1.1 H2-Kk - A Murine Major Histocompatability Complex Antigen
Initially there were two transfection strategies, one based on the use of the Oct-4
promoter and the other based on the hTERT promoter. Both of these promoters have
the unique property of being down regulated in human ES cells, upon initiation of
differentiation. In both strategies the E12-Kk gene was cloned by high-fidelity PCR
using PfuTurbo DNA Polymerase (Stratagene) using the commercially available
plasmid pMAC KK II (Milteny Biotech) plasmid DNA as a template, (see Table
1.1.1 for details).














Sterile dH20 to 50pl
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Table 1.1.1: High fidelity PCR Conditions for Cloning the H2-Kk cDNA from the pMAC Kk II
Plasmid (Milteny Biotech). Primers were produced by MWG.
Zoe Hewitt
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The blunt ended H2-Kk PCR product produced using PfuTurbo was then treated with
Taq DNA polymerase (Roche), to add a single deoxyadenosine to the 3'-ends of the
amplified fragment to enable efficient cloning into the TA vector system (pGEM-
Teasy Promega). The advantage of the pGEM-TEasy vector system was the multiple
cloning sites at each end of the integration site, which provided a selection of
restriction enzymes for future cloning strategies.
The expression vector (phTpAPN) was built (Priddle, H. Roslin Institute) using a
core (200bp) human telomerase reverse transcriptase (hTERT) promoter and
upstream transcription termination signal (kind gift of Geron Corp, USA) followed
by a multiple cloning site for cDNAs and a bovine growth hormone poly-adenylation
signal (kind gift of Geron Corp, USA). The vector also contained a constitutive
neomycin resistance gene and poly-adenylation signal driven by a PGK promoter to
provide selection in eukaryotic cells. The H2-Kk PCR product was excised from the
pGEM-TEasy Vector with EcoRI and ligated into the EcoRI site within the multiple
cloning site of phTpAPN to produce phTH2KkpAPN (Figure 1.1.1 A). The
constitutive neomycin cassette was used for selection of stable transfectants.
Expression of H2-Kk under the transcriptional control of the human Oct-4 promoter
was achieved in a similar manner. The phOCT-4-eGFP-l plasmid (a kind gift from
Debiao Zhao, Roslin Institute) was digested with Agel (sticky) and Hpal (Blunt) to
remove the eGFP-1 mini gene. The Agel 3' receded end was filled using Klenow
(NEB) and the H2-Kk PCR product cloned into the phOCT-4 vector backbone as an
EcoRI blunt fragment, which was excised from pGEM-TEasy with EcoRI and
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blunted with Klenow. The resulting construct, phOct-4-H2-K contained a


















Neomycin APa u (8035)
phOCT4-H2-Kk
8406 bp
Figure 1.1.1: A schematic representation of the H2-Kk expression constructs. A| H2-Kk was
cloned by PCR from pMAC KK II (Milteny Biotech) and TA cloned into pGEM TEasy
(Promega) before being subcloned as an Eco RI fragment into phTpA PN (Priddle H). Psil was
used as a site for linearising the construct. B] using an Agel : Hpal digest the eGFP minigene
was removed from phOCT-4-eGFP (Zhao D) and the H2-Kk PCR product subcloned in as a
blunted EcoRl fragment. Apa LI was used as a linearisation site.
In the first instance phTH2-KkpAPN was linearised (psil) and stably transfected into
106 wild type H7 human ES cells by electroporation (multiporator, Eppendorff) as
described in section 2.7.2. Cells were plated under 200pg/ml G418 selection for 7 to
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10 days, after which the resistant colonies were pooled and the resulting cell line was
referred to as H7-Kk.
1.2 Galal-3Gaipi-4GlcNAc-R (a-gal) Epitope
The al,3galactosyltransferase (al,3Gal) expression vectors used in this study were
constructed by Dr. Helen Priddle (Roslin Institute, Edinburgh). Briefly, mouse
kidney mRNA was used to amplify the al,3Gal coding sequence by reverse
transcription (RT) PCR using 5' and 3' primers outlined in Table 1.2.1. The resulting
coding sequence was designated mGT. A fucosyltransferase (FucT) leader sequence
was engineered at the N terminus of mGT prior to the transmembrane domain,
following Osman et al. (1996), by engineering PCR primers which contained the
desired leader sequence of the fucosyltransferase gene before performing PCR on the
mGT cDNA (primers described in Table 1.2.1). Following PCR, both mGT and
FucGT were TA cloned into pGEM-TEasy (Promega)
Coding
sequence
5' Forward Primer 3'Reverse Primer
MGT ggcclglactacatttgcctgga gaaatagtgtcaagtttccatcacaa
FucGT cgatgtggctgcggagccaccggcaggtaatcctgttgatgctgattgtctcaac gaaatagtgtcaagtttccatcacaa
Table 1.2.1: Primer design for cloning of mouse galactosyltransferase and the leader sequence of
the fucosyltransferase gene by RT-PCR.
Both the mGT and fucGT coding sequences were excised from pGEM-TEasy with
EcoRI and were subcloned into the EcoRI site contained within the multiple cloning
site of phTpAPN. As described above, (see section 1.1) phTpAPN contained the
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hTERT core promoter (kind gift from Geron corp.) to provided restricted expression
of al,3Gal to undifferentiated ES cells (Figure 1.2.1).
B
fooRI (1519)
EcoRl (1290) j £<x> Rt (2j6s)
hTERT
Psi I (100)
Traris Term phTpAPN mGT
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Figure 1.2.1: Schematic representation of the two constructs used to express the galal-3Gaipi-
4GlcNAc-R (a-gal) epitope of the cell surface of human ES cells. Both constructs were
engineered by Dr Helen Priddle, a] mouse kidney al,3galactosyltransferase cDNA under the
control of a core hTERT promoter b| the same construct containing the leader sequence of the
fucosyltransferase gene.
Dr H. Priddle produced transgenic mGT and fucGT cell lines, by electroporation
using hyposmolarity buffer (Eppendorf) and an Eppendorff Multiporator
(Eppendorf). Briefly, lxlO6 H9 human ES cells were electroporated with linear
DNA, plated and selected in the presence of 200pg/ml G418 for 10-14 days. From
each transfection, yielding 558 and 585 colonies respectively, 24 colonies were
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picked and expanded, from which 4 of the mGT clones and 8 of the fucGT clones
expressed the a-gal epitope.
1.3 The Undifferentiated ES Cell Reporter Construct - mOct-4-EGFP
The reporter construct mOct-4-EGFP was a kind gift from Dr Ed Gallagher (Roslin
Institute, Edinburgh) and remained unchanged (Figure 1.3.1).
2x Eco Rl 3x Bam HI
(48 & 3849) (3869, 7149 & 8570)
mOCT-4-EGFP-
12642 bp
Figure 1.3.1: A schematic representation of the Oct-4/GFP expression vector, a kind gift from
Dr Ed Gallagher. The reporter construct contains the full 8.5kb murine Oct-4 promoter driving
the wild type EGFP reporter gene. Stable cells lines were created by lipofection, using Apa LI
linearised DNA, and were selected for with 200pg G418.
The mOct-4-EGFP construct was linearised (ApaLl) and transfected into H9 human
ES cells by Lipofection (Lipofectamine 2000, Invitrogen) as described in section
2.7.1. G418 Selection (200pg) was applied 48-hours after the transfection agents
were removed, and was maintained for 7 to 10 days, after which, 9 colonies were
picked and transferred into a 24-well plate. Of the 9 picked colonies, 6 were
successfully expanded into stable cell lines, but they displayed varying degrees of
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transgene expression. Oct-4/GFP-6 showed the lowest level of variegation and was
therefore the clone of choice for subsequent experiments.
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